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Thesis Summary 
Peritoneal dialysis (PD) is a life-saving form of renal replacement therapy for 
those with End Stage Kidney Disease. Peritoneal fibrosis is a considerable problem for 
PD patients, and mesothelial cells, which line the peritoneal cavity, play a central role in 
response to injury and fibrogenesis within the peritoneum. Mesothelial cells may 
undergo mesothelial to mesenchymal transition (MMT) contributing to peritoneal 
fibrosis and treatment failure. miRNAs are important regulators of fibrosis but their roles 
in peritoneal fibrosis are largely unknown. Here, a detailed characterization of the MMT 
process was performed in primary human mesothelial cells (HPMCs) in response to 
Transforming Growth Factor beta-1 (TGF-β1). Hybridization array showed mesothelial 
miR-21 and miR-31 expression was up-regulated by TGF-β1 which was validated by RT-
qPCR in different PD associated MMT models. Mesothelial cells cultured ex vivo from PD 
patients exhibited phenotypic changes consistent with a progressive MMT process that 
correlated with an increase in miR-21 and miR-31 expression. Association of miRNA 
expression and MMT markers in 33 peritoneal biopsies from patients undergoing PD 
treatment and in PD effluent from 230 PD patients confirmed these results. In silico 
analysis combined 4 target prediction algorithms (Targetscan, miRanda, miRDB and 
Diana-microT) for miR-21 and integrated the resulting outcome with mRNA arrays 
comparing omentum vs PD effluent-derived HPMCs with epithelial (E) and non-epithelial 
(NE) phenotype. 13 possible miR-21 targets during the MMT process associated to PD 
therapy were identified and model scrutinized. Four of these were confirmed to be miR-
21 targets. Functional gene analysis indicated that selected targets may be downstream 
modulators of Snail and cooperate driving MMT during peritoneal fibrosis. Taken 
together, these data provide a detailed characterisation of mesothelial miRNA 
expression and responses to TGF-β1, and identify miR-21 and miR-31 as promising 
biomarkers for peritoneal fibrosis associated to PD therapy. 
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1.1. Chronic Kidney Disease (CKD) 
The kidneys are two bean-shaped organs localized at the back of the abdomen 
which in healthy adults are each approximately 10 cm in length, 6 cm wide and 3 cm 
thick. The kidneys are involved in regulatory functions including (i) removal of excess 
organic molecules, such as waste products of metabolism, from the blood; (ii) 
electrolyte regulation; (iii) acid-base balance maintenance; (iv) blood pressure control 
(via salt and water balance); (v) hormone (calcitriol and erythropoietin) and (vi) enzyme 
(renin) production. Incapacity to sustain blood homeostasis due to kidney injury may 
cause disease and ultimately lead to death. Kidneys are, therefore, responsible for 
monitoring blood water and molecule balance, sustaining salt and ion concentrations, 
maintaining pH and secreting toxic and waste products via urine generation. Urine 
production takes place in the nephrons, which are the functional units of the kidney, 
and work by blood filtration in the glomerulus followed by selective secretion and 
reabsorption of different molecules and water in the downstream nephron segments. 
The factors contributing to impaired renal function are variable and can trigger 
either a gradual damage in renal capacity over months or years, called chronic kidney 
disease (CKD), or a quick decline progression in less than three months, termed acute 
kidney injury (AKI). Severe deterioration in renal performance may be called uraemia, 
which is characterized by symptoms generated by toxic and waste product 
accumulation. CKD is characterized by non-specific signs comprising (i) elevated blood 
pressure, (ii) pallor, (iii) volume overload, (iv) pericarditis, (v) asterixis (hand tremor), 
and (vi) muscle cramps; as well as symptoms including (i) loss or decreased appetite, (ii) 
easy fatigability, (iii) generalized weakness, (iv) involuntary weight loss or gain, (v) 
nausea and vomiting, (vi) metallic taste, (vii) generalized itching, (viii) difficulty 
breathing, (ix) edema (interstitial fluid), (x) intractable hiccups, (xi) frothy urine, (xii) loss 
of libido (e.g., erectile dysfunction), and (xiii) restless legs (Pereira et al, 2005). The 
glomerular filtration rate (GFR) is a test that estimates how much fluid passes in total 
from blood to urinary space across the glomerular filtration barrier located at the start 
of each nephron each minute and, therefore, indicates kidney function (Pereira et al, 
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2005). The National Kidney Foundation produced clinical practice guidelines via the 
Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) programme to classify CKD into 
5 stages according to renal excretory function as estimated by GFR (Levey et al, 2003) 
(Table 1.1). 
 
Stage GFR* Description Treatment 
1 >90 
Normal kidney function and associated 
abnormalities found# 
Observation 
Blood pressure control 
2 60-89 
Moderate reduction in kidney function 
and associated abnormalities found# 
Observation 
Blood pressure monitoring 
Risk factors control 
3 
(A) 45-59 
(B) 30-44 Tolerably reduced kidney function 
Observation 
Blood pressure monitoring 
Risk factors control 
4 15-29 Severe reduced kidney function 
Planning for End-Stage 
Renal Disease (ESRD) 
5 
<15 
Dialysis 
requirement 
Very severe or ESRD Treatment need 
Table 1.1: CKD classification into 5 stages according to NKF-KDOQI and GFR. *GFR values are expressed 
in mL/min and are normalized to an average surface area per 1.73 m2. #Both of these stages are generally 
asymptomatic and require constant detection of protein in urine (proteinuria), albumin (albuminuria), red 
blood cells (haematuria) or structural abnormalities. 
UK prevalence of stage 3-5 CKD was found to be 8.5% in a cross-sectional study 
including over 130.000 adults. (Stevens et al, 2007). GFR is not analyzed in a relevant 
proportion of the community and an underestimation of the real CKD prevalence in UK 
can be inferred in the measure indicated above (Stevens et al, 2007). The estimated cost 
of CKD to the NHS in England (2009-2010) was 1.4 £ billion / year and represented 1.3% 
of the total NHS annual budget (Kerr et al, 2012). Through Europe, prevalence of CKD 
stage 1-5 and 3-5 varies between countries (adjusted CKD stages 1-5 prevalence: 3.31% 
in Norway and 17.3% in northeast Germany; adjusted CKD stages 3-5 prevalence: 1.0% 
in central Italy and 5.9% in northeast Germany) (Brück et al, 2016). 
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1.1.1. End-Stage Renal Disease (ESRD) 
CKD stage 5 is also called End-Stage Renal Disease (ESRD) defined by a GFR 
<15ml/min, taken to be the point at which renal replacement therapy (RRT) may be 
required for the patient. There are two main classes of RRT once ESRD is reached (i) 
renal transplant or (ii) dialysis. Although kidney transplant is the optimum choice for 
many ESRD patients, there are not sufficient kidney donors and all patients are not 
suitable for kidney transplant. Historically, an average of 23% of ESRD patients receive a 
renal transplant (Grassmann et al, 2005), and while transplant numbers continue to 
increase and outcomes continue to improve following transplantation, the majority of 
patients requiring RRT continue to depend on dialysis treatment to keep them alive. This 
treatment is based on an artificial replacement of the kidney function by promoting 
solute diffusion and osmosis through a semipermeable membrane. There are two 
dialysis methods (i) haemodialysis and (ii) peritoneal dialysis.  
1.1.1.1. Haemodialysis (HD) 
Haemodialysis (HD) is a therapy based on two fluids, dialysate and blood, moving 
in opposite directions separated by a semipermeable membrane (Figure 1.1). This flow 
is sustained within an artificial external kidney, called a dialyzer, designed to keep a high 
concentration gradient, enhancing the effectiveness of the process (Pereira et al, 2005). 
Consequently, this treatment cleans the blood of toxic substances and water excess, and 
regulates pH and electrolyte composition before blood is reintroduced into the body. 
HD is a highly effective technique but limitations include abrupt changes in (i) fluid, (ii) 
waste products, and (iii) electrolyte concentrations; (iv) need of access to the vascular 
system, and (v) use of anticoagulants during the procedure to prevent blood clotting. 
Haemodialysis machines monitor important parameters for the patient and can be 
home or hospital-based, with the latter being more common. 
The most frequent adverse effects experienced by patients on HD therapy are 
summarized in Table 1.2 and include (i) regular travel for in-centre treatment, (ii) dietary 
and fluid intake restrictions, (iii) low blood pressure (hypotension) with associated 
nausea and dizziness, (iv) blood clot formation, (v) higher sepsis risk, (vi) muscle cramps, 
(vii) itchy skin, (viii) dry mouth, (ix) sleep disorders, (x) bone and joint pain, (xi) loss of 
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libido (e.g., erectile dysfunction), (xii) anxiety, (xiii) tiredness, and (xiv) difficulties to 
travel associated to arrangement access to dialysis facilities (NHS choices information 
webpage: http://www.nhs.uk/pages/home.aspx; 2016, April 1) (Pereira et al, 2005; 
Saxena & West, 2006). Nevertheless, this therapy also has many advantages when 
compared to peritoneal dialysis including (i) shorter period of time and fewer days a 
week of treatment, (ii) trained health professional assistance that can quickly detect 
possible issues, (iii) higher emotional support, (iv) it may be especially suitable for people 
who are visually impaired, have dementia or poor state of health, (v) home 
haemodialysis is possible but less common than in centre therapy, and (vi) equal 
effectiveness to PD (Table 1.2) (NHS choices information webpage; 
http://www.nhs.uk/pages/home.aspx; 2016, April 13) (Pereira et al, 2005; Saxena & 
West, 2006).  
 
 
Figure 1.1. Haemodialysis diagram. (Figure modified from NHS choices information webpage; 
http://www.nhs.uk/pages/home.aspx; 2016, April 13).  
 
1.1.1.2. Peritoneal Dialysis (PD) 
Peritoneal dialysis (PD) is an alternative therapy to HD that uses the peritoneal 
membrane, which is a natural, vascularized and semipermeable membrane that lines 
the abdomen as an intrinsic, regular, dialyzer (Figure 1.2). During this treatment a sterile 
dialysate solution is introduced into the peritoneal cavity of the patient, via permanent 
abdominal catheter insertion, promoting capillary osmotic and diffusive transport of 
water and small solutes towards the instilled fluid. Dialysate solutions can have different 
compositions depending on patient requirements and remain in the cavity for a period 
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of hours to allow dialysis to occur. During this time the high concentration gradient 
created by the dialysate allows diffusion and osmosis movements of different 
substances and water between the blood and the PD solution through the peritoneal 
membrane. Eventually, the fluid containing blood toxic substances, small solutes and 
water excess is drained out and discarded, and replaced with fresh dialysate. The full 
therapy cycle is called a ‘PD exchange’, and the effectiveness of the therapy depends on 
the (i) gradient concentration, (ii) membrane surface, and (iii) membrane permeability 
(Pereira et al, 2005). 
Figure 1.2. Peritoneal dialysis diagram. (Figure modified from NHS choices information webpage; 
http://www.nhs.uk/pages/home.aspx; 2016, April 13).  
The most frequent problems experienced during PD therapy are summarized in 
Table 1.2 and include (i) permanent abdominal catheter insertion, (ii) peritonitis risk, (iii) 
need for therapy to be performed daily, (iv) gradual thickening and scarring of the 
peritoneum, (v) fewer but still diet and fluid intake restrictions, (vi) can trigger a 
reduction in protein levels, lack of energy and malnutrition, (v) weight gain, and (vi) 
higher risk of developing hernia (NHS choices information webpage; 
http://www.nhs.uk/pages/home.aspx; 2016, April 13) (Pereira et al, 2005; Saxena & 
West, 2006). Of note, this therapy comprises many advantages for patients such as the 
fact that is (i) mostly home-based with smaller, portable, machines, (ii) possible to 
perform in any clean area without special assistance, (iii) traveling freedom, (iv) 
recommended for people who still have some residual kidney function and (v) for 
Dialysate    Capillary Blood 
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children aged two or younger, (vi) lower cost, (vii) better quality of life, and (viii) equally 
effective when compared with HD (Table 1.2) (NHS choices information webpage; 
http://www.nhs.uk/pages/home.aspx; 2016, April 13) (Pereira et al, 2005; Saxena & 
West, 2006). 
 Advantages Disadvantages 
HD 
Treatment employs shorter period of time and 
fewer days a week 
( ~ 3 days/week  ~ 4 hours/session) 
Often carried out in dialysis clinic implying 
regular travel 
Need of trained health professionals that can 
quickly detect possible issues 
Dietary and fluid intake restrictions 
Higher emotional support (the patient is in 
contact with other people receiving the same 
treatment) 
Low blood pressure (hypotension) with 
associated nausea and dizziness (caused by fluid 
levels drop) 
Recommended for people who are visually 
impaired, dementia or poor state of health 
Higher sepsis risk 
(caused by blood spreading bacteria and 
multiple organ failure) 
Home haemodialysis is possible but less 
common than in centre therapy 
Muscle cramps 
(caused by fluid levels drop) 
Equally effective than PD 
Itchy skin 
(caused by mineral raise between sessions) 
Dry mouth 
(caused by fluid levels drop) 
Sleep disorders 
Bone and joint pain 
Loss of libido and erectile dysfunction 
Anxiety 
Tiredness 
Difficulties to travel associated to arrangement 
access to dialysis facilities 
 
Mostly home-based with smaller, portable, 
machines 
Permanent abdominal catheter 
 
Need of personal training but possible to 
performed in any clean area without special 
assistance 
Peritonitis risk 
(bacterial peritoneal infection) 
 Freedom to travel Needs to be performed daily 
PD 
Recommended for people who still have some 
limited kidney function; better RRF preservation 
Peritoneum gradual thickness and scarring 
 Recommended for children aged two or younger Fewer diet and fluid intake restrictions 
 
Lower cost Can trigger a reduction in protein levels, 
lack of energy and malnutrition Better quality of live 
 
Equally effective than HD 
Weight gain 
(caused by sugar reabsorption and 
increasing caloric consumption) 
 Higher hernia developing risk 
Table 1.2: Table summarizing described advantages and disadvantages of HD and PD as ESRD therapies. 
(NHS choices information webpage; http://www.nhs.uk/pages/home.aspx; 2016, April 13) (Pereira et al, 
2005; Saxena & West, 2006).   
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The number of ESRD patients increases between 6-7% annually with PD being 
the therapy experienced by 11% of RRT patients worldwide (Grassmann et al, 2005; Jain 
et al, 2012). In United States, PD treatment is growing fast due to a change in 
reimbursement policy and is expected to grow more during the following years (Golper, 
2013). In Europe, RRT statistics vary between countries, and the UK is one of the nations 
with a higher percentage of patients on PD (Byrne et al, 2010). Nevertheless, PD therapy 
showed a slow decline during the last fifteen years in UK while RRT prevalence increased 
4.4% (Byrne et al, 2010).  
1.2. Peritoneal Anatomy and Histology 
1.2.1. The peritoneum and the peritoneal cavity 
Etymologically, the word peritoneum has a Greek via Latin origin in which peri- 
indicates around whereas -ton- relates to stretching and meaning stretched around. The 
peritoneum is the widest serous membrane, lines the visceral organs (visceral 
peritoneum or mesentery) and the abdominal cavity (parietal peritoneum) and 
comprises a total surface extension comparable to the skin (1-2 m2) (Pereira et al, 2005; 
Yung et al, 2006). The space limited by these two membranes is the peritoneal cavity, 
which contains a serous liquid (< 50 ml) that favours membrane movement. During PD, 
the parietal peritoneum is largely engaged (80 %) in the efficient dialysis of water and 
solutes.  
The peritoneum also folds into other substructures named (i) ligaments, (ii) 
mesenteries, and (iii) omentum which connect organs with each other and to the 
abdominal wall (Pereira et al, 2005). From these, the omentum can be also subdivided 
into two parts, namely the (i) lesser (covering liver, stomach curvature and part of the 
duodenum) and the (ii) greater (laying the visceral peritoneum) omentum, with 
significant function as a fat store and in immunity. The anatomist Ranvier described for 
first time the presence of small white masses or ‘milky spots’ of cells in omental tissue 
(1874). These conglomerates where posteriorly characterized as clusters of macrophage 
and leukocyte cells (Krist et al, 1995). Milky spots have been associated with 
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immunocompetent cell migration towards the peritoneal cavity and local cell 
proliferation under both stimulated and unstimulated conditions (Cui et al, 2002). 
Interestingly, the frequency and dimension of these omental spots rise in patients 
receiving PD therapy (Beelen et al, 2005). Omentum also contains peritoneal 
mesothelial and fibroblast cells highly similar to those found at the peritoneal 
membrane, and has been extensively used as a primary cell source for research 
(Stylianou et al, 1990; Witowski & Jörres, 2006). 
1.2.2. The peritoneal membrane 
Histologically, the peritoneum is also called peritoneal membrane and consists 
of a mesothelial layer (mesothelium) sustained by a thin basal membrane and a 
submesothelial stratum of connective tissue (Nagy & Jackman, 1998). The mesothelium 
is a large cobblestone monolayer of ~ 1 x 109 mesothelial cells (MCs) with ~ 25 µm of 
diameter and which apical surface is densely covered by microvilli (Nagy & Jackman, 
1998). The structural integrity of the mesothelium is maintained via cell-cell and cell-
matrix interactions by tight, adherent and gap junctions as well as desmosomes. The 
thin, underlying basal membrane is generated by MCs and contains a network of 
collagen IV, proteoglycans and glycoproteins (Nagy & Jackman, 1998). Below these 
layers, the submesothelial stratum supports a higher network complexity that includes 
(i) extracellular matrix components (ECM) such as collagen, elastin, fibronectin and (ii) 
glycosaminoglicans (hyaluronan) as well as large and small (iii) blood vessels, (iv) 
draining lymphatics and (v) cellular elements like fibroblasts, resident macrophages, 
mast and adipose cells all of which contribute to maintain the homeostasis of the 
peritoneal membrane (Nagy & Jackman, 1998). 
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1.2.3. The mesothelium 
Embryologically, the mesothelium originates from the embryonic mesoderm 
that surrounds the celom of the embryo and lines all serosa cavities (i) pleural (or chest 
cavity), (ii) pericardial (heart) and (iii) peritoneal (abdomen) (Mutsaers, 2004). During 
development, the mesothelium becomes a significant source of mesenchymal cells for 
tissue and organ generation including heart (Schlueter & Brand, 2013), lung (Que et al, 
2008), gut (Wilm et al, 2005), liver (Ijpenberg et al, 2007) and fat (Chau et al, 2014). Adult 
mesothelium has a low proliferative rate (0.16 - 0.5 %) which is greatly increased after 
injury (30 – 80 %) and mesothelial cells retain the capacity to alter their phenotype via 
epithelial-to-mesenchymal transition (EMT) in response to different wound repair 
stimulus (Mutsaers, 2004; Yáñez-Mó et al, 2003). In the past, the principal function 
attributed to adult mesothelium was to favour slippery, non-adhesive movement of 
organs and tissues (Mutsaers, 2004). Nevertheless, nowadays adult mesothelial cells 
have been implicated in a broad spectrum of functions including (i) defensive barrier 
and non-adhesive surface, (ii) antigen presentation, (iii) inflammation regulation, (iv) 
coagulation and fibrinolysis, (v) extracellular matrix production, (vi) fluid and cell 
transport, and (vii) tumour cell adhesion and growth.   
1.2.4. The mesothelial cell 
Mesothelial cells are one of the largest peritoneal cell populations, ~ 1 x 109 cells 
(Nagy & Jackman, 1998). Their morphology varies between areas from flat squamous to 
cuboidal cells associated with higher activity (Mutsaers, 2002). Apical MCs surface is 
covered with highly versatile microvilli which enhance cell luminal area via length and/or 
number increase depending on physiological requirements (Mutsaers, 2002; Nagy & 
Jackman, 1998). Human peritoneal MCs (HPMCs) are ~ 0.5 – 2 µm thick, ~ 25 µm in 
diameter and maintain mesothelium structural integrity via cell-cell and cell-matrix 
interactions (Nagy & Jackman, 1998). MCs cell-cell contacts include (i) tight junctions, 
which are sealing protein complexes between adjacent MCs containing membrane 
proteins (e.g., Claudin, Occludin) and cytoplasmic proteins (e.g., Zona Occludens 1, ZO1) 
connecting transmembrane proteins with actin cytoskeleton and signalling proteins; (ii) 
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adherens junctions, which are an adhesion ‘belt’ between MCs containing membrane 
proteins (E-cadherin) and cytoplasmic proteins (e.g., β-catenin, p120 catenin) 
connecting E-cadherin with actin cytoskeleton and signalling proteins; (iii) desmosomes, 
which function as an adhesion ‘patch’ between MCs containing membrane proteins 
(desmosomal cadherin) and cytoplasmic proteins (e.g., desmoplakin) connecting 
transmembrane proteins with intermediate filaments; and (vi) gap junctions, which 
connect neighbouring MCs allowing ions and small molecule transfer between them 
while providing adherence (Lamouille et al, 2014; Mutsaers, 2004; Nagy & Jackman, 
1998). 
MCs are singular cells, able to co-express mesenchymal (vimentin and desmin) 
and epithelial (cytokeratin) intermediate filaments (Ferrandez-Izquierdo et al, 1994). 
MCs also share properties with vascular endothelium, expressing adhesion molecules 
that include ICAM-1, VCAM-1 and Platelet Endothelial Cell Adhesion 1 (PECAM-1) and 
cooperate in leukocyte migration (Jonjić et al, 1992). All the characteristics mentioned 
above mean that MCs are a versatile multifunctional cell type, with multiple implications 
in development and disease. 
1.2.5. Physiological functions of the mesothelium 
1.2.5.1. (i) Defensive barrier and non-adhesive surface 
The mesothelium offers a defensive fence towards mechanical injury and foreign 
entities. MCs are firmly attached between each other and secrete matrix ‘coat’ 
(glycosaminoglycans; mainly hyaluronan (HA)) that covers their surface, guarding the 
cells from abrasive harm and infective factors. Hyaluronan synthesis is increased with 
injury and contributes to cell differentiation, impedes adhesion formation and tumour 
cell propagation (Mutsaers, 2002). Mesothelial cells can also secrete 
phosphatidylcholine, the main component of lamellar phases and cellular surfactant, 
which reduces abrasion acting as a lubricant within serosal membranes (Mutsaers, 2002; 
2004). 
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1.2.5.2. (ii) Antigen presentation 
Mesothelial cells are prone to encounter any pathogenic organism or other 
injurious stimulus present in the peritoneal cavity due to their location lining the 
peritoneal cavity. MCs have the ability to secrete pro-inflammatory molecules including 
IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1) and RANTES following contact 
with infective agents or their secreted products (Kinnaert et al, 1996). These molecules 
contribute to inflammatory processes, triggering endothelial activation, which is 
required for leukocyte migration to the peritoneal cavity. Particular immune responses 
are developed via T cell antigen presentation and activation. This task is generally 
achieved by professional antigen presenting cells (APCs) including dendritic cells, 
macrophages, monocytes and B cells via major histocompatibility complex (MHC) class 
II molecules. Nevertheless, this immune network can be further assisted by non-
professional (APCs) via intercellular adhesion molecule-1 (ICAM-1). At the peritoneum, 
the immune system is helped by MCs, which can also display MHC class II and 
intercellular adhesion molecule-1 (ICAM-1) upon stimulation and mediate antigen-T cell 
recognition mainly via ICAM-1 (Hausmann et al, 2000; Valle et al, 1995). Additionally, 
MCs can also secrete interleukin (IL)-15 which is a pleiotropic cytokine that has been 
involved in immune response initiation and T-cell growth (Hausmann et al, 2000). 
1.2.5.3. (iii) Inflammation regulation 
MCs have important functions during serosal inflammation including synthesis 
of (i) cytokine and chemokine molecules, (ii) growth factors, (iii) ECM proteins, (iv) 
intracellular adhesion molecules, and the ability of acting as (v) antigen presenters 
(Hausmann et al, 2000; Valle et al, 1995). Activated macrophages secrete inflammatory 
mediators comprising TNF-α, IL-1β and INF-γ which trigger MCs cytokine release 
including transforming growth factor β1 (TGF-β1), monocyte chemotactic protein-1 
(MCP-1; or chemokine C-C motif ligand 2, CCL2), RANTES (or chemokine C-C motif ligand 
5, CCL5) and IL-8 (or chemokine C-X-C motif ligand 8, CXCL8) and adhesion molecules 
including ICAM-1, vascular cellular adhesion molecule-1 (VCAM-1), E-cadherin, N-
cadherin, CD49a, CD49b, CD44 and CD29 (Cannistra et al, 1994; Jonjić et al, 1992; Liberek 
et al, 1996; Mutsaers et al, 2015; Offner et al, 1996); enhancing leukocyte mobilization, 
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adherence and migration through the mesothelium to harmed areas (Liberek et al, 
1996). 
Peritoneal inflammatory responses can be challenged not only by infections but 
also via sterile dialysis fluid exposure, which promotes inflammation, cell proliferation, 
migration and ECM synthesis. These processes are led by the synthesis and secretion of 
growth factors including TGF-β1, platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), hepatocyte growth factor (HGF) and different members of the 
epidermal growth factor (EGF) (Mutsaers et al, 2015). Indeed, long-term PD therapy 
facilitates chronic sterile peritoneal inflammation and the development of long-term 
peritoneal injury via fibrotic processes.  
1.2.5.4. (iv) Coagulation and fibrinolysis 
Fibrin deposition is an early important process in peritoneal wound healing and 
is tightly regulated by MCs. These cells have the ability to produce and regulate both 
pro-coagulant and fibrinolytic enzymes. Coagulation is mainly mediated via MC 
production of tissue factor (TF), a key initiator of the coagulation cascade that activates 
thrombin, which then cleaves fibrinogen into fibrin (Bottles et al, 1997). Conversely, TF 
pathway inhibitor (TFPI) impedes TF function and is also produced by MCs (Bajaj et al, 
2000). Fibrinolytic capacity is also regulated by MCs, via tissue plasminogen activator 
(tPA), urokinase PA (uPA), uPA receptor (uPAR), plasminogen activator inhibitor (PAI)-1 
and PAI-2 (Ivarsson et al, 1998). Thus, fibrin clearance depends on the counterbalance 
between the different players of the fibrinolytic system expressed at a certain time and 
site. 
Pro- and anti-fibrinolytic pathways are coordinated by different inflammatory 
molecules, comprising lipopolysaccharide, tumour necrosis factor alpha (TNF-α), 
interleukin (IL)-1 and fibrogenic mediators including TGF-β1 and thrombin (Mutsaers, 
2004; Tietze et al, 1998). During PD therapy, peritoneal mesothelial denudation disturbs 
fibrinolytic MCs regulation and promotes fibrin aggregation which ultimately, forms 
adhesions and plaques among the peritoneal membranes (Sulaiman et al, 2002).
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1.2.5.5. (v) Extracellular Matrix Production 
MCs produce diverse ECM components that are necessary for cell function and 
peritoneal membrane restoring. ECM molecules synthesized by MCs include collagen 
type I, III, and IV, elastin, fibronectin, laminin, proteoglycans (Mutsaers et al, 2015; Yung 
et al, 2006); and molecules contributing to maintain ECM homeostasis via secretion of 
matrix metalloproteinases and tissue inhibitors of metalloproteinases (Ma et al, 1999). 
MCs stimulated in vitro with different cytokines and growth factors including TGF-β1, IL-
1β, EGF and PDGF (Leavesley et al, 1999; Yang et al, 1999a; Zhang et al, 2005) as well as 
PD effluent from patients exhibit ECM up-regulation (Perfumo et al, 1996).  
1.2.5.6. (vi) Fluid and cell transport 
The feasible routes for solute and water transfer within the peritoneal capillaries 
plasma and the PD fluid involves (i) the capillary endothelium, (ii) the peritoneal 
interstitial space, and (iii) the mesothelium (Devuyst & Rippe, 2014). The mesothelium 
is implicated in the movement and transfer of fluid and cells thought the serosa wall via 
microvilli, pinocytic vesicles, intracellular junctions and stomata (MCs junction cavities 
of 3-12 µm in diameter) (Mutsaers, 2004; Nagy & Jackman, 1998). Although the 
mesothelium does not entail an active barrier for water transport, it has been 
hypothesized that interstitial fibrosis per se accounts for trans-peritoneal ultrafiltration 
reduction (Devuyst & Rippe, 2014). Therefore, it is important to stress that peritoneal 
mesothelial MMT process (See 1.5) contributes to peritoneal fibrosis and ultrafiltration 
failure being an important factor for therapy long-term continuation.  
1.2.5.7. (vii) Tumour cell adhesion and growth 
The MC hyaluronan coat together with the secretion of other 
glycosaminoglycans and surfactants contributes to impeding tumour cell adhesion, 
dissemination and growth. Damaged mesothelium, nevertheless, helps tumor cell 
adhesion via mesothelial adhesion molecule up-regulation due to inflammatory 
mediators, local growth factors and tumoral CD44 molecules binding to hyaluronan 
(Harada et al, 2001; Lessan et al, 1999). 
15 
 
1.3. Peritoneal Dialysis Solutions What does biocompatibility 
mean? 
The term biocompatibility makes reference to the ability of a material, device or 
system to perform without clinically significant host response (Biocompatibility 
Conference, 1998). Applied to PD solutions, ‘biocompatibility’ involves the biological 
effect that the solution exerts on the normal functioning of peritoneal cells unchanging 
anatomical and physiological peritoneal characteristics once treatment ends (Di Paolo 
et al, 1995; Holmes, 1993). Indeed, PD solutions have a bio-incompatible essence 
traditionally characterized by high glucose concentrations, glucose degradation 
products (GDPs), lactate buffers, high osmolality and low pH (Table 3.1). These non-
physiological properties cause peritoneal sterile chronic inflammation and healing 
mechanisms that trigger the development of structural and functional peritoneal 
membrane modifications (Sherif et al, 2006; Williams et al, 2002) (Figure 1.3 and 1.4; 
Table 1.3). These changes are contemplated as higher contributors of peritoneal 
ultrafiltration loss and dialytic ability (Margetts & Churchill, 2002). Additionally, these 
changes indirectly lead to patient systemic effects including fluid retention, left 
ventricular hypertrophy, heart failure, higher cardiovascular morbidity and mortality risk 
(Table 1.3. Modified from Chan & Yung 2007). 
1.3.1. Glucose, Glucose Degradation Products (GDPs) and Advanced 
Glycation Products (AGEs) 
Glucose has traditionally been the master osmotic agent in PD due to several 
factors including low price, safety, efficacy as osmotic colloid agent, and that it is easy 
to sterilise by heat. Nevertheless, a good amount of data implicates conventional, 
glucose-based solutions, as the main factor triggering PM alterations. Long-term PD 
patients are constantly subjected to PD solutions with 15 – 40 x physiological glucose 
concentrations to generate an appropriate osmotic gradient (Chan & Yung, 2007). 
Nevertheless, high glucose levels per se have been shown to trigger some of the above 
mentioned effects in MCs including (i) increased synthesis of MCP-1, TGF-β1, laminin,  
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 Affected  
cells 
Effect on peritoneal resident 
 or infiltrating cells 
Effect on peritoneal 
membrane References 
G
lu
co
se
 
Mesothelial
Cells 
Increased synthesis of MCP-1,  
TGF-β1, laminin, and fibronectin 
Inflammation and fibrosis 
(Ha et al. 2001;  
Medcalf et al. 2001; Wong 
et al. 2003) 
Decreased tight junctions expression  
and epithelial markers 
Mesothelial disintegration and  
membrane permeability 
(Ito et al. 2000) 
Reduced perlecan synthesis Increased membrane permeability (Yung et al. 2004) 
Increased mitochondrial damage  (Ishibashi et al. 2002) 
Inhibition of cell proliferation Impaired re-mesothelialization (Gotloib et al 1999) 
Increased lactate dehydrogenase 
release 
 (Medcalf et al. 2001) 
Fibroblasts 
Increased synthesis of matrix proteins  
and hyaluronan 
Peritoneal fibrosis  
Stimulation of proliferation Peritoneal fibrosis  
Increased insulin receptors and IGF-1 Peritoneal fibrosis  
Induction of chemokines and cytokines Inflammation  
Leukocytes 
Decreased phagocytosis Impaired peritoneal host defense  
Altered cytokine secretion Impaired peritoneal host defense  
G
D
Ps
 
Mesothelial 
cells 
Reduced cell proliferation and viability, 
ROS formation 
Impaired cell growth, GDP toxicity (Witowski et al. 2000) 
Inhibition of re-mesothelialization Mesothelial denudation (Morgan et al. 2003) 
Decreased epithelial and increased 
mesenchymal markers synthesis 
Impaired cellular functions, MMT 
(Leung et al. 2005;  
Bajo et al. 2011) 
Increased expression of  
pro-inflammatory and pro-angiogenic 
factors: TGF-β1, IL-1β, IL-6, VEGF 
Inflammation, Angiogenesis 
(Inagi et al. 1999; 
Witowski et al. 2000; 
Leung et al. 2005) 
Fibroblasts Inhibition of cell growth Impaired wound healing  
Leukocytes Increased number of rolling leukocytes Inflammation  
A
G
Es
 
Mesothelial 
cells 
Increased VEGF and TGF-β1 synthesis Peritoneal fibrosis 
(Schwenger et al. 2006; 
Yang et al. 2015) 
Decreased synthesis of epithelial and 
increase synthesis of  
mesenchymal markers 
Impaired cellular functions, MMT (Yang et al. 2015) 
Accumulation in cells Fibrosis (Nakayama et al. 1997) 
Table 1.3: Effect of glucose, glucose degradation products (GDPs) and advanced glycosylation end-
products (AGEs) on specific peritoneal cell populations including mesothelial cells, fibroblasts and 
leukocytes. Monocyte chemoattractant protein-1 (MCP-1); transforming growth factor-β1 (TGF-β1); 
insulin-like growth factor-1 (IGF-1); reactive oxygen species (ROS); interleukin-1β (IL-1β); interleukin-6 (IL-
6); vascular endothelial growth factor (VEGF). (Modified from Chan & Yung 2007). 
17 
 
and fibronectin (Ha et al, 2001; Medcalf et al, 2001; Wong et al, 2003); (ii) decreased 
expression of tight junctions and epithelial markers (Ito et al, 2000), (iii) reduced 
perlecan synthesis (Yung et al, 2004), (iv) increased mitochondrial damage (Ishibashi et 
al, 2002), (v) inhibition of cell proliferation (Gotloib et al, 1999), and (vi) increased lactate 
dehydrogenase release (Medcalf et al, 2001) (Table 1.3. Modified from Chan & Yung 
2007).  
In addition, conventional PDF are heat sterilized under acidic pH to avoid glucose 
caramelization but still resulting in the generation of breakdown glucose products or 
glucose degradation products (GDPs) which further accumulate during storage. 
Numerous PDF GDPs have been identified and characterized suggesting differential 
biological activities. These studies showed that GDPs, acidic pH and the use of a lactate 
buffer are probably the main factors associated with traditional glucose-founded PD 
fluids driving peritoneal damage (Table 1.3. Modified from Chan & Yung 2007). Within 
the alterations driven by GDPs in MCs it is important to point (i) reduced cell 
proliferation and viability, ROS formation (Witowski et al, 2000); (ii) inhibition of re-
mesothelialization (Morgan et al, 2003), (iii) decreased synthesis of epithelial and 
increased synthesis of mesenchymal markers (Bajo et al, 2011; Leung et al, 2005) and, 
(iv) increased expression of pro-inflammatory and pro-angiogenic factors including TGF-
β1, IL-1β, IL-6, VEGF (Inagi et al, 1999; Leung et al, 2005; Witowski et al, 2000) (Table 
1.3. Modified from Chan & Yung 2007).  
Glucose and GDPs can also mediate non-direct peritoneal injury via non-
enzymatic glycosylation (glycation); binding to local proteins and generating advanced 
glycation end-products (AGEs). In vivo, catalysis degree is determined by protein and 
sugar concentrations as well as the time of exposure (Lamb et al, 1995). The reaction by 
which AGEs are formed is called Maillard and consists in non-enzymatic reaction of 
glucose with protein primary amino groups rising glycated residues termed Amadori 
products (Friedlander et al, 1996). These early products are reversible but through a set 
of dehydration and fragmentation processes give rise to stable, highly insoluble, 
covalent molecules called AGEs (Friedlander et al, 1996). AGEs not only trigger intra- and 
extra-cellular protein cross-linking but also interact with cellular membrane receptors 
(receptors for AGEs; RAGEs) to modify intracellular signalling. RAGEs are expressed in 
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multiple peritoneal cells including MCs, macrophages and fibroblasts suggesting 
important consequences for peritoneal homeostasis (Boulanger et al, 2002; Nakamura 
& Niwa, 2004). Therefore, soluble and structural protein glycation (AGEs) play important 
roles in long-term PD due to the high glucose concentrations in the peritoneum and have 
been associated with harmful consequences in MCs including (i) increased VEGF and 
TGF-β1 synthesis (Schwenger et al, 2006; Yang et al, 2015), (ii) decreased synthesis of 
epithelial and increased synthesis of mesenchymal markers (Yang et al, 2015), and (iii) 
accumulation in cells (Nakayama et al, 1997) (Table 1.3. Modified from Chan & Yung 
2007). Indeed, AGEs presence is increased in PD effluent and peritoneal biopsies from 
long term PD patients and associates with filtration and ultrafiltration failure (Devuyst 
et al, 2010; Margetts & Bonniaud, 2003).  
The principal systemic effect of PD fluids is to support blood cleaning, water and 
uraemic waste products removal, via diffusive and osmotic movements. Nevertheless, 
conventional PD solutions have some downside effects associated to the therapy 
including (i) fluid and sodium retention, (ii) left ventricular hypertrophy, (iii) 
hyperglycaemia, (vi) hyperinsulinemia, (v) hyperlipidaemia, and (vi) abdominal obesity 
(Figure 1.3) (García-López et al, 2012). Newer PD fluids have been refined expecting to 
diminish the disadvantageous consequences of long-term exposure to PD fluids and will 
be discussed during the next section.  
1.3.2. Newer PD solutions 
Iterative refinement of PD solutions has occurred, aiming to solve the challenges 
associated with conventional fluids and intending to be more ‘biocompatible’. Newer 
PD solutions are based on the modification of one or more of the traditional perceived 
inadequacies associated with conventional fluids including (i) novel osmotic agents, (ii) 
alternative buffers, (iii) more physiological pH, and (iv) reduced GDP content (García-
López et al, 2012). Nowadays, two novel osmotic agents are available at the market: 
icodextrin (Extraneal) and amino acids based (Nutrineal) (Table 3.1). Icodextin is an iso-
osmolar mixture of glucose polymers with variable molecular weights that uses lactate 
as a buffer and is glucose-free (UFR = 2.27% glucose/initial hours) (Posthuma et al, 
2001). This osmotic agent has slow absorption compared with glucose and is especially 
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appropriate for fluid and sodium removal during long dwells (8-12 h) (Ho-dac-Pannekeet 
et al, 1996). Nevertheless, Icodextrin use is still not approved in some countries and its 
use has been limited to one daily exchange due to increased maltose circulating levels 
(García-López & Lindholm, 2009). Amino acid-based solutions are also lactate buffered 
and glucose free (UFR = 1.36% glucose) (Grzegorzewska et al, 1999). This osmotic agent 
was particularly designed to improve nutrition by acting as a source of amino acids. 
Nonetheless, its use has also been restricted to single daily exchange to decrease 
acidosis (Grzegorzewska et al, 1999). Most last-generation solutions are glucose-based 
and use lactacte (Balance), bicarbonate (BicaVera) or a combination of both (Physioneal) 
as a buffer (Table 3.1). These solutions introduced the use of multi-chamber PD bags to 
favour glucose sterilization and storage with minimal GDP generation (pH 3-4) due to 
physical separation from the remaining electrolytes. Once mixed, the fluid has 
neutral/nearly-neutral pH. 
  
 
Figure 1.3. Schematic figure summarizing the effects of new and conventional PD solutions on the 
peritoneal membrane. AGE, advanced gycaltion end products; PD, peritoneal dialysis; RRF, residual renal 
function; UF, ultrafiltration (Modified from Gracίa-Lόpez et al. 2012). 
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Some studies suggest that new PD solutions preserve better the peritoneal 
membrane and prolong the time on therapy compared with conventional solutions. 
Nevertheless, the evidence that last-generation of PD solutions can improve patient 
survival compared with classical PD fluids is not solid. When considering the potential 
benefits of new solutions it is important also to recognise that (i) icodextrin elicits 
greater ultrafiltration, improving patient fluid balance; and (ii) the use of non-glucose 
solutions during the long-dwell reduces the mean blood glucose levels of patients 
(Figure 1.3) (García-López et al, 2012). Nevertheless, there is still controversy regarding 
their potential to improve (i) preservation of RRF, (ii) peritonitis rate, and (iii) systemic 
inflammation (Figure 1.3) (García-López et al, 2012). Further large, randomized, 
controlled studies comparing these PD solutions with conventional fluids and reporting 
their specific effects and patient outcomes would be necessary to finally elucidate their 
full therapeutic potential.  
1.3.3. Membrane changes during PD therapy 
PD therapy involves constant exposure of the peritoneal membrane to 
bioincompatible PD solutions and a high basal inflammatory state. This results in a long-
term alteration of the peritoneal cavity homeostasis characterized by progressive 
fibrosis (Margetts & Bonniaud, 2003; Williams et al, 2002), inflammation (Witowski et 
al, 2000), MCs denudation (Baroni et al, 2012), angiogenesis and vasodilation (Jiménez-
Heffernan et al, 2008; Krediet et al, 2000), and MCs morphological and structural 
changes associated to a mesothelial to mesenchymal transition or (MMT) (Aguilera et 
al, 2005; Aroeira et al, 2007; Yáñez-Mó et al, 2003). Ultimately, the combination of these 
processes drives ultrafiltration failure and may necessitate a patient therapy switch 
(Aroeira et al, 2007). 
The success of long-term PD therapy depends on the maintenance of the 
structural and functional integrity of the peritoneal membrane, across which solute 
transfer occurs. Although different cell types are involved in the loss of peritoneal 
membrane homeostasis there is particular interest in peritoneal mesothelial cells (MCs), 
one of the most numerous cell types of the peritoneal cavity. PD failure has been largely 
associated with the TGF-β1-driven conversion of MCs to myofibroblasts, via mesothelial-
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to-mesenchymal transition (MMT) and mesothelial cell loss (see 1.5) (Selgas et al, 2006). 
This phenotypic conversion leads to increased synthesis of extracellular matrix 
components and release of pro-inflammatory and pro-angiogenic factors (Loureiro et al, 
2011) (Figure 1.5).  
1.3.3.1. Encapsulating Peritoneal Sclerosis (EPS) 
Encapsulating Peritoneal Sclerosis (EPS) is a rare but severe disorder associated 
with prolonged PD therapy that may result in severe membrane fibrosis, intestinal 
obstruction, malnutrition and a high mortality rate. EPS patients also undergo a 
reduction in solute or fluid removal during PD therapy which is characteristic of 
membrane failure. The insults driving this condition are controversial, but it has been 
associated with recurrent or non-resolved peritonitis, malignancies, tuberculosis, 
autoimmune disease, β-blockers, intraperitoneal disinfectants and liver transplantation 
(Kawaguchi et al, 2000). Some authors defend the ‘two hit’ hypothesis to develop this 
condition, which will comprise prolonged PD therapy together with peritonitis or quick 
therapy cessation (Honda & Oda, 2005). Satisfactory outcomes for patients with EPS 
may often be hampered by advanced disease at the time of diagnosis and by the 
frequent occurrence of comorbidity, for example a malnutrition state. Nowadays, EPS 
diagnosis is mainly performed via gastrointestinal dysfunction symptoms and computed 
tomography scanning (Kawaguchi et al, 2000) but the sensitivity of these diagnostics is 
deficient highlighting the necessity to develop earlier sensitive diagnostic tools for EPS 
(Yiannoullou et al, 2015).   
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1.4. The complexity of TGF-β1 in Peritoneal Dialysis 
Peritoneal dialysis is a successful but non-physiological therapy. Repeated 
injurious stimuli lead to a programme of wound healing responses in which, in common 
with similar processes in other contexts, TGF-β1 plays a central regulatory role. TGF-β1 
is a highly pleiotropic factor associated with the development of peritoneal injury 
including MMT, fibrosis and angiogenesis described in long-term PD patients. During PD, 
uraemia, PD solution bioincompatibility and inflammation have been associated with 
local TGF-β1 production in both animal models and humans (Margetts et al, 2005; 
Margetts et al, 2001; Zweers et al, 1999). In vitro, these solutions cause MCs alterations 
that are characterized by an increased expression of different factors including TGF-β1 
(Ha et al, 2001; Wong et al, 2003; Yang et al, 2015). Animal PD models blocking TGF-β1 
signalling via SMAD7 (Guo et al, 2007; Nie et al, 2007), BMP7 (Loureiro et al, 2010; Yu et 
al, 2009) or TGF-β1 direct inhibition (Loureiro et al, 2011) have found beneficial effects 
on mesothelial MMT and peritoneal injury/fibrotic responses. Human studies have 
highlighted that it is challenging to make reliable inferences from measurements of TGF-
β1 in PD effluent due to (i) low fluid concentration and (ii) detection of the predominant 
inactive form of TGF-β1 (see 1.4.1), which is probably not indicative of tissue active TGF-
β1 levels (Margetts & Bonniaud, 2003).  
Studies in rat (Margetts et al, 2001) and mouse (Margetts et al, 2005) models of 
adenoviral-mediated active TGF-β1 gene transfer to the peritoneum highlighted the 
importance of TGF-β1 in PD therapy. In these in vivo models, peritoneal TGF-β1 
overexpression closely mimicked structural and functional alterations observed in the 
peritoneum of long-term PD patients (Margetts et al, 2005; Margetts et al, 2001). These 
alterations included MMT, fibrosis, angiogenesis, higher solute transport, and 
ultrafiltration failure. Extended TGF-β1 overexpression in mouse peritoneum using a 
helper-dependent adenovirus also showed bowel encapsulation and peritoneal 
adhesions resembling those observed in EPS patients (Liu et al, 2009). TGF-β1-driven 
peritoneal MMT, fibrosis and angiogenesis depends on downstream SMAD signalling 
pathway (see 1.4.1.), although other pathways are also implicated in this process (see 
1.4.1.). The multifaceted function of TGF-β1 during PD therapy is wide playing 
23 
 
evidencing the importance to identify downstream effectors coordinating early versus 
late stages in PD treatment. This knowledge will be crucial to implement PD treatment 
via targeting defined targets into TGF-β1 pathway to combat side effects during PD 
therapy.  
1.4.1. TGF-β1 signalling from membrane to nucleus 
The TGF-β cytokine family comprises growth and differentiation factors including 
activins, bone morphogenetic proteins (BMPs), growth/differentiation factors (GDFs) 
and TGF-βs (Shi & Massagué, 2003). Among all TGF-β cytokine family of factors, TGF-β1 
and BMP7 equilibrium may be especially important to sustain peritoneal MCs phenotype 
during fibrosis (Loureiro et al, 2010; Vargha et al, 2006). TGF-β1 is member of the TGF-
β/Activin/Nodal subfamily while BMP7 is a member of the BMP/GDF/MIS subfamily. 
Non-active, monomeric TGF-β1 cytokine contains different disulfide-bond interlocked β 
strands termed ‘cyteine knot’ (Sun & Davies, 1995). Active dimeric TGF-β1 is formed and 
stabilized via hydrophobic and disulfide bridges. Both factors act through 
transmembrane heterotetramer receptors (type I/type II) with intrinsic 
serine/threonine kinase activity (Shi & Massagué, 2003; Weiskirchen & Meurer, 2013). 
TGF-β receptor serine/threonine kinase family includes 12 different members, 7 type I 
and 5 type II, and generate different transmembrane heterotetramers for particular 
factors triggering specific signalling (Groppe et al, 2002). Active TGF-β1 dimeric 
stoichiometry indicates interaction with two (type I/type II) receptor complexes and is 
regulated via soluble ligand trap proteins and membrane-anchored accessory protein 
receptors (Shi & Massagué, 2003). Active BMP7 has also dimeric stoichiometry 
indicating similar interaction with specific receptors and regulation (Groppe et al, 2002; 
Shi & Massagué, 2003).  
Upon TGF-β1 ligand binding to its primary receptor (type II, TGFBR2), signalling 
receptor (type I) is recruited, trans-phosphorylated and activated (Shi & Massagué, 
2003). TGF-β1 activated receptor type I (also actividin receptor-like kinase 5, ALK5) has 
serine-threonine capacity to phosphorylate Smad2 and Smad3 (Shi & Massagué, 2003). 
Gene knockout studies in mice have shown that TGF-β1 null mice is embryonic lethal 
(Sanford et al, 1997) or die shortly after birth by multifocal inflammatory disease (Shull 
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et al, 1992) while heterozygous mice display mixed inflammatory infiltrations and 
hyperplastic lesions (Boivin et al, 1996). Additionally, TGFBR2 (Oshima et al, 1996) and 
ALK5 (Larsson et al, 2001) knockouts die at the embryonic stage, displaying abnormal 
yolk sac hematopoiesis and vasculogenesis. Similarly, in mice genetic Smad2 deletion is 
embryonic lethally (Nomura & Li, 1998), while null Smad3 mice are born with impaired 
immunity (Yang et al, 1999b). In contrast to TGF-β1, BMP-7 activated receptor type I 
(ALK3) phosphorylates the R-Smads Smad1, Smad5 and Smad8. Receptor activated (R-
Smads) access and recognition by the receptors is facilitated by Smad anchor for 
receptor activation (SARA) proteins (Tsukazaki et al, 1998). Following phosphorylation, 
R-Smads associate with Smad4, a common Smad (Co-Smad) partner and a shared Smad 
pathway mediator (Shi & Massagué, 2003). The consequent R-Smad/Co-Smad 
complexes shuttle to the nucleus and activate target gene transcription in conjunction 
with other nuclear factors associated with MCs MMT (Smad2/3) or MMT reversion 
(Smads1/5/8). Transcription factor Smad3/4 directly binds DNA Smad-binding elements 
(SBEs) and GC-rich sequences within TGF-β target genes with a low energy binding 
fashion (Davis et al, 2010; Massagué et al, 2005). In addition, Smads can also interact 
with various DNA-binding cofactors into the transcriptional complex stabilizing Smads 
interaction (Feng & Derynck, 2005). There are over 30 Smad-interacting cofactors in 
mammals drawing a complicated and diverse picture of TGF-β1-driven gene responses 
depending on time, cell type and microenvironment (Feng & Derynck, 2005). TGF-β1 and 
BMP-7 signalling can be inhibited by Smad6 and Smad7, which act by blocking R-Smad 
phosphorylation and nuclear translocation by competitive interaction with the Co-Smad 
(Smad 4) together with receptor complex degradation via ubiquitin ligase recruitment 
(Gui et al, 2012; Shi & Massagué, 2003; Weiskirchen & Meurer, 2013). Smad signalling 
termination can be achieved via activated R-Smads (i) de-phosphorylation by 
phosphatases (Randall et al, 2002), (ii) ubiquitination and proteasomal degradation (Shi 
& Massagué, 2003), and (iii) histone phosphorylation and consequent changes in gene 
architecture (Shi & Massagué, 2003).  
TGF-β1-induced EMT is not only a consequence of Smad-dependent pathways 
but also of so-called Smad-independent TGF-β1 signalling. Other pathways activated by 
TGF-β include mitogen-activated protein kinases (MAPKs), ERKs 1/2, JNK, and p38, along 
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with NF-κB, TAK-1 and PI3-K/Akt signalling, which together may tune TGF-β1-driven 
Smad responses and hence EMT. TGF-β1 activated Smads are firmly controlled by a 
network of pathways that can modulate the initial Smad wave and contribute to the 
diversity of TGF-β1 effects (Derynck & Zhang, 2003; Massagué, 2000). Thus, ERKs 1/2, 
JNK, NF-κB and TAK-1 appear to contribute to TGF-β1-triggered EMT (Strippoli et al, 
2012; Strippoli et al, 2008), while p38 signalling has been shown to antagonize TGF-β1-
effects via ERKs 1/2, NF-κB and TAK-1 activity modulation (Strippoli et al, 2010). It is 
therefore, the integration of these complex signals in context which ultimately 
determines cellular responses to TGF-β1 stimulus.  
1.4.2. TGF-β1 effects in context 
TGF-β1 signalling is involved in the control of (i) cell proliferation, (ii) apoptosis, 
(iii) fibrosis and scar formation, (vi) immune response regulation, (v) angiogenesis, and 
(vii) epithelial to mesenchymal transition (EMT). The signalling machinery underlying the 
different scenarios enumerated above is fundamentally the same. Specific cellular 
context and phenotype are a key component in shaping pathway outcome.  
1.4.2.1. (i) Cell proliferation control 
For most cells including, epithelial, endothelial, myeloid and lymphoid, TGF-β is 
a negative regulator of cell proliferation. TGF-β1 proliferative-regulatory mechanisms 
are the result of a combination of cooperative Smad-dependent gene responses, 
comprising (i) transcriptional activation of cyclin-dependent kinase (CDK) inhibitors 
(Toyoshima & Hunter, 1994) and (ii) c-Myc downregulation and inhibition (Pietenpol et 
al, 1990). CDKs regulate the cell cycle and are tightly controlled via cyclins and CDK 
inhibitors (CKIs), which act by enhancing or limiting CDKs activity respectively. In human 
peritoneal MCs TGF-β1 induces the expression of two CKIs, p21CIP1 and p27KIP1 (Ksiazek 
et al, 2007). Enhanced p21CIP1 and p27KIP1 expression impedes cyclin-CDK association 
blocking G1 phase progression. On the other side, c-Myc regulates cell cycle via gene 
transcription regulation including cyclin-D and transcription factor E2F, which are also 
involved in G1 to S transition as well as transcriptionally repressing p21CIP1 and p27KIP1.  
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1.2.5.2. (ii) Apoptosis 
TGF-β1 has also been shown to induce apoptosis, or programmed cell death, in 
numerous cell types. TGF-β1 pro-apoptotic regulatory mechanisms are a result of TGF-
β1’s capacity to activate genes triggering apoptosis. In MCs, TGF-β1 may induce 
apoptosis via connective tissue growth factor (CTGF) (Szeto et al, 2006) or Smad2 (Lv et 
al, 2012) mediation of Bax expression up-regulation and down-regulation of anti-
apoptotic Bcl2 gene expression. Nevertheless, these studies do not show strong 
evidence for a predominant proapoptotic effect of TGF-β1 and further confirmatory 
research is needed in the particular context of PMCs.  
1.2.5.3. (iii) Angiogenesis 
The term angiogenesis describes the development of capillaries from blood 
vessels during physiological and pathological processes comprising embryonic 
development, wound healing and tumour growth. This process is controlled by different 
cytokines and growth factors, including TGF-β1. TGF-β1 drives VEGF expression in 
vascular endothelial cells (Ferrari et al, 2006; Hicklin & Ellis, 2005). VEGF is involved in 
angiogenesis and activates tyrosinase kinase receptors 1 (VEGFR-1) and 2 (VEGFR-2) 
(Hicklin & Ellis, 2005). VEGF, VEGFR-1 and VEGFR-2 are necessaries for angiogenesis and 
their lack has been associated with embryonic lethality (Carmeliet et al, 1996).  
In the peritoneum, TGF-β1 overexpression leads to enhanced VEGF expression, 
angiogenesis and ultrafiltration failure (Margetts et al, 2013; Margetts et al, 2001). Local 
VEGF production is increased during PD treatment and has been associated with 
peritoneal angiogenesis and long-term technique failure (Aroeira et al, 2005). It has 
been suggested that mesenchymal MCs can produce VEGF in vitro and contribute to 
angiogenesis increasing local VEGF levels (Aroeira et al, 2005). Indeed, TGF-β1 is a well-
known inducer of mesenchymal MCs transformation that has been shown to increase 
VEGF expression in primary peritoneal MCs and pleural Met5A cell line (Young et al, 
2015).  
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1.2.5.4. (iv) Immune response regulation 
TGF-β1 is the TGF-β isoform that is principally expressed in the immune system. 
TGF-β1−/− mice manifested multiple foci of inflammation which associated with up-
regulated cytokine generation (Kulkarni et al, 1993). Nevertheless, TGF-β1 pleiotropism 
obscured specific and direct immune cells that were cytokine targets. Mice expressing 
TGF-βRII−/− under a CD4 promoter in T cells (hence exhibiting abrogation of TGF-βRII in 
CD4+ and CD8+ T cells) developed an autoimmune response triggered by non-controlled 
CD4+ T-cell differentiation into effector cells (Gorelik & Flavell, 2000). Clinically, these 
observations resemble those noticed in some Sézary disease patients in which CD4+ T 
cells display low TGF-βRII expression, triggering an enhanced uncontrolled T cell 
proliferation (Capocasale et al, 1995). In vitro, TGF-β1 prevents activation and 
differentiation of naïve T cells abolishing Th1 and Th2 cytokine production (Lúdvíksson 
et al, 2000). TGF-β1 can differentiate CD4+CD25− T cells into Tregs (Chen et al, 2003) and, 
together with Il-17, iTreg into pro-inflammatory Th17 cells in vitro. TGF-β1 also regulates 
macrophage and monocyte proliferation, chemo-attraction, enhances monocytic 
cytokine expression and phagocytic macrophage capacity.  
1.2.5.5.  (v) Fibrosis and Scarring 
After injury, wound healing is controlled by multiple pro-fibrotic and anti-fibrotic 
cytokines and factors. Among them, TGF-β1 is considered to be a key fibrotic response 
mediator. Indeed, TGF-β1 deficient mice present defective wound repair, comprising 
low re-epithelialization and collagen synthesis (Böttinger et al, 1997). Complete TGF-β1 
knockout mice displayed critical weight loss, general inflammatory response and tissue 
necrosis with consequent organ failure and death (Kulkarni & Karlsson, 1993). In the 
peritoneum, TGF-β1 stimulates fibroblasts and mesenchymal cells to proliferate and 
generate ECM contributing to the fibrotic response, both in vivo and in vitro. Similarly, 
TGF-β1 inhibits the synthesis of matrix-metalloproteinases (MMPs), enzymes degrading 
ECM components, and enhances tissue inhibitor metalloproteinases (TIMPs) and 
Plasminogen activator inhibition (PAI-1). CTGF is a cytokine released by MCs upon TGF-
β1 stimulation (Leung et al, 2009), and a downstream mediator of pro-fibrotic signals on 
fibroblasts (Grotendorst, 1997). TGF-β1 also induces MCs epithelial to mesenchymal 
transformation, which contributes to fibrosis and wound healing. 
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1.2.5.6. (vi) Epithelial to mesenchymal transition (EMT) 
Epithelial to mesenchymal transition (EMT) is a cellular mechanism that permits 
a polarized epithelial cell to experience complex biochemical alterations leading to 
mesenchymal cell phenotype conversion. The molecular changes occurring during this 
transformation include (i) activation/inhibition of transcription factors, (ii) 
expression/repression of particular cell surface proteins, (iii) cytoskeletal 
rearrangements, (iv) production of ECM degradative enzymes, and (v) specific miRNA 
expression. These changes lead to the acquisition of new cellular abilities comprising (i) 
increased migratory capability, (ii) invasiveness, (iii) anti-apoptosis, and (iv) elevated 
ECM expression.  
EMT is a highly complicated and regulated process that entails structural and 
molecular rearrangements orchestrated by a particular expression regulation (Aguilera 
et al, 2005; Aroeira et al, 2007). This process is initiated with the loss of inter-cellular 
junctions and down-regulation of adhesion molecules followed by front-back polarity 
rearrangements, α-SMA expression acquisition, and enlarged migratory capabilities. 
Down the line, cells acquire the ability to degrade the basal membrane up-regulating 
matrix metalloproteinases (MMPs) expression and invading the submesothelial 
compartment. EMT culmination is achieved via basement membrane disruption and 
mesenchymal cell migration from its original location. 
EMT in physiological contexts 
The principle of cellular division as a mechanism to increase cell numbers 
generating tissues and organs was raised 150 years ago (Virchow, 1858). Pivotal in this 
inference was the comprehension that whole body cells raised from a unique cell, the 
zygote. This concept established the basis to sequentially understand that (i) cells adopt 
different phenotypic status through development, (ii) specific adult epithelial cells are 
plastic and maintain the ability to develop late EMT processes, or (iii) to develop a 
reverse process called mesenchymal to epithelial transition (MET), and (iv) terminally 
differentiated cells can also activate an EMT program depending on microenvironment 
stimulus (Kalluri & Weinberg, 2009; Lamouille et al, 2014). Thus, EMT mechanisms are 
now classified into three different subtypes: (type 1) implantation, embryogenesis and 
organ development; (type 2) tissue regeneration and organ fibrosis, and (type 3) cancer 
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progression and metastasis (Kalluri & Weinberg, 2009). The particular signals that 
determine each specific EMT are not well defined yet but TGF-β1 signalling has been 
involved in all these processes.  
Type 1: Implantation, embryogenesis and organ development 
Specifically, TGF-β1 has been shown to play critical roles in EMT associated to 
cardiac valve development as indicated by knockout mice (Mercado-Pimentel & Runyan, 
2007). Moreover, TGF-β superfamily members have been involved as key molecules 
triggering EMT during most morphogenetic events (Yang & Weinberg, 2008). TGF-β1 
superfamily control of vertebrate embryonic development includes (i) mesoderm 
formation (Nodal), (ii) neural crest formation (BMP), (iii) cardiac valve formation (TGF-
β1, 2, 3, BMP), and (iv) secondary palate formation (TGF-β3) (Yang & Weinberg, 2008).  
Type 2: Tissue regeneration and organ fibrosis 
This mechanism starts as a repair-related episode triggered after trauma, injury 
and/or via an inflammatory microenvironment, causing an increase in EMT, ECM 
expression and organ fibrosis. Perpetuation of the EMT process may be subsequently 
controlled by local inflammation, ending with inflammatory signal reduction and, 
conversely, leading to tissue fibrosis and organ destruction under persistent 
inflammation. EMT type 2 has been described in kidney, liver, lung and peritoneum and 
was highlighted via transgenic mice (Margetts et al, 2013). More broadly, TGF-β1 has 
been described to be a major inducer of EMT in kidney, liver, biliary tract, lung and 
peritoneum (Kasai et al, 2005; Margetts et al, 2013; Nitta et al, 2008; Zeisberg et al, 
2003). 
Type 3: Cancer progression and metastasis 
Cancer acquisition of invasiveness capabilities has also been linked to cellular 
EMT program activation. In this context, TGF-β1 is a relevant inhibitor of cell 
proliferation and primary tumorigenesis (Bierie & Moses, 2006). Nevertheless, TGF-β1 
has also been described to be elevated in particular cancer types during late stages 
contributing to induce EMT program (Bierie & Moses, 2006; Padua & Massagué, 2009).
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1.5. MMT in peritoneal dialysis 
MCs have a mesodermal genesis and possess features from epithelial, 
mesenchymal and endothelial cells. Consequently, some authors suggested adapting 
the classical ‘EMT’ terminology for the particular mesenchymal MCs conversion by a 
more adequate term: mesothelial to mesenchymal transition (MMT). The first 
description of MMT in PD patients was shown by Yáñez-Mó et al. 2003, who identified 
this conversion in peritoneal tissue and PD effluent derived cells (Yáñez-Mó et al, 2003). 
Studies undertaken at that time described that omentum-derived MCs treated with TGF-
β1 in vitro acquired myofibroblastic characteristics by an MMT-like process (Yang et al, 
2003). Mesenchymal MCs have higher migratory and invasive capabilities, allowing 
them to infiltrate the submesothelial stratum (Aroeira et al, 2007; Yáñez-Mó et al, 2003). 
Indeed, peritoneal biopsies from PD patients manifest the existence of submesothelial, 
fibroblast-like, cells expressing cytokeratins, E-cadherin and ICAM-1 which are 
characteristic MCs markers (Aroeira et al, 2007; Jiménez-Heffernan et al, 2004). In these 
biopsies, α-SMA expression was particularly patent in the higher-submesothelial stroma 
where often co-stained with cytokeratins (Jiménez-Heffernan et al, 2004).  
MCs transformation was determined in an in vivo rodent model of 
intraperitoneal adenoviral vector driving the active form of TGF-β1 (Margetts et al, 
2005). In this model TGF-β1 induced peritoneal fibrosis, characterized by accumulation 
of α-SMA positive interstitial cells, neoangiogenesis and increased peritoneal membrane 
solute transport (Margetts et al, 2005; Margetts et al, 2001). Consistently, an in vivo 
Smad3 knockout mouse model showed peritoneal fibrosis protection with lower 
collagen deposition and reduced MMT, indicating Smad2/3 signalling importance during 
TGF-β1-driven MMT (Patel et al, 2010a). Indeed, Smad7-triggered Smad2/3 inhibition 
stops MMT and decreases peritoneal fibrosis (Shi & Massagué, 2003; Weiskirchen & 
Meurer, 2013). Smad2/3 pathway inhibition mediated by hepatocyte growth factor 
(HGF) and BMP-7 has also been associated with MMT blockage (Loureiro et al, 2010; Yu 
et al, 2009). Briefly, HGF up-regulates the expression of SnoN and TG-interacting factor 
(TGIF), two transcriptional co-repressors that bind activated Smad2/4 and Smad3/4, 
repressing Smad-mediated transcription (Dai & Liu, 2004; Tan et al, 2007; Yang et al, 
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2005). Additionally, BMP-7 stimulates Smad1/5/8 signalling which antagonizes TGF-β1-
induced Smad2/3 and downstream MMT (Loureiro et al, 2010; Weiskirchen & Meurer, 
2013).  
In vivo, MMT arises from the combination of multiple signals, initiated by 
different factors, which increases the difficulty in defining an order or classification of 
events (Aroeira et al, 2007; Selgas et al, 2006). These molecules bind to specific cellular 
receptors and stimulate different intricate signal transduction networks including TGF-
β1, integrin-linked kinase (ILK), notch, phosphatidylinositol-3-kinase (PI3K)/Akt and the 
mammalian target of Rapamycin (mTOR) (PI3K/Akt/mTOR), extracellular signal-
regulated kinases 1/2 (ERKs1/2), TGF-β-activated kinase-1 (TAK-1) and c-jun-N-terminal 
kinase (JNK) signalling pathways. These networks coordinate the loss of inter-cellular 
adhesion structures, cytoskeletal rearrangements and the gain of migratory and invasive 
capabilities characteristics of the MMT process (Aroeira et al, 2007; Patel et al, 2010a; 
Selgas et al, 2006; Strippoli et al, 2012; Zhu et al, 2010). Thus, TGF-β1-induced MMT does 
not only act via Smad-dependent pathways but also via so-called Smad-independent 
TGF-β1 signalling. Consequently, TGF-β1-associated peritoneal MMT occurs as a 
consequence of Smad-dependent and -independent signalling, indicating the possible 
need of abolishing both signals to block MMT. 
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1.5.1. Origin of peritoneal myofibroblasts during peritoneal dialysis: an 
open debate  
Myofibroblasts, or activated fibroblasts, may be broadly characterized as the 
major effector cells of fibrosis. Myofibroblast differentiation is induced by cytokines, 
including TGF-β1, and characterized by α-SMA expression. The term myofibroblast 
designates a particular type of activated fibroblast, with cellular characteristics halfway 
between those of fibroblasts and of smooth muscle cells. The first description of 
myofibroblasts came from Gabbiani et al. 1972, who identified them in different models 
of open wounds (Gabbiani et al, 1972). Today, myofibroblasts have been implicated in 
practically all remodelling and healing contexts, and are recognised as key protagonists 
in human pathologies. Their crucial role in wound healing and tissue remodelling 
includes synthesis of extracellular matrix components, growth factors and cytokines, 
guiding the tissue inflammatory response, and physical remodelling of the tissue via 
their contractile capabilities. 
The source of myofibroblasts is a polemic topic in kidney research (Fragiadaki & 
Mason, 2011; Grgic et al, 2012; Humphreys et al, 2010; Kriz et al, 2011; LeBleu et al, 
2013; Quaggin & Kapus, 2011; Zeisberg & Duffield, 2010). Overall, in kidney, there is 
little evidence that renal epithelial cells migrate to the interstitium and become 
myofibroblasts in vivo (Humphreys et al, 2010). Nevertheless, proximal tubular epithelial 
cells (PTECs) have been shown to display mesenchymal characteristics and become local 
producers of collagens as part of their response to injury. Additionally, kidney 
myofibroblasts have been described to arise from different extra-renal sources including 
local resident cells, bone-marrow derived cells, endothelial cells via EnMT and pericytes 
(Humphreys et al, 2010; LeBleu et al, 2013). Their specific contribution is currently 
subject to intense research. A possible explanation for the lack of PTECs full EMT 
reported in these observations may be that the chronic, slow-developing human disease 
process, in which cycles of epithelial injury and healing can alternate is more prone to 
mobilize the EMT program rather than acute and robust UUO models. Nevertheless, it 
is commonly recognized that myofibroblasts comprise a diverse cell population that may 
arise from several origins, which may differ between organs and/or through organ areas. 
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Therefore, traditional extrapolation of conclusions from kidney fibrosis research studies 
into the peritoneal fibrosis field should be avoided. Instead, the aforementioned 
literature emphasizes the importance of particular tissue and organ microenvironments 
governing the distinct contributions and origins of myofibroblast subpopulations.  
Myofibroblastic origin of cells during peritoneal fibrosis associated to PD therapy is also 
a controversial question that can be divided into three different hypothesis. 
Hypothesis 1:  
Mesothelial cells are the source of myofibroblasts associated to PD therapy 
fibrogenesis 
Long-term exposure of peritoneal mesothelial cells to non-biocompatible PD 
solutions during dialysis therapy induces peritoneal injury, MMT and myofibroblastic 
conversion (Margetts et al, 2005; Yáñez-Mó et al, 2003). This transition is characterized 
by a loss of epithelial morphology and markers, including cytokeratin and E-cadherin, 
accompanied by an increase in migratory phenotype and mesenchymal markers, such 
as snail and α-SMA expression. Although the MMT is a progressive step-wise process, 
ultimately, MCs may completely switch to myofibroblasts or active fibroblasts losing any 
possible trace of their initial identity (Margetts et al, 2005). Indeed, TGF-β1 and LacZ 
adenoviral gene co-administration to pleural rat mesothelium induced pleural fibrosis 
and progressive mesothelial cell migration into the fibrotic tissue (Decologne et al, 
2007).  
Hypothesis 2: 
Submesothelial fibroblasts cells are the source of myofibroblasts associated to PD 
therapy fibrogenesis 
Long term PD treatment induces peritoneal fibrogenesis where the major 
precursors of myofibroblasts are submesothelial fibroblasts (Chen et al, 2014). This 
hypothesis is supported by in vivo genetic lineage analysis in which MCs (Cyto+) were 
labelled via red florescence protein (RFP) expression employing Wilms tumor-1 homolog 
(Wt1)-CreERT2 mice. Different peritoneal fibrosis mouse models showed MCs 
(Cyto+/RFP+) did not significantly contribute to the myofibroblast population during 
fibrogenesis (Chen et al, 2014). Nevertheless, it is important to mention that mesothelial 
cell MMT cannot be completely disqualified by the Chen et al. 2014 study due to genetic 
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labelling weaknesses. Indeed 24% of all peritoneal RFP+ cells were Wt1+/RFP+ while only 
65% of submesothelial fibroblasts were label-tracked (Chen et al, 2014). Additionally, 
the Wt1-CreERT2 mice model used for the study is not peritoneal MCs specific as Wt1+ 
precursor cells may differentiate to MCs, submesothelial cells, hepatic stellate cells and 
perivascular mesenchymal cells in liver models using analogous lineage tracing 
approaches (Asahina et al, 2011; Li et al, 2013). Indeed, the liver models above 
mentioned showed MCs (Wt1+) were able to contribute to the myofibroblast population 
via MMT (Asahina et al, 2011; Li et al, 2013). Ultimately, Chen et al. 2014 also showed 
that MCs (Cyto+) were significantly labelled in a Col1a1-GFP transgenic reporter mice 
(Col1a1-GFPTg) after hypochlorite injury and AdTGF-β1 intraperitoneal injection (Chen 
et al, 2014). Despite the fact that Cyto+ cells did not show migration or α-SMA 
expression, collagen expression in injured MCs indicated fibrotic phenotype transition. 
Indeed, this observation is consistent with Patel et al. 2010 who identified a ‘non-
invasive peritoneal MMT process’ characterized by the presence of activated, collagen 
and growth factor producing, MCs which were not transformed into submesothelial 
myofibroblasts but critically contributed to peritoneal fibrosis (Patel et al, 2010b). 
Therefore, it will still be crucial to replicate these data in more clinically relevant animal 
models using specific peritoneal MCs labelling before drawing conclusions from this 
single study. 
Hypothesis 3: 
Myofibroblasts came from multiple sources during PD therapy fibrogenesis 
This last hypothesis integrates the prior hypotheses with compelling data for 
diverse myofibroblast origins during peritoneal fibrosis including (i) mesothelial cell 
MMT differentiation (Cyto+/FSP-1+), (ii) bone-marrow-derived circulating cells or 
fibrocytes (CD45+/FSP-1+), (iii) endothelial to mesenchymal (EnMT) conversion 
(CD31+/FSP-1+), and (iv) activated resident interstitial fibroblasts (-/FSP-1+) (Herlihy et al, 
2015; Loureiro et al, 2011). The specific contribution of each myofibroblastic source is 
obscure in human patients and the only population percentage data published come 
from a PD mouse model in which MMT (Cyto+/FSP-1+, 37%), fibrocytes (CD45+/FSP-1+, 
34%), EnMT (CD31+/FSP-1+, 5%), and resident fibroblasts (-/FSP-1+, 24%) contributed to 
fibrosis (Loureiro et al, 2011). Thus, although there is controversy regarding 
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myofibroblast relative source contributions, mesothelial cells are suggested to be the 
predominant origin of myofibroblasts associated to fibrosis in PD treatment and 
therefore were the focus for this study.  
As well as the stimuli leading to fibrosis and the source of myofibroblasts, a third 
key question are the downstream regulatory molecules responsible for changes in 
cellular behaviour and hence tissue remodelling. miRNAs are an important class of 
downstream regulator that are strongly implicated as effectors of TGF-β1 responses in 
other contexts, but have not previously been examined in depth in peritoneal fibrosis or 
in mesothelial cells. miRNAs are short non-coding RNAs that regulate gene expression 
at the post-transcriptional level. Aberrant miRNA levels associated with PD therapy may 
affect the regulation of a multitude of mRNA species resulting in significant cellular 
effects including mesothelial cell MMT process. Indeed, recent studies suggest that 
miRNAs are likely to be important in the regulation of mesothelial cell phenotype and 
homeostasis in the peritoneal cavity during PD therapy (Chen et al, 2012a; Zhang et al, 
2012). Consequently, miRNA alterations associated with PD therapy may be valuable in 
understanding peritoneal cavity changes and predicting the clinical course of PD 
patients.  
1.6. miRNA Discovery 
miRNAs were initially discovered in C. elegans as critical developmental 
regulators over two decades ago (Lee et al, 1993; Wightman et al, 1993). Victor Ambros 
and his colleagues identified lin-4, a gene important in C. elegans larval development 
that did not encode a protein but two transcripts of 61 and 22 nt. Lin-4 mutants were 
restrained by first larval stage (L1) not being able to reach the adult form. Conversely, 
the lin-14 gene was known to contribute to cell lineage differentiation by specific 
temporal-graded activity. Subsequently, lin-4 was shown to act as negative regulator of 
LIN-14 protein level, originating a timely reduction in LIN-14 after L1 stage (Lee et al, 
1993; Wightman et al, 1993). In their original descriptions of this phenomenon, the 
authors suggested that small lin-4 transcripts enclosed sequences matching with 
repeated elements in the 3’ untranslated region (UTR) of lin-14 mRNA, indicating that 
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lin-4 controls lin-14 translation through partial RNA complementarity (Lee et al, 1993; 
Wightman et al, 1993). Further analysis of lin-4 transcripts revealed that the longer 
transcript (61 nt) was predicted to stem loop fold which was suggested to act as a 
precursor of the shorter lin-4 transcript (22 nt) that also exhibited lin-14 mRNA antisense 
complementarity (Lee et al, 1993). 
A seven-year gap then occurred before the next key ncRNA discovery. In 2000, 
Reinhart and Slack identified let-7, a gene important in C. elegans larval development 
which encoded a 21 nt ncRNA complementary to the 3’UTR of different genes including 
lin-14, lin-28, lin-41 and daf-12 (Reinhart et al, 2000; Slack et al, 2000). Let-7 loss caused 
persistence of larval cell fates in adult stages while let-7 up-regulation showed 
development of adult fates in larval stages indicating let-7 regulation of temporal 
developmental processes (Reinhart et al, 2000; Slack et al, 2000). Let-7 conservation 
analysis demonstrated that it was highly conserved in a wide range of animal species, 
indicating that let-7 regulation may broadly contribute to control temporal transitions 
in development (Pasquinelli et al, 2000).  
miRNA post-transcriptional gene regulation has been described in animals, 
plants, bacteria and viruses (Bartel, 2004; Pfeffer et al, 2004; Shmaryahu et al, 2014). 
The term miRNA was established in 2001 (Ruvkun, 2001). Since then, alterations in 
miRNA expression have been described in a wide range of in vitro and in vivo models 
(Landgraf et al, 2007). miRBase 21 (June 2014) is the main miRNA database and 
considers a total number of 1881 human miRNAs precursors and 2588 mature 
sequences (Kozomara & Griffiths-Jones, 2014). Last miRBase version deleted duplicated, 
dubious and mis-annotated miRNA sequences (Kozomara & Griffiths-Jones, 2014). 
Certainly, the increase in high throughput sequencing studies will further continue 
updating miRBase ‘high confidence’ datasets to identify new important miRNAs 
contributing to post-transcriptional cell regulations.  
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1.6.1. miRNA biogenesis and regulatory functions 
miRNAs can be located in their own genes (intergenic) or in introns and exons of 
protein coding genes (intronic). Intergenic miRNAs are controlled by independent 
promoters while intronic miRNAs can be controlled by the host gene promoter or by 
their own promoter (Lagos-Quintana et al, 2001; Ramalingam et al, 2014; Wang et al, 
2009). In addition, miRNAs can also occupy nearby positions called genomic clusters 
which are co-regulated and expressed via a common primary transcript (pri-miRNA) unit 
(Altuvia et al, 2005). A recent paper also identifies that intronic miRNAs clusters can be 
independently utilized via alternative splicing, leading to generation of different pri-
miRNAs (Ramalingam et al, 2014).  
miRNAs biogenesis begins in the nucleus where these small RNAs are transcribed 
by the RNA polymerase (Pol II) or Pol III enzyme (Borchert et al, 2006; Lee et al, 2004) as 
a long, poly-adenylated primary miRNA (pri-miRNA) molecule (Lee et al, 2002). The pri-
miRNA transcript is a single stranded RNA of a few thousand nt with a stem-loop 
structure that is processed by a protein complex called ‘microprocessor’. The 
microprocessor is composed by Drosha, a nuclear RNase III endonuclease; DiGeorge 
syndrome critical region gene 8 (DGCR8) cofactor that assists Drosha in pri-miRNA 
recognition to generate a precursor miRNA (pre-miRNA) and other regulatory factors 
including p68 and p72 (Lee et al, 2003). Of note, intronic-coded miRNAs that are 
transcribed as part of precursor mRNA (pre-mRNA) molecules are processed via pre-
mRNA splicing to produce the miRNA in a manner that is not fully understood yet 
(Macfarlane & Murphy, 2010).  
Pre-miRNAs are 60-70 nt stem-loop hairpin molecules that are actively 
transported to the cytoplasm by export receptor Exportin-5 and a Ran-GTP (Grishok et 
al, 2001; Yi et al, 2003). In this complex, Exportin-5 stabilizes nuclear pre-miRNA 
impeding its degradation and assists in pre-miRNA translocation to the cytoplasm while 
Ran-GTP to Ran-GDP hydrolysis allows pre-miRNA release once in the cytoplasm 
(Grishok et al, 2001; Yi et al, 2003).  
miRNA/miRNA* duplexes (~22-25 nt) are generated by Dicer complex, a 
cytoplasmic RNase III that cleaves pre-miRNA into a small double stranded RNA duplex 
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(Bernstein et al, 2001). Dicer complex contains a long N-terminal ATPase/Helicase 
domain, a DUF283 domain, two C-terminal tandem RNase III nuclease domains and a 
Piwi, Argonaute and Zwille (PAZ) domain, named after three proteins that bind the 3’ 
end of small RNAs (Bernstein et al, 2001). One single mature miRNA stand is 
preferentially incorporated into the RNA-induced silencing complex (RISC). The RISC 
complex contains the trans-activating response RNA-Binding Protein (TRBP) that recruits 
Argonaute 2 (AGO2) and other proteins (Chendrimada et al, 2005). Initially, it was 
thought that RISC-loaded the miRNA strand that had lowest 5’ terminal thermodynamic 
stability while the partner strand was degraded. Nevertheless, different studies have 
challenged this hypothesis, showing that the partner strand can also target mRNAs via 
RISC complex incorporation (Finnegan & Pasquinelli, 2013).  
miRNA-RISC complex binds to 3’ un-translated regions (3’UTRs) of specific target 
genes by partial complementarity, which results in repression of translation and/or 
degradation of the target mRNA (Pasquinelli, 2012). Both regulatory systems require the 
presence of one of the Ago proteins. These proteins contain four domains: (i) N-
terminal, (ii) PAZ (Piwi-Argonaute-Zwille) domain which hooks the 3’ end of the selected 
miRNA, (iii) MID domain which has large 5’ miRNA end specificity and terminal four 
bases discrimination capacity, and (iv) a PIWI element which has endonuclease activity, 
mediating RNA cleavage (Kim et al, 2009). The mRNA degradation process is mediated 
via miRNA-mRNA partial Watson-Crick base pair complementarity, in which the 5’ 
miRNA nucleotides in the 2nd to 8th positions, termed the seed sequence, are especially 
important (Bartel, 2009). mRNA degradation takes place via AGO2-mediated 
endonucleolytic cleavage (Gu & Kay, 2010) or deadenylase-mediated mRNA poly(A) tail 
removal stimulated by partial miRNA complementarity (Wu & Belasco, 2008).  
miRNAs control the expression of the majority of protein coding genes in the 
human genome, thereby affecting most biochemical pathways implicated in cellular 
homeostasis. Additionally, one miRNA may regulate the expression of hundreds of 
target mRNAs, profoundly affecting cell phenotype and function. Studies on miRNA 
expression in different model systems and body fluids have also emphasized their 
potential as therapeutic targets and disease biomarkers (Brown & Naldini, 2009; Cortez 
et al, 2011; Kota et al, 2009; Turchinovich et al, 2011) (Figure 1.4 and 1.5A). 
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 Figure 1.4. miRNA biogenesis and 
ribonucleoprotein complexes assembly. 
miRNAs are transcribed as precursor 
molecules (pri-miRNAs) from independent 
miRNA genes or protein-coding introns. 
Individual pri-miRNA may comprise various 
different miRNAs and fold into stem-loop 
structures that are processed in two steps 
catalysed by the RNase III type endonucleases 
Drosha and Dicer as a part of larger protein 
complexes containing additional accessory 
proteins. Drosha complex processes pri-
miRNAs to ~70nt hairpins called pre-miRNAs 
which are transported to the cytoplasm by 
Exportin5 where they are further processed 
by Dicer complex to ~20pb miRNA duplexes. 
miRNAs are assembled into ribonucleoprotein 
(RNP) complexes which contain Argonaute 
(AGO) proteins and are essential for inducing 
miRNA mediated repression (Modified from 
Filipowicz et al, 2008). 
 
 
1.6.2. miRNAs in TGF-β1 signalling and EMT processes 
TGF-β1 alters miRNA expression via R-Smad (i) intronic or intergenic 
transcriptional miRNA regulation, and (ii) promoting Drosha association with miRNA 
containing SMAD binding elements (SBE) hairpins and miRNA maturation (Davis et al, 
2008; Davis et al, 2010). On the other hand, miRNAs can also regulate TGF-β1 signalling 
via direct interaction with (i) downstream members of the pathway, and (ii) TGF-β1 
target genes. This section reviews some of the best-described examples of miRNAs that 
are induced downstream TGF-β1 signalling and are known to contribute to the EMT 
process to highlight the importance and potential of miRNAs controlling mesenchymal 
cell fate (Table 1.4).   
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miRNA Target Function References 
miR-200 family  
(miR-200a, b, 
c, miR-141,  
miR-429) 
ZEB1, 
ZEB2, 
SIRT 
TGF-β1 down-regulates all miR-200 
members allowing ZEB1 and ZEB2 
accumulation, which are two E-cadherin 
transcriptional repressors. miR-200a also 
targets SIRT1 affecting epigenetic EMT 
regulation and promotion. 
(Gregory et al. 2008;  
Eades et al. 2011) 
miR-205 ZEB1, ZEB2 
TGF-β1 down-regulates miR-205 allowing 
ZEB1 and ZEB2 accumulation, which are 
two E-cadherin transcriptional repressors 
and promoting EMT. 
(Gregory et al. 2008) 
miR-192 
ZEB1, 
ZEB2 
TGF-β1 down-regulates miR-192 allowing 
ZEB1 and ZEB2 accumulation, which are 
two E-cadherin transcriptional repressors 
and promoting EMT. 
(Krupa et al. 2010) 
miR-155 RHOA 
TGF-β1 up-regulates miR-155 decreasing 
RHOA protein levels contributing to cell 
migration, cytoskeletal re-organization 
and promoting EMT. 
(Kong et al. 2008) 
miR-491-5 PAR3 
TGF-β1 up-regulates miR-491-5 
decreasing PAR3 protein levels which are 
critical for the integrity of the tight 
junctions and promoting EMT. 
(Zhou et al. 2010) 
miR-10b HOXD10 
TGF-β1 up-regulates Twist and 
downstream miR-10b decreasing 
HOXD10 protein levels which is a critical 
transcripiton factor regulating 
invasiveness and metastasis. 
(Ma et al. 2007) 
miR-24 NET1A 
TGF-β1 up-regulates miR-24 decreasing 
NET1A protein levels, a RHO-GEF that 
activates RHOA. 
(Papadimitriou et al. 2012) 
miR-21 
PDCD4, 
SPRY1, 
TIAM1, 
PTEN, 
etc. 
TGF-β1 up-regulates miR-21 decreasing 
PDCD4, SPRY1, TIAM1, PTEN protein 
levels which are implicated in EMT 
processes. 
(Asangani et al. 2008; Yao et al. 
2011; Thum et al. 2008; Brᴓnnum et 
al. 2013; Cottonham et al. 2010; 
Meng et al. 2007; Dey et al. 2012) 
miR-31 
TIAM1, 
LATS2, 
STK40, 
etc. 
TGF-β1 up-regulates miR-31 decreasing 
TIAM1, LATS2 and STK40 protein levels, 
which are implicated in EMT, G1/S cell 
cycle inhibition, and cytokine 
/chemokine expression. 
(Cottonham et al. 2010;  
Liu et al. 2010;  
Xu et al. 2013) 
Table 1.4. miRNAs in TGF-β1 signalling and EMT processes. (Table summarizing section 1.6.2.). 
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TGF-β1 downregulates miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 
and miR-429), miR-205 and miR-192 allowing Zinc finger E-box binding homeobox 1 
(ZEB1) and ZEB2 accumulation, two miRNA downstream targets involved in E-cadherin 
transcriptional repression (Gregory et al, 2008; Krupa et al, 2010). TGF-β1 driven miR-
200a downregulation also triggers histone deacetylase silent information regulator-1 
(SIRT1) overexpression, implicated in E-cadherin gene silencing (Eades et al, 2011).  
TGF-β1 facilitates tight junction and cell polarity loss via miRNA up-regulation, 
including miR-155 and miR-491, which target RHOA and polarity protein PAR3 
respectively (Kong et al, 2008; Zhou et al, 2010). Additionally, RHOA signalling is TGF-β1 
regulated via miR-24 increase, which targets neuro-epithelial cell-transforming-1A 
(NET1A) that activates RHOA (Papadimitriou et al, 2012). TGF-β1 also up-regulates miR-
10b via Twist transcription factor; and inhibits homeobox D10 (HOXD10) transcription 
factor increasing RHOC mediated invasiveness and metastasis (Ma et al, 2007).  
miR-21 and miR-31 were the most strongly induced miRNAs in a three dimension 
colon EMT model triggered by TGF-β1. Both miRNAs were found to regulate the 
expression of T-lymphoma invasion and metastasis 1 (TIAM1), a guanine nucleotide 
exchange factor (GEF) for the Rac GTPase that has been implicated in cell invasion 
(Cottonham et al, 2010). TGF-β1 is known to promote an EMT process while up-
regulating miR-21 in a wide spectrum of cell types. Between the numerous validated 
miR-21 targets by several independent groups it is important to mention that miR-21 
can down-regulate tumour suppressor (i) programmed cell death protein 4 (PDCD4) 
(Asangani et al, 2008; Brønnum et al, 2013; Yao et al, 2011); (ii) Sprouty homologue 1 
(SPRY1) (Brønnum et al, 2013; Thum et al, 2008); and (iii) phosphatase and tensin 
homolog (PTEN) (Dey et al, 2012; Meng et al, 2007) transcripts contributing to 
mesenchymal phenotype and stimulating cell motility, migration and invasion. PTEN has 
also being shown to be directly targeted by miR-216a and miR-217 downstream of TGF-
β1 stimulation (Kato et al, 2009). miR-31 has been less extensively studied but also 
described to target different important transcript molecules including (i) large tumor 
suppressor 2 (LATS2) (Liu et al, 2010), and serine/threonine kinase 40 (STK40) (Xu et al, 
2013) which have been involved in G1/S cell cycle transition, EMT processes and 
cytokine/chemokine expression respectively.  
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1.6.3. miRNA-changes during PD therapy 
The cellular homeostasis of the peritoneal cavity is dramatically affected during 
long-term PD therapy (Bos et al, 1991; Fernandez de Castro et al, 1994). Aberrant miRNA 
levels associated to PD therapy may affect the regulation of a multitude of mRNA 
species, resulting in significant cellular effects. In the context of PD, continuous dialysis 
fluid exchanges allows easy access to monitor peritoneal cells and miRNA expression in 
PD effluent (PDE), presenting the enticing possibility of monitoring peritoneal cavity 
homeostasis during PD treatment. Additionally, the development of micro-sample 
analysis techniques, together with structural and functional similarities of human 
peritoneal physiology compared with rodent models may permit in vivo scrutiny of PD 
characteristics (González-Mateo et al, 2009). 
Only two articles describing miRNAs in PD therapy were published before this 
research project started in September 2012 (Table 6.1) (Chen et al, 2012a; Zhang et al, 
2012). Chen et al. 2012 selected the following candidate miRNAs based on a report on 
EMT and kidney disease (Li et al, 2010): miR-15a, miR-17-92, miR-21, miR-30, miR-192, 
miR-216a, miR-217 and miR-377 (Chen et al, 2012a). Total PDE-derived cells from 110 
PD patients (82 new, 28 prevalent) showed significant miRNA up-regulation of miR-15a, 
miR-21 and miR-192 when comparing new, prevalent and UF failure while miR-17, miR-
30 and miR-377 expression was similar between groups (Chen et al, 2012a). miR-30 
significantly correlated with GFR and no detectable expression of miR-216a and miR-217 
was found in patient samples (Chen et al, 2012a). By contrast, Zhang et al. 2012 used 
their unpublished data of miRNA expression profiles in HPMCs of PD patients and 
HMrSV5 cells treated with TGF-β1 to focus their studies on miR-589 (Zhang et al, 2012). 
miR-589 down-regulation was confirmed in HPMCs from PD patients and HMrSV5 cells 
treated with TGF-β1, in which overexpression of miR-589 attenuated the MMT changes 
induced by TGF-β1 (Figure 1.5C) (Zhang et al, 2012).  
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1.6.4. miRNAs as biomarkers of the PD cavity during PD therapy 
miRNAs have shown a sound potential as biomarkers in several fields and are 
easy to detect in different body fluids in which may associate with proteins, 
microvesicles, exosomes or necrotic bodies (Kosaka et al, 2010). PDE-derived miRNAs 
may be particularly suitable as biomarkers due to their specific pattern of expression, 
potential for easy detection, stability, and reliability (Akat et al, 2014; Di Leva et al, 2014; 
Liang et al, 2007; Lorenzen et al, 2012). PD-miRNA research is in early stage but there is 
a particular interest regarding miRNA as biomarkers to help individualizing PD 
treatment. Few studies have investigated the role of microRNAs in the peritoneum as 
discussed previously (see 1.6.3, Figure 1.5C) and later (see Chapter 6, Figure 6.1, Table 
6.1), and have primarily focused on candidate miRNA evaluation (rather than unbiased 
profiling approaches) measuring miRNAs that may be associated with mesothelial EMT. 
These in vitro and murine models provide some association (Bao et al, 2015; Chen et al, 
2012a; Lin et al, 2015; Liu et al, 2015; Zhang et al, 2012; Zhang et al, 2013) and functional 
Figure 1.5 miRNA dysregulation in Peritoneal dialysis. (A) miRNA biogenesis pathway. miRNAs are 
transcribed by RNA polymerase (Pol II) or Pol III as primary miRNA (pri-miRNA) transcripts that are 
processed by Drosha to generate precursor miRNAs (pre-miRNAs). Pre-miRNA hairpins are 
transported by Exportin-5 to the cytoplasm, where mature miRNAs are generated by Dicer, and 
incorporated into the RNA-induced silencing complex (RISC). miRNA-RISC complexes bind to the 3’ 
un-translated regions (3’UTRs) of target mRNAs by partial complementarity, resulting in repression of 
translation and/or mRNA degradation. (B) Peritoneal mesothelial-to-mesenchymal transition (MMT) 
is associated with PD therapy. Healthy peritoneal mesothelial cells (PMCs; left hand side) undergo 
morphological changes during PD-driven MMT, invading the submesothelium where they contribute 
to to angiogenesis, fibrosis and increase extracellular matrix components (ECM) deposition during PD 
therapy (right hand side). (C) Dysregulated miRNA expression resulting from PD therapy. Only miRNAs 
for which specific evidence in HPMCs existed by the beggining of this project on September 2012 are 
shown. Figure 6.1 at the general discussion reproduces this Figure (C) with additional, up to date, 
biblioraphy (Figure modified from Lopez-Anton et al. 2015). 
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data (Liu et al, 2014; Xiao et al, 2015; Yu et al, 2014; Zhou et al, 2013), but their utility as 
PDE biomarkers has yet to be established. Ultimately, unbiased multi-center miRNA 
expression analysis of PDE samples combined with robust function data would be 
essential for the establishment of miRNA-biomarkers associated to PD therapy.  
1.7. Aims 
The overall purpose of this work was to study miRNAs in the context of PD.  
My specific research objectives were: 
1. To identify miRNAs expressed in peritoneal mesothelial cells and changes 
seen in peritoneal mesothelial MMT. To confirm miRNA changes in different 
models of peritoneal dialysis associated fibrogenesis.  
 
Hypothesis: peritoneal mesothelial cells undergoing MMT display associated 
changes in miRNA expression. 
 
2. To develop a robust technique for extracting miRNAs from PD effluent and 
quantifying them. To evaluate the use of miRNAs as biomarkers in PD effluent 
from patients. 
 
Hypothesis: miRNAs can be measured in PD effluent from patients and 
correlate with clinical parameters 
 
3. To determine the function of candidate miRNAs identified in aims 1 and 2 in 
peritoneal mesothelial MMT.  
 
Hypothesis: differentially expressed miRNAs control the expression of a panel 
of mRNA targets and contribute to the MMT process  
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Chapter 2 – Methods
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2.1. Samples 
2.1.1. PD Effluent: Fresh Overnight and Global Fluid Study Samples 
Fresh overnight PDE samples from different stable patients were collected from 
the Renal Unit in the University Hospital of Wales. Patient ethical approval and informed 
consent for the use of their PDE for research purposes was obtained in all cases. These 
samples were collected for methodological parameters optimization needed for this 
study and developed in Chapter 4.  
The Global Fluid Study is an international, multicenter, prospective, 
observational cohort study of 959 patients. This biobank was designed to examine 
potential local and systemic biomarkers for the maintenance of the structural and 
functional integrity of the peritoneal membrane on long-term PD therapy. The study has 
been previously described by Lambie et al. 2013. Samples from a single center were 
used, to exclude center effects. Stable PD patients were recruited from University 
Hospital of North Staffordshire, Stoke-on-Trent, UK. The sample size of the study was 
the maximum feasible by the registry (n=230) and the samples analyzed were, in all 
cases, the first sample collected from each patient once enrolled for study. Dialysate 
cytokine levels had been measured previously by electrochemiluminescence (Lambie et 
al, 2013). 4-hour dwell dialysate samples (peritoneal equilibration test; PET) were stored 
at - 80°C and thawed on ice. 600 μl aliquots were centrifuged at 12,000 x g (relative 
centrifugal force, RCF) at 4°C for 20 min prior RNA extraction. Ethical approval for this 
study was obtained from the Multi-Centre Research Ethics Committee for Wales.  
2.1.2. Tissue Samples: Human Peritoneal Membrane Study 
Formalin-Fixed, paraffin-embedded (FFPE) peritoneal membrane samples from 
43 pediatric patients (1.83-19.16 years old) included in the International Pediatric PD 
Biopsy Study were used in this analysis. Patient samples were age and sex-matched. 
Average PD duration and submesothelial thickness was equivalent between PD patients 
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and controls respectively. Patients with previous peritonitis, systemic diseases and 
abdominal surgery other than catheter insertion, revision or kidney transplantation 
were excluded. Comprehensive individual clinical data were collected and assessed 
before analysis to exclude disparity regarding disease susceptibility or comorbidity. 
Approval was obtained from local ethics committees, and written informed consent 
obtained from patient and parents. FFPE samples were cresyl violet stained and the 
mesothelial and submesothelial compact zone were manually microdissected from a 
total of 40 μm section using a Leica RM 2165 rotary sliding microtome and a Leica S8 
APO stereo microscope prior RNA isolation. Experiments performed on these samples 
were physically performed at the Department of Nephrology, Heidelberg University, 
Germany during a short stay, and are the result of an established collaboration with ESR 
Maria Bartosova and Prof Claus Schmitt, who are partners of the EU project EuTRiPD 
that funded this research. 
2.1.3. Tissue Samples: Mouse Peritoneal Membrane Study 
Uraemic PD mouse model was developed by ESR Evelina Ferrantelli at 
Department of Molecular Cell Biology and Immunology, VU University Medical Center, 
Amsterdam, Netherlands, as part of the EuTRiPD project. Mouse parietal peritoneal 
biopsies were collected by ESR Evelina Ferranteli from the opposite side from the 
catheter installation. Model biopsies included mice undergoing PD with and without 5/6 
nephrectomy (Nx) and uraemic controls and were fixed in Bouin’s solution and 
embedded in paraffin. Paraffin samples were sent to Cardiff where they were sectioned 
(5 μm) and H&E stained by Mr. Dilwyn Havard at the Histopathology Department, 
University Hospital of Wales. Biopsy tissue was placed in the middle third of an 
uncharged, uncoated glass slide (VFM White coat slides CellPath Ltd). Peritoneal 
membrane thickness was determined using Arcturus Pixcell IIe infrared laser enabled 
LCM system (Applied Biosystems) and camera. Thickness measurement was performed 
using Image J software. Six independent measures were taken from different membrane 
areas and average was used for statistical analysis.  
Peritoneal mesothelial and submesothelial compact zone were dissected using 
Arcturus Pixcell IIe infrared laser enabled LCM system (Applied Biosystems). Biopsy 
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tissue was laser selected and bound to a polymer membrane located on a cap (Arcturus 
® Capsure ® Macro LCM caps, Applied Biosystems) that is on a slide and holds the 
selected tissue when lifted after the process. These experiments were carried out after 
Dr Christopher Carrington guidance at the Institute of Nephrology, Cardiff University. 
These experiments were possible thanks to ESR Evelina Ferrantelli and Prof R.H.J. Beelen 
collaboration who are partners of the EuTRiPD project that founded this research. 
2.2. Cell Culture: Primary HPMCs and HeLa cell line 
2.2.1. Cell culture conditions 
Human peritoneal mesothelial cells (HPMCs) were obtained from omental 
donors undergoing abdominal surgery, with ethical approval and informed consent for 
the use of their omentum for research purposes (Stylianou et al, 1990; Yung et al, 2006). 
Peritoneal dialysis effluent (PDE) derived HPMCs were obtained from random stable PD 
patients by dialysis fluid centrifugation as described in Yáñez-Mo et al., 2003. These 
samples were kindly provided by Dr Manuel Lopez-Cabrera who is a partner of the 
EuTRiPD project. Omentum derived HPMCs extraction has been previously carefully 
characterized by a panel of markers described in Yáñez-Mo et al, 2003 and showed to 
be little or non-contamination from different cellular contents other than fibroblasts. 
Omentum derived cultures with fibroblasts contamination are easy to identify under the 
microscope and were in all cases disqualified for following studies. After trypsin 
digestion of the tissue, PDE isolation or vial thaw, cells were cultured in Earle’s M199 
medium (Life Technologies) supplemented with 10% fetal calf serum, 2 mM L-
Glutamine, 100 U/ml penicillin, 100 μg/ml Streptomycin, 5 μg/ml Transferrin, 5 μg/ml 
Insulin and 0.4 μg/ml hydrocortisone from Sigma-Aldrich. HeLa cell line was kindly 
provided by MSc Hung-Chang Chen and were cultured in RPMI 1640 medium 
(Invitrogen) supplemented with 10% fetal calf serum, 50 mg/ml penicillin/streptomycin, 
2 mM L-Glutamine, 1% sodium pyruvate and 100 µM non-essential amino (NEAA) from 
Sigma-Aldrich. Cells were grown at 37°C in a humidified incubator with 5% CO2. The 
medium was changed every 2-3 days and cells were passaged at ≥ 90% confluence by 
regular trypsinization. All experiments were performed on second passage cells for 
HPMCs and passage < 15 for HeLa cell line at 80 - 90% confluence.  
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2.2.2. Cell viability 
AlamarBlue assay was used for examination of relative cell number and/or 
viability. This method employs a non-toxic, cell permeable, blue and non-fluorescent 
dye, resazurin, converted to the pink and fluorescent dye resorufin in response to 
metabolic activity of cultured cells. The fluorescent and colorimetric signal is 
proportional to the number of living cells in the sample. To perform the assay, cells were 
incubated new culture medium without FBS at 37°C and 10% (v/v) solution of 
AlamarBlue reagent. After 1 hour of incubation the medium was transferred to a black 
96 well plate (100 µl/well) and the fluorescenct signal was monitored using 544 nm 
excitation wavelength and 590 nm emission wavelength. Medium with 10% (v/v) 
AlamarBlue reagent was kept in the incubator for one hour before the measurement to 
use as a blank.  
2.2.3. Cell stimulations 
HPMCs were treated for different time periods and concentrations of human-
recombinant TGF-β1 (R&D Systems) as specified in text and figure legends, and were 
growth arrested for 24 h prior to experimentation. In all cases, control cells were treated 
with growth-arrested medium (medium without FBS) for the indicated time period. Of 
note, TGF-β1 is used here as a simple and unique stimulus for mesothelial cells as a 
simplification of the multiple external and autocrine stimulus integrated by HPMCs in 
real disease context.  
HPMCs treatment with different PD solutions was optimized prior experiment. 
1:2 and 1:4 PD solution or phosphate buffered saline (PBS) solution in medium with no 
FBS was used for HPMC treatment over times to 48 h. In preliminary experiments, using 
dilutions of medium with PBS solution (as control) and PD solutions under study, 
compromised cell viability and made difficult to draw any conclusions on PD solution 
differences. 1% FBS supplementation of the medium prevented this compromise of 
viability, and was adopted for these experiments.  
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2.2.4. Transfections 
Two kinds of plasmids have been used for this study: plasmids for the expression 
of 3’UTR reporter genes and plasmids for the expression of miRNA precursors (pre-
miRNAs) (Figure 2.1). Plasmids containing specific 3’UTR sequences downstream the 
firefly luciferase coding sequence were generated using pMIR-REPORT Luciferase vector 
(Applied Biosystems, AM5795) (Figure 2.1A) to study miRNA mediated post-
transcriptional regulation. Renilla luciferase encoding plasmid (pRL, Promega) under a 
strong, constitutive promoter (Simian Virus 40, SV40) was co-transfected with firefly 
luciferase reporter as a transfection efficiency control for reporter assays (ratio 5:50). 
Plasmids to express pre-miRNA sequences were generated using psiSTRIKE vector 
(Promega, 4397MA11_3A) (Figure 2.1B) with insertion downstream of the human U6 
promoter, which is recognized by the RNA polymerase III.  
 
 
 
 
 
 
 
 
Figure 2.1. Vector circle map and sequence reference points. (A) pMIR-REPORT Luciferase vector. 
CMV Promoter (2210–2813), Firefly luciferase (540–2210), MCS (467–539), SV40 Poly(A) (404–467), 
SV40 Promoter (6139–6438), Puromycin (5447–6046), SV40 pA signal (5153–5188), Ampicillin (4083–
4943), ColE1 Origin (3138–4024). (B) psiSTRIKE Puromycin Vector. T7 RNA polymerase transcription 
initiation site (1), U6 promoter (16-275), U6 transcription initiation site (276), SP6 RNA polymerase 
promoter (330-349), SP6 RNA polymerase transcription initiation site (332), Binding site of pUC/M13 
Reverse Sequencing Primer (367-388), SV40 enhancer and early promoter (601-1019), SV40 minimum 
origin of replication (917-982), Puromycin-N-acetyltransferase coding region (1042-1641), Synthetic 
polyadenylation signal (1686-1734), β-lactamase (Ampr) coding region (2686-3546), Binding site of 
pUC/M13 Forward Sequencing Primer (4298-4321), T7 RNA polymerase promoter (4348-3). 
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miRNA reporter construction (pMIR-REPORT based plasmid) 
PDZD2 3’UTR has a total length of 2875 pb. The average length of 3’UTR in 
vertebrates is variable but in humans is ~ 800 pb (Mignone et al, 2002). In addition, long 
sequences may have non-desired effects on reporter plasmid performance. Thus, a full 
PDZD2 3’UTR reporter (2545 pb) as well as three extra PDZD2 3’UTR reporters containing 
~ 800 pb each (Figure 2.2) were generated. Other 3’UTR reporters generated included 
FGF-18 (814 pb), S100A10 (245 pb) and MATN2 (1004 pb).  
3’UTR amplification 
Specific primers for PDZD2, FGF-18, S100A10, and MATN2 3’UTRs were designed 
(Table 2.1) according to In-Fusion HD Cloning Kit User Manual recommendations. PCR 
specific primers for sequences of interest contained 20 – 23 pb for the specific 3’UTRs 
sequence (black) followed at the 5’ end by a MluI enzyme target sequence (green), 10 
pb extensions complementary to pMIR-REPORT vector (red) and an extra CC (blue) to 
avoid start-synthesis complications (Table 2.1). 3’UTRs of interest were amplified using 
CloneAmp HiFi PCR Premix (Clontech, Cat. No. 639298) following protocol 
recommendations. 4 µl of diluted cDNA (10 ng of RT-RNA) from control HPMCs were 
mixed with 0.25 µM of designed primers, 12.5 µl of CloneAmp HiFi PCR premix and water 
in a total reaction volume of 25 µl. PCR amplification conditions were product-optimized 
and used as following detailed: PDZD2 1st 3’UTR (2 min at 98.0°C, 40 cycles of 15 sec at 
98.0°C, 30 sec at 54.5°C and 1 min at 72.0°C, followed by an extension step of 5 min at 
72.0°C and a cooling step at 4°C); PDZD2 2nd and 3rd 3’UTR (2 min at 98.0°C, 40 cycles of 
15 sec at 98.0°C, 30 sec at 54.0°C and 1 min at 72.0°C, followed by an extension step of 
5 min at 72.0°C and a cooling step at 4°C) and PDZD2 Full 3’UTR (2 min at 98.0°C, 40 
cycles of 15 sec at 98.0°C, 30 sec at 55.0°C and 3 min 30 sec at 72.0°C, followed by an 
extension step of 5 min at 72.0°C and a cooling step at 4°C). Primers designed for FGF-
18, S100A10 and MATN2 full 3’UTR amplification owned very different melting 
temperatures, therefore, touchdown PCR amplification protocols were used to 
overcome this issue. Touchdown PCR amplification used for FGF-18 3’UTR was (2 min at 
98.0°C; 41 cycles of 82.0 to 41.0°C for 15 sec with 1°C decrement per cycle and 30 sec at 
72.0°C; 25 cycles of 15 sec at 98.0°C, 30 sec at 41.0°C and 30 sec at 72.0°C; followed by 
an extension step of 5 min at 72.0°C and cooling step at 4°C); and S100A10 and MATN2 
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3’UTRs were (2 min at 98.0°C; 27 cycles of 64.0 to 37.0°C for 15 sec with 1°C decrement 
per cycle and 30 sec at 72.0°C; 25 cycles of 15 sec at 98.0°C, 30 sec at 37.0°C and 30 sec 
at 72.0°C; followed by an extension step of 5 min at 72.0°C and cooling step at 4°C). 
Similar reaction as described above but using water instead of cDNA was used as a 
Control Negative (CN). PCR amplification was verified using conventional agarose gel 
electrophoresis in 1% (w/v) agarose gel containing Ethidium bromide for DNA band 
visualization and was run in 1x TAE buffer. 
Electrophoretic DNA mobility depends on fragment size and is slightly modified 
by DNA conformation, agarose type and concentration, applied voltage and 
electrophoresis buffer. Specific PCR product was cut from the agarose gel and spin-
column purified using QIAquick gel extraction kit (Quiagen, Cat. No. 28706). Briefly, gel 
slice was weighted, mixed with 3 volumes of Buffer QG and incubated at 50°C for 10 min 
while constant vortexing the tube every 2 – 3 min. Subsequently, 1 volume of 
isopropanol was added and the mixture was passed through a QIAquick spin column by 
1 min centrifuge at maximum speed. Column was successively washed by 500 µl Buffer 
QG, 750 µl Buffer PE, extra centrifuged with no wash buffer to remove residual fluid and 
DNA eluted in 50 µl of water. 
 
 
 
 
 
Figure 2.2. PDZD2 3’UTR luciferase reporter generation using pMIR-REPORT Luciferase vector. 
Reporter constructs diagram. The 3’UTR of PDZD2 (~ 2.88 kb) was cloned downstream firefly in the 
pMIR-REPORT Luciferase vector generating four different reporter constructs: 1
st 
3’UTR, 818pb, 
containing one putative binding site for miR-21 and one for miR-31; 2
nd 
3’UTR, 863pb, containing no 
putative binding sites; 3
rd 
3’UTR, 864pb, containing one putative binding sites for miR-21 and two for 
miR-31; and Full 3’UTR, 2545pb, containing the whole three sequences described above. miR-21 
binding site – blue arrow, miR-31 binding site – Green arrow. 
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Plasmid 
generation 
Inserts or PCR-primers (5’ – 3’) 
miRNA reporter construction (pMIR-REPORT based plasmid) 
pMIR-hPDZD2 1st 
F: CCGATATCACGCACGCGTACACTGGTACAGACACGGAC 
R: CCGCCGGCATAGACGCGTTGTCTGCTCTTGGACTGACC 
pMIR-hPDZD2 2nd 
F: CCGATATCACGCACGCGTGGTCAGTCCAAGAGCAGACA 
R: CCGCCGGCATAGACGCGTACCTCTCTAGGCCGACTTCA 
pMIR-hPDZD2 3rd 
F: CCGATATCACGCACGCGTTGAAGTCGGCCTAGAGAGGT 
R: CCGCCGGCATAGACGCGTAGATGGAAATGAAACCCAGCCT 
pMIR-hFGF-18 
F: CCGATATCACGCACGCGTGCCACCCCGCCGCGGCCCCT 
R: CCGCCGGCATAGACGCGTTTAAATAATTTGTCTGTTGT 
pMIR-hS100A10 
F: CCGATATCACGCACGCGTGCAGAAATGAGCAGTTCGCT 
R: CCGCCGGCATAGACGCGTGGAACTAAAAAAGAACTTTA 
pMIR-hMATN2 
F: CCGATATCACGCACGCGTAGATTAGAAATCGCGACACA 
R: CCGCCGGCATAGACGCGTGAGTTTGACCATTTATTTGT 
pMIR FGF-18 
Mut-m21 
F: TATATTTCGTATTTATTTCACCTCTCTGTAT 
R: AAATACGAAATATATATATAATATATATAATATAGCTGGTTTTT 
pMIR S100A10 
Mut-m21 
F: CAGATTTCGTTTTGATTTTT 
R: CAAAACGAAATCTGGTATTT 
Pre-miRNA plasmid construction (psiSTRIKE U6 based plasmids) 
psiSTRIKE 
pre-miR-CN 
A: ACCGCGTATCGTAAGCAGTACTAAGTTCTCTAGTACTGCTTACGATACGCTTTTTC; 
B: TGCAGAAAAAGCGTATCGTAAGCAGTACTAGAGAACTTAGTACTGCTTACGATACG 
psiSTRIKE 
pre-miR-21 
A: ACCGTGTCGGGTAGCTTATCAGACTGATGTTGACTGTTGAATCTCATGGCAACACC 
AGTCGATGGGCTGTCTGACATTTTTC; B: TGCAGAAAAATGTCAGACAGCCCATCGA 
CTGGTGTTGCCATGAGATTCAACAGTCAACATCAGTCTGATAAGCTACCCGACA 
psiSTRIKE 
pre-miR-31 
A: ACCGGGAGAGGAGGCAAGATGCTGGCATAGCTGTTGAACTGGGAACCTGCTATGC 
CAACATATTGCCATCTTTCCTTTTTC; B: TGCAGAAAAAGGAAAGATGGCAATATGTTG 
GCATAGCAGGTTCCCAGTTCAACAGCTATGCCAGCATCTTGCCTCCTCTCC 
 
Table 2.1. Plasmids generated for this study and oligonucleotide sequences used for cloning. Bold F and 
R indicate PCR primer sequences while A and B indicate inserts. 
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pMIR-REPORT vector digestion 
1 µg of pMIR-REPORT vector was digested using 1 µl of MluI enzyme (New 
England BioLabs, R01985) and 1 µl of Buffer 3.1 in a total volume of 10 µl at 37°C 
overnight. A similar reaction using water instead of vector was used as a CN. Digested 
plasmid and CN sample were mixed with 2 µl of loading buffer (GelPilot DNA Loading 
Dye, 5x, QUIAGEN, Cat. No. 239901) and loaded into 1% electrophoresis gel. 1Kb ladder 
(New England BioLabs, N0552G) was also loaded into the gel and run at 90 V during 60 
min. A single band containing the linear plasmid was cut and plasmid was purified using 
QIAquick gel extraction kit as previously described above. 
In-Fusion Cloning reaction 
In-Fusion protocol was followed for cloning reaction with minor modifications. 
In brief, 25 ng of PCR purified fragment was mixed with 25 ng of linearized vector, 1 µl 
of In-fusion HD enzyme premix and water in a total volume of 5 µl.  
Escherichia coli Transformation 
Stellar competent Escherichia coli (E. coli) were thawed on ice and 25 µl of 
bacteria suspension were incubated with 1.25 µl of In-Fusion reaction previously 
described for transformation during 30 min in 12 ml polypropylene tube. The suspension 
was placed at 42°C for 45 sec and chilled on ice for 2 min. 500 µl of 37°C pre-warmed 
SOC medium were subsequently added to the bacteria suspension and incubated for 1 
hour at 37°C with shaking. 25 µl of transformed bacteria were seed on YTx2 agar plate 
(Appendix) containing 100 µg/ml ampicillin and growth at 37°C overnight. 
E. coli purification 
Single colony was transferred to a new 12 ml polypropylene tube containing 5 
ml YTx2 broth (Appendix) with 100 µg/ml ampicillin and incubated overnight at 37°C 
with shaking. Plasmid purification was performed using GenElute HP Plasmid MiniPrep 
Kit (Sigma-Aldrich, NA0160), following manufacturer’s recommendations. 4 ml bacterial 
culture was centrifuged for 3 min at ≥ 12,000 x g and room temperature (RT). Bacterial 
pellet was re-suspended in 200 µl of Resuspension Solution, and 200 µl of Lysis Buffer 
were added and mixed by inversion. After 5 min at RT, 350 µl of cold, Neutralization 
Buffer were added, mixed by inversion and centrifuged for 10 min at ≥ 12,000 x g and 
RT. Miniprep Binding Columns were washed with 500 µl of Column Preparation Solution 
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prior cleared bacterial lysate load, and passed through the column by centrifugations for 
1 min at ≥ 12,000 x g at RT. The column was further washed with 500 µl of Wash Solution 
1 (41% ethanol) and 750 µl of Wash Solution 2 (44% ethanol) followed by 1 min at ≥ 
12,000 x g at RT with no wash buffer to remove residual fluid and plasmid DNA eluted 
in 50 µl of water. 800 µl of bacterial culture were mixed with 200 µ of glycerol and stored 
frozen at - 80°C.  
pMIR-REPORT Plasmid Verification 
pMIR-REPORT containing 3’UTR inserts of interest included two MluI sites 
flanking the insert. MluI digestion of plasmids containing the expected insert will 
produce two products ( ~ 0.8 or 2.5 Kb and 6.47 Kb). Thus, plasmid concentration was 
quantified using NanoDrop 2000 UV spectrophotometer. NanoDrop uses absorbance 
wavelength 260 nm (A260nm) measures to calculate nucleic acid concentration using the 
following equation:  
[Total DNA µg/ml] = A260nm x 50 x dilution factor. 
1 µg of plasmid DNA was digested with 1 µ of MluI (New England Biolabs, 
R0140S) and 1 µl of NEBuffer 3.1 in a total volume of 10 µl and run in 1% (w/v) agarose 
gel together with samples processed without enzyme (Figure 2.3). Plasmid positive 
sequences were confirmed by sequencing (Eurofins Genomics, Prepaid Barcodes, 3098-
000PPB). 
pMIR-REPORT plasmid mutation 
Specific primers for FGF-18 and S100A10 seed miRNA sequence mutation were 
designed (Table 2.1) according to In-Fusion HD Cloning Kit User Manual 
recommendations. Primers were designed to overlap with each other 15 pb (purple and 
orange) at their 5’ end and incorporate the desired substitution (orange). As previously 
described (Clovis et al, 2012), four nucleotides (corresponding to seed sequence 
positions 2nd – 5th) were mutated to the same miRNA nucleotide found in miRNA seed 
sequence to maximize repulsive effect. pMIR-REPORT containing FGF-18 and S100A10 
3’UTR were amplified using CloneAmp HiFi polymerase following protocol 
recommendations. 5 ng of pMIR-R plasmid were mixed with 0.25 µM of designed 
primers, 12.5 µl of CloneAmp HiFi PCR premix and water in a total reaction volume of 25 
56 
 
µl. PCR amplification conditions were product-optimized: 2 min at 98.0°C, 40 cycles of 
15 sec at 98.0°C, 30 sec at 55.0°C and 1 min at 72.0°C, followed by a cooling step at 4°C. 
PCR amplification was verified on 1% (w/v) agarose gel and specific PCR product was cut 
from the gel and spin-column purified as detailed above. 25 ng of linear construction 
containing the desired mutation was incubated with 0.5 µl of In-Fusion enzyme in a total 
volume of 5 µl at 50°C for 15 min. 25 µl of competent cells were transformed using 1.25 
µl of the above reaction as previously described (see 2.2.3.).  
Pre-miRNA plasmid construction (psiSTRIKE U6 based plasmids) 
miR-21, miR-31 and miR-CN pre-miRNA plasmids were generated by ligation of 
annealed DNA oligonucleotides A and B (Table 2.1) into the psiSTRIKE U6 vector 
following manufacturer’s recommendations. 
Oligonucleotide design 
Oligonucleotide (A) contained pre-miRNA sequences described in miRBase 
release 21 (Kozomara & Griffiths-Jones, 2014) for miR-21 and miR-31 followed by the 
U6 termination sequence (TTTTT, green) and an additional C residue (orange). This last 
residue will create a new PstI restriction site upon insert ligation that will allow positive 
plasmid discrimination. Oligonucleotide (B) includes TGCAG overhang sequence (red), 
which is complementary to siSTRIKE U6 sticky end, and an oligonucleotide (A, blue) 
complementary sequence excluding the last four nucleotides. Pre-miR-CN sequences 
were previously designed by Krupa 2010 based on miR-CN sequences used by Life 
Technologies and recommended loop sequence AAGTTCTCT (Krupa, 2010) (Table 2.1). 
Oligonucleotide annealing 
Oligonucleotide A-B annealing was performed by incubation at 90°C for 3 min 
followed by a second incubation at 37°C for 15 min in the Oligo Annealing Buffer 
(Promega) at 40 ng/µl final concentration each. The resulting, double-stranded DNA, 
owns psiSTRIKE U6 complementary 5’ overhangs to enable effective directional ligation.
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Figure 2.3. Potential positive E. Coli colonies selection for each specific 3’UTR luciferase reporter 
generated prior sequencing confirmation. (A) E. Coli colonies potentially containing pMIR-REPORTER 
PDZD2 1
st
 3’UTR insert of interest MluI digested. (B) E. Coli colonies potentially containing pMIR-
REPORTER PDZD2 2
nd
 3’UTR insert of interest MluI digested. (C) E. Coli colonies potentially containing 
pMIR-REPORTER PDZD2 3
rd
 3’UTR insert of interest MluI digested. (D) E. Coli colonies potentially 
containing pMIR-REPORTER PDZD2 full 3’UTR insert of interest MluI digested. (E) E. Coli colonies 
potentially containing pMIR-REPORTER MATN2 3’UTR insert of interest MluI digested.  (F) E. Coli 
colonies potentially containing pMIR-REPORTER FGF-18 and S100A10 3’UTR insert of interest MluI 
digested.  
58 
 
psiSTRIKE U6 vector digestion 
1 µg of psiSTRIKE U6 vector were digested using 1 µl of BbsI enzyme (New 
England BioLabs, R0539S) and 1 µl of NEBuffer 2.1 in a total volume of 10 µl at 37°C 
overnight. Digested plasmid was mixed with 2 µl of loading buffer, loaded into 1% 
electrophoresis gel and run at 90 V during 60 min as previously described (see 2.2.3.). 
Single band containing amplified linear plasmid was cut and purified as described above 
(see 2.2.3.). 
Annealed oligonucleotide-psiSTRIKE U6 ligation and subsequent cloning steps 
4 ng of annealed oligonucleotide were mixed with 50 ng of linear psiSTRIKE U6 
vector and 1 µl of quick T4 DNA ligase (New England Biolabs, M2200S) in 5 µl of quick 
ligation buffer and a total volume of 10 µl. Ligation was carried out for one hour at RT. 
Competent E. coli transformation was performed as described above (see 2.2.3.) with 
minor changes including the use of 50 µl of bacteria suspension together with 2.5 µl of 
ligation reaction previously described for transformation. 50 µl of transformed bacteria 
were seed this time on YTx2 agar plate (Appendix) containing 100 µg/ml ampicillin and 
growth at 37°C overnight. E. coli plasmid purification was performed as described above 
(see 2.2.3.).  
Plasmid Verification 
siSTRIKE U6 plasmid contains one PstI site prior ligation and a second one is 
created as a successful ligation result. Therefore, PstI digestion of plasmids containing 
the expected insert will produce two products (~3.0 and 1.4 Kb). Similarly as described 
above (see 2.2.3.), 1 µg of plasmid DNA were digested with 1 µ of PstI (New England 
Biolabs, R0140S) and 1 µl of NEBuffer 3.1 in a total volume of 10 µl. Digested samples 
were separated in 1% (w/v) agarose gel as described in detail in (see 2.2.3.). Samples 
without the enzyme were processed and run into the same gel. In adition, plasmid 
sequences were confirmed by sequencing by (Eurofins Genomics, Prepaid Barcodes, 
3098-000PPB). 
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Transient HPMCs transfections: Protocol optimization. 
Human primary MCs are very delicate to culture in vitro and not easy to transfect. 
No previous protocol had been established in this laboratory to successfully transfect 
HPMCs with small RNAs and/or plasmids before this study. Therefore, the use of 
different transfection reagents before to set up a protocol for the project was tested. 
Details of the transfection reagents and protocols tested are summarized in Table 2.2. 
24-well plates were seed and transfected by 80% confluence following described 
protocols (Table 2.2). After drop-wise transfection-mixture addition to HPMCs, plates 
were mixed gently by agitation, pipetting when indicated, and placed into the incubator. 
In all cases, medium was replaced 4 h after transfection by serum-free medium and 
miRNAs were measured 48 h after transfection. Transfection reagents were tested by 
using psiSTRIKE-miR-CN (Control) and psiSTRIKE-miR-31 as miR-31 was less expressed 
than miR-21 in HPMCs and differences would be easier to measure. Lipofectamine LTX 
& PLUS (Thermo Fisher Scientific, 15338100) reagent showed the greatest miR-31 
induction when cells were transfected with psiSTRIKE-miR-31 compared to psiSTRIKE-
miR-CN plasmid (Figure 2.4). Nevertheless, subsequent experiments showed significant 
HPMCs morphological changes associated with psiSTRIKE-miR-CN plasmid 
overexpression which threshold was difficult to determine as they were highly 
dependent on donor. No morphological differences were observed when HPMCs were 
transfected with pMIR-REPORT and Renilla luciferase encoding plasmids. 
Transient transfections with DNA plasmids and small RNAs 
Four kinds of small RNAs have been used for this study including mirVana miRNA 
mimic (Thermo Fisher Scientific), Silencer Select siRNA (Thermo Fisher Scientific), 
miRCURY LNA miRNA inhibitor (Exiqon) and mirVana miRNA inhibitor (Thermo Fisher 
Scientific) (Table 2.3). mirVana miRNA mimics are small, chemically modified double-
stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis 
by up-regulation of miRNA activity using cell machinery mechanisms. Silencer Select are 
annealed siRNA duplexes, algorithm designed, off-target effect predicted and 
functionally confirmed. miRCURY LNA miRNA inhibitors are antisense oligonucleotides 
with perfect target sequence complementary that when introduced into cells sequester 
their target miRNA in highly stable hetero-duplexes preventing miRNA regulation of its 
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normal cellular mRNA targets. mirVana miRNA inhibitors are small, chemically modified 
single-stranded RNA molecules that bind and inhibit specific miRNAs allowing functional 
analysis by miRNA activity down-regulation.  
 
Product 
(Manufacturer) 
Delivery Requirements Brief Protocol 
K2 
Transfection 
system 
(Biontex 
Laboratories 
GmbH, T060) 
Cationic lipid 
(liposome) 
delivery 
combined with 
decreased cell 
ability to detect 
nucleic acids 
Suitable 
complete 
growth medium 
containing 
antibiotics and 
FBS 
Add 9.5 µl of K2 Multiplier to each well 
2 h prior transfection. Mix by gently 
pipetting Solution A containing 28.5 µl 
serum-free medium and 0.25 µg DNA 
with Solution B comprising 28.5 µl 
serum-free medium and 2.3 µl K2 
Transfection Reagent. Incubate the 
mixture 15 - 20 min at RT and add 
immediately after to the cells. 
Viromer Yellow 
(Lipocalix, 
VY-01LB-01) 
Alkyl moieties 
combined with 
long chain fatty 
acids that switch 
conformation 
facilitating 
membrane 
crossing during 
endocytosis due 
to acidic 
environment. 
Suitable 
complete 
growth medium 
containing 
antibiotics and 
FBS 
Recommended 
for cells known 
as ‘non-
transfectable’. 
Dilute DNA to 9 ng/µl using Buffer E and 
mix separately 4 µl Viromer Yellow with 
96 µl Buffer E following the indicated 
order. Place 15 µl of pre-diluted 
Viromer in a sterile tube and add 85 µl 
of DNA solution in Buffer E. Mix by 
gentle pipetting and allow 
complexation for 15 min prior 
transferring 33 µl of the complexes to 
the cells. 
FuGENE HD 
(Promega, E2311) 
A mixture of 
lipids and other 
components in 
80% ethanol 
 
No antibiotics in 
the 
transfection 
medium 
Suitable with 
FBS 
 
Dilute 0.25 µg of DNA using 100 µl Opti-
MEM Reduced Serum Medium and add 
1-5 µl of FuGENE HD Transfection 
Reagent to the mixture immediately. 
Incubate the mixture 5 - 15 min at RT 
and add 25 µl of the FuGENE HD 
Transfection Reagent/DNA mixture per 
well while mixing by pipetting during 30 
sec. 
Lipofectamine LTX 
& PLUS Reagent 
(Thermo Fisher 
Scientific, 
15338100) 
Cationic lipid 
formulation 
No antibiotics in 
the 
transfection 
medium 
Suitable with 
FBS 
 
Dilute 0.25 µg of DNA using 100 µl Opti-
MEM Reduced Serum Medium and mix 
gently prior and after adding 0.5 µl of 
PLUS Reagent. Incubate the mixture for 
5 min at RT and add 1.25 µl of 
Lipofectamine LTX Reagent to the mix 
and incubate for 30 min at RT prior 
transferring 100 µl of the complexes to 
the cells. 
jetPRIME 
Transfection 
Reagent 
(Polyplus 
transfection, 
Cat. No. 114-07) 
Polymer 
formulation 
 
Suitable 
complete 
growth medium 
containing 
antibiotics and 
FBS 
Dilute 0.25 µg of DNA using 50 µl 
jetPRIME Buffer, mix by vortexing and 
add 1 µl of jetPRIME Reagent, mix and 
incubate for 10 min at RT. Add 50 µl of 
transfection mix onto the cells. 
 
Table 2.2. Table summarizing transfection systems used for this study. Quantities described above are 
adapted for experiment size equivalent to 24-well plate. 
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Small RNA Catalog Number 
mirVana miRNA mimic 
hsa-miR-31-5p 
Cat. No. 4464066 
MC11465 
mirVana miRNA mimic 
hsa-miR-21-5p 
Cat. No. 4464066 
MC10206  
mirVana miRNA Mimic Negative 
Control #1 
Cat. No. 4464058 
Silencer Select 
FGF18 siRNA 
Cat. No. 4392420 
S17213 
Silencer Select 
S100A10 siRNA 
Cat. No. 4392420 
S12429 
Silencer Select 
MATN2 siRNA 
Cat. No. 4392420 
S8533 
Silencer Select  
PDZD2 siRNA 
Cat. No. 4392420 
S22889 
Silencer Select Negative Control No.1 
siRNA 
Cat. No. 4390843 
miRCURY LNA microRNA inhibitor 
hsa-miR-21-5p 
Cat. No. 4102261-001 
miRCURY LNA microRNA inhibitor 
hsa-miR-31-5p 
Cat. No. 4100872-001 
miRCURY LNA microRNA inhibitor 
 Negative Control A 
Cat. No. 199006-001 
mirVana miRNA inhibitor 
hsa-miR-21-5p 
Cat. No. MH10206 
mirVana miRNA inhibitor 
hsa-miR-31-5p 
 Cat. No. MH11465 
mirVana miRNA Inhibitor  
Negative Control #1 
Cat. No. 4464078 
 
Table 2.3. Small RNAs used in this study. 
Figure 2.4. HPMCs transfection 
system optimization. 24-well plates 
were seed and transfected by 80% 
confluence following described 
protocols for K2 transfection system, 
Viromer Yellow, FuGENE HD, 
Lipofectamine LTX & PLUS Reagent 
and jetPRIME Transfection Reagent 
together with psiSTRIKE-miR-CN and 
psiSTRIKE-miR-31 as detailed in Table 
2.1. Relative miR-31 expression was 
measured 48 h after cell transfection 
by RT-qPCR and normalized to miR-
191 expression. Data were analyzed 
by two-way ANOVA for matched 
samples by both factors followed by 
post-hoc Holm-Sidak’s test within 
each each transfection method mean 
compared with control mean. Data 
represent the mean S.E.M. from three 
independent donor experiments. *p < 
0.05; ***p < 0.005; ****p < 0.001. 
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mirVana miRNA mimic were used at concentrations of 5 pM, 10 pM and 20 pM 
for target mRNA measurements (48 h after transfection) to prove treatment 
consistency.5 pM concentrations were used for protein quantification (72 h after 
transfection). No morphological differences were observed when HPMCs were 
transfected with different concentrations of miRNA mimic-CN neither when compared 
with mimic-21 or mimic-31 at concentrations described for experiment. Silencer Select 
siRNA was tested for transfection in HPMCs at different concentrations including 10 nM, 
20 nM, 30 nM and 40 nM. 30 nM was the concentration that showed higher target 
transcript down-regulation after 48 h of transfection for PDZD2 while 40 nM showed 
greater target mRNA down-regulation for FGF-18, S100A10 and MATN2 and were, 
therefore, chosen for subsequent analysis (Figure 2.5). Finally, miRCURY LNA inhibitors 
performance can be measured by de-repression of endogenous miRNA targets 
(validated or predicted) and can be measured at mRNA level. miRNA RT-qPCR, 
sometimes reported in literature, is not a reliable method for measuring miRNA knock-
down as these inhibitors do not degrade their targets but form stable complexes that 
cause miRNA accumulation. In addition, LNA oligonucleotides have been described to 
interfere with miRNA PCR primers rising aberrant results. Thus, miRCURY LNA inhibitors 
were tested at 25 pM, 50 pM, 1 nM, 25 nM, 50 nM, 75 nM, 100 nM and 200 nM; mRNA 
targets (PDCD4, SPRY1, PTEN for LNA-miR-21 and LATS2, STK40 for LNA-miR-31) were 
measured 24, 48 and 72 h after transfection and possible differences by transfection 
methods were chased by comparing Lipofectamine LTX & PLUS Reagent with 
Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific, Cat. No. 13778030). 
Additionally, HPMCs were transfected twice with miRCURY LNA inhibitors using 25 pM, 
50 pM, 25 nM, 50 nM and 12 h of difference between transfections. No differences in 
mRNA target expression were measured under all conditions described above. Exiqon 
specialists were contacted to share this outcome and found no clear explanation for the 
results obtained. Literature describes final use concentrations of miRCURY LNA 
inhibitors much higher than those described by Exiqon standard protocol in vitro which 
indicates potent activity at final concentrations of 1 - 50 nM, although pointing out that 
a more extensive range of 1 - 100 nM can be analyzed in optimization experiments. 
miRCURY LNA inhibitor concentration required may be even higher for this specific 
research as miR-21 and miR-31 were two of the highest miRNAs expressed in HPMCs. 
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Longer research time to develop this part of the project would have allow to test higher 
miRCURY LNA inhibitor concentrations and target protein levels with the concentrations 
and methods already described. Nevertheless, there are other miRNA inhibitors 
currently available at the market including mirVana miRNA inhibitor. Indeed, these 
miRNA inhibitors were used at concentrations of 5 pM, 10 pM and 20 pM for target 
mRNA measurements (48 h after transfection) and showed significant and consistent 
complementary results to those displayed by mirVana miRNA mimics for already 
described miR-21 and miR-31 targets. 
 
 Figure 2.5. siRNA transfection optimization for PDZD2, FGF-18, S100A10 and MATN2. 24-well plates 
were seed and transfected by 80% confluence following described protocol for Lipofectamine LTX & 
PLUS Reagent together and different siRNA concentrations. PDZD2, FGF-18, S100A10 and MATN2 
relative expression was measured 48 h after cell transfection. 
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2.3.  RNA analysis 
2.3.1. RNA isolation 
2.3.1.1. RNA extraction from PD samples 
When this project was initiated there was no published and validated protocol 
for miRNA extraction from PD effluent. Initial experiments using isolation protocol for 
urine samples previously developed at the department by Dr Beltrami (Beltrami, 2014) 
was compared with newly reported protocols for highly diluted samples (Burgos et al, 
2013). Two commercially accessible kits for RNA and/or miRNA extraction from fluid 
samples were used: the Qiagen miRNA-easy mini kit (QIAGEN, Cat. No 217004) was used 
with minor modifications recommended by Dr Beltrami (Beltrami, 2014), while the 
mirVana PARIS kit (Thermo Fisher Scientific, Cat. AM1556) was used with progressive 
addition of minor modifications recommended by Burgos et al. 2013 (Burgos et al, 
2013). Full protocol optimization for RNA extraction from 4h PDE from patients is 
developed in Chapter 4 (see 4.2.1-6) and included the use of (i) mirVana PARIS kit, (ii) 
1/3 volume ethanol to the aqueous phase, (iii) no use of MS2 RNA carrier, and (iv) cold 
Speed-Vac for 40 min.  
For RNA isolation using mirVana PARIS kit, PD effluent samples from PD patients 
were handled consistent with manufacturer’s recommendation with the following 
modifications. 600 µl of PDE sample were centrifuged for 20 min at 400 x g at 4°C. 500 
µl of sample were transferred to a new eppendorf to which 500 µl of denaturing solution 
and 0.5 pM of spike in Caenorhabditis elegans (cel-miR-39) (Ambion, Cat. No 4464066, 
Part No. MC10956) were subsequently added. Of note, order of reagent addition was 
important in this step as previous cel-miR-39 spiked into the PDE could trigger RNAse 
mediated cel-miR-39 degradation. Subsequently, samples were processed according to 
manufacturer’s protocol. After recovering 900 µl of aqueous phase (E1) the remaining 
organic layer was re-hydrated with 900 µl of water and an extra 1000 µl of aqueous 
phase (E2) were re-isolated (Figure 4.3A). Following sample processing was performed 
according to manufacturer’s guidelines, with the entire aqueous phase from each 
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sample loaded onto a single affinity column. RNA extracts were eluted in 100 µl of water 
previously warmed at 95°C in a silicon coated eppendorf and cold Speed-Vac during 40 
min. Final RNA concentrated extracts were stored at -80°C before experiment. 
2.3.1.2. RNA extraction from tissue samples (LCM and manual microdissection) 
Formalin-fixed, paraffin-embedded (FFPE) samples were processed immediately 
after sectioning using RecoverAllTM Total Nucleic Acid Isolation kit (Thermo Fisher 
Scientific; AM1975) according to the manufacturer’s recommendations. Membrane 
polymer situated upon LCM caps was carefully removed from the caps and miRNAs were 
extracted with minute protocol modifications. Variants introduced include (i) 
deparaffinization step was required and performed before LCM and (ii) 1 µg of RNA 
carrier MS2 (Roche; Cat. No. 10165988001) was added during the nucleic acid isolation 
stage to improve RNA recovery.  
Briefly, 400 µl of Digestion Buffer and 4 µl of Protease were combined into 
eppendrofs containing LCM membrane polymers and incubated at 50°C for 15 min and 
at 80°C for 15 min. 120 µl of Isolation Additive together with 275 µl of 100% ethanol and 
1.25 µl of MS2 RNA carrier were added to each sample. 700 µl of mixture was placed 
into a filter cartridge and centrifuged during 30 sec at 10,000 x g. Nucleic acids bind to 
the cartridge filter while the remaining substances pass through and are discarded. 
Filters are subsequently washed using wash 1 buffer and wash 2/3 buffer. DNA was 
degraded by incubating the filter with 60 µl of DNA mix containing 6 µl 10 x DNase 
Buffer, 4 µl DNase and 50 µl water for 30 min at RT. Cartridge filters were newly washed 
using wash 1 buffer and wash 2/3 buffer. Clean RNA was eluted with pre-heated water 
95°C (60 µl). RNA was stored in all cases at -80°C prior experiment. 
2.3.1.3. RNA extraction from HPMCs 
HPMCs were lysed in TRI reagent (Termo Fisher Scientific; Cat. No. 15596-026), 
and RNA was extracted as recommended by the manufacturer. TRI reagent combines 
phenol and guanidine thiocyanate in a single phase to quickly inhibit RNase activity. 6-
well plated cells were lysed in 1 ml TRI Reagent solution and incubated at room 
temperature for 5 min to favor total dissociation of nucleoprotein complexes. 200 µl of 
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chloroform (Sigma) were added to the homogenate, vortexed vigorously, incubated 5 
min at room temperature and centrifuged at 12,000 x g for 15 min at 4°C to separate 
aqueous and organic phases. RNA stays at the upper (aqueous phase) while DNA and 
proteins displace to the interphase or organic phase respectively. Aqueous phase was 
isolated and RNA precipitated by adding 500 µl of isopropanol (Sigma) and centrifuging 
at 12,000 x g for 10 min at 4°C. RNA precipitates were washed 3 times with 1 ml of 75% 
ethanol (Sigma) and centrifuged 12,000 x g for 5 min at 4°C. Clean RNA pellet was air-
dried for 15 min and rehydrated in 10 µl of nuclease-free water. Sample purity and RNA 
concentration was measured using 1 µl of sample by NanoDrop 2000 
spectrophotometer (Thermo Scientific). RNA was stored in all cases at -80°C prior 
experiment. 
2.3.1.4. RNA quantification and quality control 
RNA concentration was measured using NanoDrop 2000 UV spectrophotometer. 
NanoDrop uses absorbance wavelength 260 nm (A260nm) measures to calculate nucleic 
acid concentration using the following equation:  
[Total RNA µg/ml] = A260nm x 40 x dilution factor. 
NanoDrop also measures absorbance wavelength 280 nm (A280nm) to provide a 
contamination parameter. A260nm/A280nm ratio of ~2.0 is accepted as ‘pure’ RNA while 
lower ratios indicate sample contamination by other molecules that may include 
protein, phenol or other contaminants that absorb strongly at or near 280 nm. 
A260nm/A230nm ratio was also used as a second indicator of nucleic acid sample purity. 
A260nm/A230nm ratio of ~2.0 – 2.2 is accepted as ‘pure’ RNA while lower ratios indicate 
sample contaminants that absorb near 230 nm. EDTA, carbohydrates (plant extractions) 
and phenol absorb near 230 nm while TRI Reagent (phenolic solution) absorbs at 230 
nm and ~270 nm. RNA chemical contamination may result in concentration 
overestimation and/or affect downstream analysis. Only samples with a ratio above 1.5 
were used for further analysis.  
Total RNA/miRNA extracted, mean A260/A280 and A260/A230 purity ratios from PDE 
samples were low and inaccurately read using NanoDrop 2000c. NanoDrop 2000c uses 
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1-2 µl of sample to measure absorbance of UV-visible light to quantify nucleic acid 
concentration and has a usable range between 0.4 - 15,000 ng/µl. Sample pH and ionic 
strength changes cause Absorbance variation (Wilfinger et al, 1997). Further RNA quality 
and concentration assessment were performed using 1.5 μl of sample and Agilent 2100 
Bioanalyzer in conjunction with RNA 6000 Pico assay which has a usable range between 
50 – 5000 pg/μl. Samples were run by the Central Biotechnology Service (CBS) of Cardiff 
University. Although the ladder ran properly something interfered with the run of the 
PDE samples suggesting a cofounding factor in the lavage solution that was causing the 
effects (Figure 2.6). This possibility was reported and confirmed by Dr Krystyna Nahlik, 
genomics support scientist from Agilent Technologies. Dr Krystyna Nahlik indicated that 
Pico kit was very sensitive to increased salt concentration in the samples which can 
greatly reduce the overall signal. Therefore, it was not possible to accurately estimate 
RNA yield and purity using the above mirVana PARIS optimized protocol for PDE 
samples. Following the results obtained from this first study (Figure 4.1-3) the mirVana 
protocol was employed for further research.                                       .
Figure 2.6. PD Effluent miRNA purity and quantification. (A) Example of total RNA sample analyzed 
by electropherogram and displaying miRNA and small RNAs region. (B) Capilar electrophoresis of six 
independent RNA extracted PDE samples. (C) Ladder. (D) RNA extracted PDE independent 
electropherograms (n=6).  
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2.3.2. miRNA detection 
miRNAs can be detected by different methods including northern blot, solution 
hybridization and RT-PCR-based methods. RT-PCR-based methods are more sensitive, 
accurate, do not use radiolabeled reagents and can be quantitative, therefore, were 
chosen as a first option for this project.  
miRNA size (~ 22 nt) does not allow common RT-PCR reaction used for mRNA. 
Two short RNA quantitative RT-PCR systems were described a decade ago based on 
stem-loop RT-qPCR (Applied Biosystems TaqMan miRNA assays; now Thermo Fisher 
Scientific) and polyadenylation-based RT-qPCR (Invitrogen NCode miRNA Detection 
System) (Chen et al, 2005; Shi & Chiang, 2005) (Figure 2.7). miRNA detection using stem-
loop system (Thermo Fisher Scientific) involved two-steps quantitative reverse 
transcription – polymerase chain reaction (RT-qPCR) (Chen et al, 2005) (Figure 2.7A). RT 
step uses a miRNA specific RT primer that contains few nucleotides complementary to 
the mature miRNA 3’ end and a long extra-sequence. This unrelated sequence forms a 
stem-loop structure that cannot interact with non-specific molecules in the RT reaction 
including pre- and pri-miRNA, increasing assay specificity. Assay PCR primers are 
identical to the mature miRNA 5’ end and a sequence into the long stem-loop RT primer. 
TaqMan probes provide fluorescence signal needed for quantitative detection and bind 
between the miRNA and RT-primer. Thermo Fisher Scientific TaqMan miRNA assays are 
tested and amplification efficiency values range from 100% (±10%). Invitrogen NCode 
miRNA Detection System employs a polyadenylation reaction and a subsequent RT 
transcription of the resulting tailed miRNA (Shi & Chiang, 2005) (Figure 2.7B). 
Nevertheless, this system was previously analyzed at the department and showed poor 
sensitivity and reliability (Krupa, 2010). Of note, Thermo Fisher Scientific recently 
released TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher Scientific, 
A28007) which provides a universal RT approach for all TaqMan Advanced miRNA Assays 
(Figure 2.7C). This new method uses 3’ poly-A tailing and 5’ ligation of an adaptor 
sequence to extend the miRNA prior RT while cDNA is universally amplified using miRNA 
specific primers. Nevertheless, TaqMan Advanced technology was not available when 
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this project started and miRNA detection using two-step stem-loop system (Thermo 
Fisher Scientific) was used during this thesis. 
 
 
 
 
 
 
 
 
2.3.2.1. Reverse Transcription 
miRNA Reverse transcription (RT) was performed using the High-Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Scientific, Cat. No. 4372814). RT master mix 
contained: 4.25 µl water, 1.5 µl 10 x Reverse Transcription Buffer, 0.15 µl 100 mM 
dNTPs, 0.1 µl 40 U/µl RNase Inhibitor (New England BioLabs® Inc, Cat. No. M0307S), 1 
µl 50 U/µl MultiScribe Reverse Transcriptase and 3 µl 5x miRNA RT-primer specific (Table 
2.4). 10 µl of RT master mix were added to 5 µl of cell extracted RNA (10 ng) or 5µl of 
tissue isolated RNA. Alternatively, 5.75 µl of RT master mix lacking water was added to 
Figure 2.7. Schematic overview of RT-qPCR miRNA detection systems. (A) Stem-loop RT-qPCR miRNA 
detection system. miRNA quantification using this technology entails two consecutive steps. Firstly, RT 
reaction combines a long stem-loop specific miRNA primer containing few nucleotides complementary 
with a particular miRNA 3’ end. Secondly, quantitative PCR with a specific miRNA forward primer, a 
reverse primer localized into the long stem-loop RT-primer sequence and TaqMan probes as a 
fluorescence source binding to the region between the two PCR primers (Chen et al. 2005). (B) 
Polyadenylation-based RT-qPCR miRNA detection system. miRNA quantification using this technology 
entails three consecutive steps. Firstly, total RNA is polyadenylated (poly(A)). Secondly, poly(A) miRNAs 
are RT using poly(T) adapter. Finally, quantitative PCR with a specific forward primer, reverse primer 
complementary to poly(T) adapter and SYBR green fluorescent DNA binding dye which binds all double 
- stranded DNA, is performed (Shi & Chiang 2005). (C) TaqMan advanced RT-qPCR miRNA detection 
system. miRNA quantification using this technology entails four consecutive steps. Firstly, total RNA is 
polyadenylated (poly(A)). Secondly, poly(A) miRNAs are RT using poly(T) adapter. Thirdly, 
oligonucleotide adapter is ligated to the miRNA 5’ end. Finally, quantitative PCR with a specific adapter 
forward primer, reverse primer complementary to poly(T) adapter and TaqMan probes as a 
fluorescence source binding to the region between the two PCR primers.  
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9.25 µl of PDE extracted RNA. RT non-template control (RT-NTC) or negative control 
reaction contained an equal volume of water instead of diluted RNA. Thermal cycling 
conditions used were: 30 min at 16°C, 30 min at 42°C, 5 min at 85°C, followed by a 
cooling step at 4°C. Generated cDNA was diluted with water 1:3 prior use in qPCR 
reaction which will be detail in the next section (see 2.3.2.2.). 
2.3.2.2. Quantitative Polymerase Chain Reaction 
miRNA quantitative polymerase chain reaction (qPCR) was performed combining 
1 µl of miRNA specific PCR primers and TaqMan probe (designed and supplied by 
Thermo Fisher Scientific, Table 2.4), 5 µl of water and 10 µl of Universal PCR Master Mix 
with No AmpErase UNG consisting of an optimized and thermostable solution of DNA 
polymerase, deoxynucleotides, and passive reference dye ROX (Thermo Fisher Scientific, 
Cat. No. 4440047). 16 µl of miRNA specific master mix and 4 µl of (1:3) diluted cDNA, 
diluted (RT-NTC) and water (qPCR-NTC) were added to wells into Optical 96-Well Fast 
Plate (Thermo Fisher Scientific, Cat. No. 4346906). MicroAmp Optical Adhesive Film 
(Thermo Fisher Scientific, Cat. No. 4311971) was used to seal the plate previous reaction 
performance on ViiA7 Real-Time PCR System (Thermo Fisher Scientific, Cat. No. 
4453534) according to manufacturer’s cycling parameter recommendations: 10 min at 
95°C, 40 cycles of 15 secs at 95°C and 1 min at 60°C. 
 
miRNA assay Catalog Number 
cel-miR-39 
Part. Number 4427975 
Assay ID 000200 
has-miR-21-5p 
Part Number 4440887 
Assay ID 000397 
hsa-miR-31-5p 
Part Number 4440887 
Assay ID 002279 
hsa-miR-191-5p 
Part Number 4440887 
Assay ID 002299 
mmu-miR-31-5p 
Part Number 4427975 
Assay ID 000185 
 
          Table 2.4. TaqMan RT-qPCR assays used in this study. 
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2.3.2.3. miRNA microarrays 
Microarray assays were performed on HPMCs derived from four independent 
donors. miRNA expression was measured in control samples and after 1 ng/ml of TGF-
β1 treatment for 48 h. TGF-β1-driven MMT was confirmed in all samples by analysis of 
the eight molecular markers previously described. RNA was extracted using TRI reagent 
with minimal changes to the manufacturer’s recommendations (see 2.3.1.3.). A total of 
1 μg in a volume of ≤2 μl of total RNA from each sample was subsequently used for Toray 
microarray analysis, performed by Central Biotechnology Services at Cardiff University 
as described previously (Jenkins et al, 2014). 
RNA quality and concentration assessment were performed using 1 μl of sample 
(˂ 500 ng/μl) Agilent 2100 Bioanalyzer. A final 500 ng of total RNA from each sample was 
labeled with Cy5 using the Label IT miRNA labeling kit. 3D-Gene antisense-miRNA oligo 
chips were hybridized with the resulting labeled miRNAs. The chips were rigorously 
washed prior fluorescent signal scanner by ScanArray Lite Scanner and analyzed using 
GenePix Pro software (see 2.6.1.).  
2.3.3.  mRNA detection 
mRNAs were measured in whole samples by two-step quantitative reverse 
transcription – polymerase chain reaction (RT-qPCR). 
2.3.3.1. Reverse Transcription 
mRNA Reverse transcription (RT) and consequent cDNA generation was 
performed using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific, Cat. No. 4372814). RT master mix contained: 4.1 µl nuclease-free water, 2 µl 
10 x RT Buffer, 0.8 µl 100 mM dNTPs, 0.1 µl 40 U/µl RNase Inhibitor (New England 
BioLabs® Inc, Cat. No. M0307S), 1 µl 50 U/µl MultiScribe Reverse Transcriptase and 2 µl 
10 x RT random primers. 10 µl of RT master mix were added to 10 µl of cell extracted 
RNA containing 1 µg of RNA. RT non-template control (RT-NTC) or negative control 
reaction contained an equal volume of water instead of diluted RNA. Thermal cycling 
conditions used were: 10 min at 25°C, 2 h at 37°C and 5 secs at 85°C, followed by a 
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cooling step at 4°C. Generated cDNA was diluted by adding 60 µl of water prior use in 
qPCR reaction which will be detail in the next section (see 2.3.3.2.). 
2.3.3.2. Quantitative Polymerase Chain Reaction 
mRNA quantitative polymerase chain reaction (qPCR) was performed combining 
0.6 µl of mRNA specific PCR primers (300 nM, forward and reverse, Table 2.5), 10 µl of 
Power SYBR® Green PCR Master Mix (Thermo Fisher Scientific, Cat. No. 4367659) and 
4.8 µl of water. 16 µl of mRNA specific master mix and 4 µl of diluted cDNA, diluted (RT-
NTC) and water (qPCR-NTC) were added to wells into Optical 96-Well Fast Plate (Thermo 
Fisher Scientific, Cat. No. 4346906). MicroAmp Optical Adhesive Film (Thermo Fisher 
Scientific, Cat. No. 4311971) was used to seal the plate previous reaction performance 
on ViiA7 Real-Time PCR System (Thermo Fisher Scientific, Cat. No. 4453534) according 
to manufacturer’s cycling parameter recommendations: 10 min at 95°C, 40 cycles of 15 
secs at 95°C and 1 min at 60°C. Single PCR product amplification was confirmed by 
melting curve analysis. 
Specific mRNA primers were designed using Primer-BLAST and NCBI sequence 
database, to amplify all known splice-variants. To elude genomic DNA amplification, 
primers were in different exons or bound to exon-exon junctions for design. PCR product 
length was, ideally, between 75 – 150 bp. 
2.3.4.  RT-qPCR data analysis 
For qPCR data analaysis, Viia7 software and GraphPad Software version 6 were used. 
Relative expression was calculated using the 2-∆∆CT method (Livak & Schmittgen, 2001). 
Threshold cycle (Ct), indicates the number of PCR cycles needed to detect fluorescence 
during specific PCR product amplification. Thus, 100% efficiency denotes double number 
of product copies with every PCR cycle. Single cycle difference (∆Ct = 1) between two 
samples indicates 2-fold change in gene expression between samples. Two cycles 
difference (∆Ct = 2) indicates 4-fold (22) change in gene expression, ∆Ct = 3 indicates 8-
fold (23) change, etcetera. miR-191 and GAPDH have been used here as endogenous 
housekeeping genes for data analysis. Other miRNAs and mRNA controls were evaluated 
including miR-16, 18S rRNA and U6 snRNA but showed poorer performance. 
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Symbol Reverse and Forward Primers (5’-3’) Primer design 
E-CADHERIN 
F: TCCCAATACATCTCCCTTCACA 
R: ACCCACCTCTAAGGCCATCTTT 
By T.Bodenham 
ZO-1 
F: GGAGAGGTGTTCCGTGTTGT 
R: GGCTAGCTGCTCAGCTCTGT 
By D.D.Luo 
OCCLUDIN 
F: TAAATCCACGCCGGTTCCTGAAGT 
R: AGGTGTCTCAAAGTTACCACCGCT 
Subramanyam et al., 2011 
CLAUDIN-1 
F: CGGGTTGCTTGCAATGTGC 
R: CCGGCGACAACATCGTGAC 
Kaarteenaho et al., 2010 
FIBRONECTIN 
F: CCGAGGTTTTAACTGCGAGA 
R: TCACCCACTCGGTAAGTGTTC 
By T.Bodenham 
COLLAGEN1A1 
F: CATGTTCAGCTTTGTGGACCTC 
R: TTGGTGGGATGTCTTCGTCT 
By T.Bodenham 
SNAIL 
F: TTTACCTTCCAGCAGCCCTA 
R: GGACAGAGTCCCAGATGAGC 
By D.D.Luo 
α-SMA 
F: AACTGGGACGACATGGAAA 
R: AGGGTGGGATGCTCTTCAG 
By T.Bodenham 
GAPDH 
F: CCTCTGACTTCAACAGCGACAC 
R: TGTCATACCAGGAAATGAGCTTGA 
By A.Krupa 
NPPB 
F: CTTTCCTGGGAGGTCGTTCC 
R: GTTGCGCTGCTCCTGTAAC 
By M. Lopez-Anton 
S100A10 
F: TCGCTGGGGATAAAGGCTAC 
R: GCCAGAGGGTCTTTTTGATTTTCC 
By M. Lopez-Anton 
SASH1 
F: CCTGGAAGTGGAGAAACCCG 
R: GCCAAGCGACTCTTCGATCT 
By M. Lopez-Anton 
TIMP3 
F: TGCAACTTCGTGGAGAGGTG 
R: AGCAGGACTTGATCTTGCAGT 
By M. Lopez-Anton 
AIM1L 
F: CAGACTGTGAGTAGAGGGAGC 
R: CAACCTGTCTGGAGGTGTCC 
By M. Lopez-Anton 
CASKIN1 
F: GAGGGCAAGAGCTCTGAGG 
R: TGATGAAGTTGGGGGCGTAG 
By M. Lopez-Anton 
DUSP8 
F: GAGCGAGGTCCAGCACCAT 
R: GGTGACCCCTGAAGTGAGGA 
By M. Lopez-Anton 
FGF18 
F: GACGATGTGAGCCGTAAGCA 
R: GAGCTGGGCATACTTGTCCC 
By M. Lopez-Anton 
MATN2 
F: CGGTGCAAGAAATGCACTGA 
R: CCAGTGACAAACTGCTTCACG 
By M. Lopez-Anton 
NELL2 
F: GCACATGCCTGAATGGAACC 
R: AGTGGGCAGTCAGGATTTGG 
By M. Lopez-Anton 
RHOB 
F: TTGCAACTGACTTGGGGAGG 
R: GACAGGCACAAAGTTCGCTT 
By M. Lopez-Anton 
PDCD4 
F: TGGATTAACTGTGCCAACCA 
R: TCTCAAATGCCCTTTCATCC 
By M. Lopez-Anton 
SPRY1 
F: AGATGCATGCCAGGTTTCCA 
R: TAACGAACTGCCACTGCCAT 
By M. Lopez-Anton 
PDZD2 
F: CCTGGCATTGGGAGAAGTGT 
R: CATCCAGACTCAGTCCCAGC 
By M. Lopez-Anton 
LATS2 
F: CAGATTCAGACCTCTCCCGT 
R: CTTAAAGGCGTATGGCGAGT 
By M. Lopez-Anton 
STK40 
F: CCAGTGCCCTTGCCTCATAA 
R: AATCTCGGCTCAAAAGGGCA 
By M. Lopez-Anton 
 
Table 2.5. Quantitative PCR SYBER Green primers designed and used in this study. 
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Differences between sample starting RNA concentration, or subsequent process 
inaccuracies, were normalized to the expression of a non-experimentally influenced 
gene/miRNA called endogenous control. 2-∆∆CT method, calculates sample specific Ct 
differences between target gene/miRNA and endogenous control (∆Ct = CtTARGET-
CtENDOGENOUS CONTROL). 2-∆∆CT method expresses quantity relative to a selected base sample, 
called calibrator, (e.g. untreated control) in a way that calibrator expression = 1 and all 
other quantities are expressed as an n-fold difference relative to the calibrator (∆∆Ct = . 
∆Ct - ∆CtCALIBRATOR). Final sample specific 2-∆∆CT calculation proportionate target 
gene/miRNA expression that is endogenous control normalized and calibrator relative, 
called relative expression (RQ). Alternatively, 40-Ct was used when adequate.  
2.4.  Protein analysis 
2.4.1.  Western blot 
Detection of already described miRNA targets by Western blot was used to 
evaluate miRNA manipulation of specific targets of study.  
Cell lysis 
Whole cell samples were collected using RIPA Lysis Buffer (Santa Cruz 
Biotechnology, sc-24988). Cells were previously washed 3 times with cold PBS. 
Immediately prior use 10 μl PMSF, 10 μl sodium orthovanadate and 10 μl protease 
inhibitor cocktail solution per 1X ml of RIPA Lysis Buffer, containing Tris-HCl, NP-40, Na-
deoxycholate, SDS, NaCl, EDTA and NaF, were prepared and 200 μl/well of complete 
RIPA were added on experimental 6 well-plates. Cells were incubated on ice during 5 
min and lysate was collected with a cell scraper help into an Eppendorf to centrifuge for 
10 min and 16,000 xg at 4°C. Cell supernatant was collected, aliquoted and - 80°C stored 
until needed. 
Bradford Assay protein quantification  
BioRad Protein Assay (BioRad, 5000001) is based on the Bradford method and 
consists on a dye-binding assay in which a dye color changes in response to protein 
concentration (Bradford, 1976). Coomassie Brilliant Blue G-250 dye maximal absorbance 
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shifts from 465 nm to 595 nm when protein binding occurs. Standard Bovine Serum 
Albumin (BSA) curve was prepared by 2 - fold serial dilutions (1000 – 15.6 ng/μl range) 
and protein cell lysates were diluted 4 - fold. Bradford reagent 5x was diluted with water 
1:5 and 200 μl/well were added into 96 well-plate wells containing 5 μl of BSA standards, 
samples or water (blank) in triplicate. Absorbance at 595 nm was measured after 5 min 
using a FLUOstar OPTIMS plate reader. 
SDS-PAGE 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed by the method of Laemmli (Laemmli, 1970). Protein samples were thawed 
on ice and 15 µg or 30 µg of sample were mixed with 3x Reducing Loading Buffer (see 
Appendix) and heated at 95°C for five minutes. Samples were ice cooled and gel loaded 
for electrophoresis (Table 2.6). Additionally, 5 μl of ladder were loaded in one of the 
wells. Gel electrophoresis was performed using BioRad Mini Protein II devices, in 
Running Buffer (see Appendix), at 100 V for 20 min and 150 V for considered time. 
Components 
Resolving gel  
7.5% (w/v) 
Stacking gel 
Water 7.275 ml 6.1 
Buffer 
1.5 M Tris-HCl pH 8.8 
3.75 ml 
0.5 M Tris-HCl pH 6.8 
2.5 ml 
10% (w/v) SDS 150 µl 100 µl 
Acrylamide 29.2% (w/v)/ 
Bisacrylamide 0.8% (w/v) 
3.75 ml 1.3 ml 
10% Ammonium Persulphate  
(0.05 g in 500 µl water) 
75 µl 75 µl 
TEMED 7.5 µl 10 µl 
 
Table 2.6. Sodium dodecyl sulfate-polyacrylamide gels for electrophoresis (SDS-PAGE) 
Protein transfer to nitrocellulose membrane 
Nitrocellulose membrane (GE Healthcare, Life Sciences) transfer of gel 
electrophoresis separated proteins was performed using BioRad Mini Blot II devices. 
Membrane, filter paper and pads were pre-soaked in cold Transfer Buffer (see 
Appendix). Transfer cassette was assembled following the negative charge by a pad, 
paper, gel, membrane, two papers, pad and positive charge. The cassette was installed 
into the holder and the device was filled with pre-chilled Transfer buffer, an ice pack and 
stirring bar. Transfer was performed for 1 hour at 100 V. 
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Antibodies Incubation 
Nitrocellulose membrane was blocked to prevent non-specific antibody binding 
for 1 hour with 5 % BSA (w/v) in Phosphate-Buffered Saline (PBS) solution containing 0.1 
% (v/v) Tween-20. Membrane was washed with 0.5 % (v/v) Tween-20 in PBS for 10 min 
and subsequently incubated overnight at 4°C with primary antibodies in PBS with 0.1 % 
(w/v) BSA and 0.1 % (v/v) Tween-20. Membranes were washed 3x with 0.5 % (v/v) 
Tween-20 in PBS for 10 min each and subsequently incubated overnight at 4°C with 
appropriated secondary antibody. Primary and secondary antibodies were PDCD4 
(1:1000; #9535 D29C6; Cell Signalling Technology), GAPDH (1:2000; ab9885; Abcam), 
goat anti-rabbit IgG-HRP (1:10000; sc-2004; Santa Cruz Biotechnology) and goat anti-
mouse IgG-HRP (1:10000; sc-2005; Santa Cruz Biotechnology. Following, secondary 
antibody incubation membrane was washed with 0.5 % (v/v) Tween-20 in PBS for 10 
min, excess of solution was removed while keeping the membrane wheat and ladder 
was underlined using a (WesternSureTM Pen, LI-COR) pen. Membrane was 
homogenously sprayed using WesternBright ECL Spray (Advansta, K-12049-D50) and 
incubated at room temperature for 1 min, protein detected images were captured via 
C-DiGit Chemiluminescent Western Blot Scanner and densitometry analysis was 
conducted using Image Studio Version 5.2 Software. 
Membrane stripping and re-probing 
Membrane stripping was performed by incubation in Stripping Buffer (Re-BlotTM 
Plus-Strong, Merck Millipore), at room temperature for 30 min. Subsequently, 
membranes were washed 3x with 0.5 % (v/v) Tween-20 in PBS for 10 min each and 
process adequacy was confirmed by lack of membrane signal after HRP substrate 
incubation. Membranes were then washed and re-probed as described previously. 
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2.4.2.  Immunohistochemistry 
Immunohistochemical staining of peritoneal membrane study samples was 
performed on 5 μm sections mounted on glass slides as previously described (Heller et 
al, 2007). After deparaffinization and rehydration the sections were incubated in 3% 
hydrogen peroxide to block endogenous peroxidases. Heat-induced antigen retrieval 
was performed in a microwave oven, using 0.005 M citrate buffer (pH 6). Polyclonal 
rabbit anti p-SMAD2/3 (Santa Cruz; sc-11769) was incubated for 1 h at room 
temperature (1:100). Monoclonal rabbit anti PDCD4 (Cell signalling, D29C6) was 
incubated overnight at 4°C (1:200). Incubation with biotinylated secondary reagents 
(Vector) for 30 min was followed addition of ABC reagent (Vector) and detection carried 
out using 3ʹ-Diaminobenzidine (DAB, Sigma, Taufkirchen, Germany). Cell nuclei were 
counterstained with hematoxylin. Isotype control antibody in PBS was used as a negative 
control.  
Aperio Analysis 
Immunohistochemical images were captured and evaluated using Aperio 
Precision Image Analysis Software (USA). The Positive Pixel Count Algorithm (version 9) 
output was used to calculate total p-SMAD2/3 and PDCD4 staining. The algorithm 
quantifies the positive pixels in a scanned virtual slide. Input algorithm parameters are 
specific color ranges in the HSI colorspace (Hue value 0.1; Hue width 0.5) and intensity 
ranges to differentiate between weak, medium, strong and negative staining.  Intensity 
thresholds (upper/lower limit): weak 220/175, medium (175/100), strong (100/0) and 
negative (255/220). Thresholds were optimized and validated specifically for p-
SMAD2/3 and PDCD4. Positivity was calculated as total number of positive pixels divided 
by total number of pixels: (Ntotal-Nn)/( Ntotal). 
2.4.3.  Luciferase activity 
Firefly (Photinus pyralis) luciferase coding DNA sequence (CDS) was used for all 
reporter plasmids created in this study and was routinely co-transfected with a control 
plasmid coding for Renilla (Renilla reniformis) luciferase. Firefly and Renilla luciferases 
have different origin, structures and substrate requirements allowing bioluminescent 
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reaction discrimination. Dual-Luciferase Reporter Assay System (Promega, E1910), both 
luciferase activities can be measured sequentially in a single sample.  
Briefly, transfected cells were washed 3x with PBS and 50 µl of Passive Lysis 
Buffer (1:5 diluted in water) was added per well (48 well-plate). Experimental cells were 
incubated with gentle rocking during 15 min at room temperature and cell lysates were 
subsequently transferred to Eppendorfs. 20 µl of aliquoted sample was transferred into 
white 96-well-plate wells and 50 µl of Luciferase Assay Reagent II (firefly luciferase 
substrate) was added prior luminescence measurement on FLUOstar OPTIMA plate 
reader. 50 µl of Stop & Glo Reagent (Renilla luciferase substrate and previous reaction 
quencher) were added to 96-well-plate wells prior Renilla luminescence measurement. 
Untransfected cell lysates were used to determine background. Results express relative 
ratio of experimental firefly vector to control Renilla vector luciferase activity introduced 
in HeLa and HPMCs.  
2.5.  Bioinformatics 
2.5.1. microRNA target prediction 
miRNA target prediction programs are routinely used to find miRNAs that may 
regulate genes of interest and/or to identify possible targets of specific miRNAs. Diana 
(Paraskevopoulou et al, 2013; Reczko et al, 2012), miRanda - mirSVR (Betel et al, 2010; 
Betel et al, 2008), miRDB (Wang & El Naqa, 2008; Wong & Wang, 2015) and TargetScan 
(Agarwal et al, 2015; Nam et al, 2014) are between the algorithms most commonly used 
for predictions and were chosen to identify possible new targets of the miRNAs of 
interest. An actualized summary Table 2.7 based on Peterson et al. 2014 is displayed 
below to compare these tools (Agarwal et al, 2015; Peterson et al, 2014; Wong & Wang, 
2015). The threshold used for each one of these algorithms and comparison on Figure 
5.6 was Diana = 0.7, miRanda – mirSVR = - 0.95, miRDB = all targets and TargetScan = - 
0.24. The use of these tools as well as their quality and reliability will be further discussed 
in Chapters 5 and 6. 
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Tool Name 
Seed 
match 
Cons. 
Free 
energy 
Site 
access. 
Target-site 
abundance 
Machine 
learning 
References 
Diana X X X X X X 
(Paraskevopoulou 
et al, 2013; 
Reczko et al, 
2012) 
miRanda-
mirSVR 
X X X X  X 
(Betel et al, 2010; 
Betel et al, 2008) 
miRBD X X X X No* X 
(Wang & El Naqa, 
2008; Wong & 
Wang, 2015) 
TargetScan X X X* X* X* No* 
(Agarwal et al, 
2015; Nam et al, 
2014) 
 
Table 2.7. Summary of in silico miRNA target prediction methods used for this study. Acess. 
(accessibility), Cons (Conservation). Table displayed is based on Peterson et al. 2014 summary table and 
*actualized with references that were not available for Petersons et al. 2014 review. 
2.5.2. miRNA conservation and mRNA – miRNA hybrid prediction 
mRNA 3’UTR target site conservation for identified genes of interest was 
analyzed across different animals including human, chimpanzee, rhesus, rabbit, mouse, 
rat, cow, horse, dog and elephant. Target sequences were acquired using TargetScan 
and alignment was performed with mega 6. mRNA-miRNA hybrid was predicted using 
Diana v5.0 (Paraskevopoulou et al, 2013; Reczko et al, 2012). 
2.6. Statistical analysis 
Differences between two individual experimental groups of normally distributed 
values were compared by matched or non-matched two-tailed t test. In the case of 
multiple comparisons, one- or two-way analysis of variance (ANOVA) followed by post 
hoc Holm-Sidak’s test was used. 
For the clinical data, Pearson’s correlations were used for normally distributed 
variables, transformed as necessary, and Spearman’s for other variables, with no 
correction for multiple testing in an exploratory analysis. Multivariable linear regression 
with backwards stepwise variable selection was used for natural log transformed miR-
21 and square root transformed miR-31 variables, and to avoid problems with 
suppressor effects dialysate cytokine values were entered as a block.  
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2.6.1. miRNA microarrays 
GenePix Pro software considers a valid spot any probe hybridization which signal 
intensity is greater than the mean intensity of the background signal plus 2 standard 
deviations. A normalization step for each specific miRNA adjusted median value is 
subsequently performed. This will identify and remove sources of systematic variation 
within arrays correcting for spatial and dye bias. The relative miRNAs expression level is 
determined by comparing the mean signal intensity of the real hybridizated spots with 
their average value across the microarray experiment. To reliably compare data from 
multiple chips a quantile-normalization was applied to the values. This last normalization 
minimizes non-biological differences between arrays giving to disparate datasets the 
same histogram distribution by transforming the quantiles to obtain the same value. 
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Chapter 3 – Identification of miRNAs involved in  
Peritoneal Mesothelial MMT 
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3.1  Introduction 
PD therapy leads to a complex microenvironment that drives peritoneal 
membrane damage via altered expression of a broad spectrum of cytokines and factors. 
TGF-β1 is a pro-fibrotic cytokine, the up-regulation of which has been associated with 
poor PD results, and is assumed to be a key molecule in peritoneal deterioration (Gangji 
et al, 2009; Lai et al, 2000; Yao et al, 2008). The importance of TGF-β1 in peritoneal 
decline has also been indicated by (i) rodent studies (Margetts et al, 2005; Margetts et 
al, 2001; Patel et al, 2010a), (ii) overexpression of TGF-β1 antagonist molecules including 
Smad7 and BMP-7 (Guo et al, 2007; Loureiro et al, 2010; Nie et al, 2007; Yu et al, 2009), 
and (iii) TGF-β1-blockade via synthetic peptides (Loureiro et al, 2011). TGF-β1 is a well 
characterized molecule triggering EMT in different tissues and organs (Gui et al, 2012; 
Xu et al, 2009), and an essential molecule for mesothelial cell MMT conversion during 
PD treatment (Aguilera et al, 2005; Loureiro et al, 2011; Yang et al, 2003; Zhu et al, 2010). 
TGF-β1-driven phenotypic change in primary mesothelial cells was, therefore, the 
primary model chosen to study mechanisms of peritoneal MMT progression associated 
with PD therapy (Selgas et al, 2006), although this model was also supplemented in 
subsequent experiments by additional in vitro, ex vivo and in vivo approaches. 
Limited research has studied miRNAs implications in the regulation of key 
molecular pathways driving peritoneal membrane alterations leading to PD failure (see 
1.6.3). In vitro models, although more simplistic, may be critical to understand the 
specific pattern of miRNA expression in response to a known stimulus in a specific cell 
type where mechanistic research can be pursued. The study of miRNA profile associated 
to TGF-β1-driven MMT process in mesothelial cells was found to suit this research in 
four ways. miRNAs are (i) variable, (ii) specific, (iii) highly stable, and (iv) regulate gene 
expression. On the other hand in vitro mesothelial cells TGF-β1-driven MMT model is (i) 
simple, unique stimulus; and (ii) cell specific. miRNA characteristics (i) and (ii) associated 
to the models of study would be developed during this chapter while (iii) and (iv) would 
be further deepened and characterized in Chapters 4 and 5 respectively.  
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Consequently, the research pursued in this chapter (i) characterized mesothelial 
miRNA profile and responses to TGF-β1 in vitro, which identified miR-21 and miR-31 for 
further study, (ii) found increased miR-21 and miR-31 in mesothelial cells and 
supernatant after treatment with different PD fluids in vitro, (iii) identified miR-21 and 
miR-31 up-regulation in PD effluent (PDE) derived mesothelial cells exhibiting a 
mesenchymal phenotype when cultured ex-vivo, (iv) determined elevated miR-21 and 
miR-31 expression in peritoneal membrane biopsies from PD patients, (v) evaluated 
peritoneal membrane thickness and miRNA pattern of expression in an uraemic PD 
mouse model, and (vi) assessed miRNA miR-21 and miR-31 expression in supernatant 
from TGF-β1-treated mesothelial cells.  
3.2.  Results 
3.2.1. TGF-β1 induces Phenotypic Changes in Human Peritoneal 
Mesothelial Cells in vitro 
Before profiling mesothelial miRNA expression, a careful characterization of in 
vitro mesothelial-to-mesenchymal transition (MMT) was performed using primary 
cultures of mesothelial cells with replicate experimental cells from different omental 
donors. Converting a mesothelial cell to a mesenchymal cell is a complicated and 
organized series of processes that entails cellular structural and functional changes, 
including a deep molecular rearrangement and distinct changes in gene expression 
regulation. The MMT process begins with the detachment of inter-mesothelial 
adhesions and the down-regulation of adhesion molecules including E-cadherin, ZO-1, 
Claudins and Occludins. Here, TGF-β1 down-regulated mRNA expression of epithelial 
markers E-cadherin, ZO-1, Occludin and Claudin-1 at 48 h (Figure 3.1A). This effect was 
TGF-β1-concentration dependent and showed a threshold for statistical significance at 
1 ng/ml for all the markers of study (Figure 3.1A). 
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Snail1 is a key early transcription factor up-regulated during peritoneal TGF-β1-
mediated MMT and known to repress E-cadherin expression. Consequently, mesothelial 
cells lose their apical-basal polarity and assume a front-back organization via 
cytoskeleton rearrangement, α-SMA expression acquisition and enhanced migratory 
capabilities. Ultimately, cells develop the ability to degrade the basal membrane up-
regulating matrix metalloproteinases (MMPs) expression and invading the 
submesothelial compartment. Throughout the course of the MMT, mesothelial cells 
acquire greater competences to synthesize extracellular matrix (ECM) components 
including Fibronectin and Collagen I (Aroeira et al, 2005). Here, TGF-β1 up-regulated 
mRNA expression of mesenchymal markers Fibronectin, Collagen I, and α-SMA at 48 h 
(Figure 3.1B). Nevertheless, only α-SMA transcript showed a threshold for statistical 
significance at 1 ng/ml and Snail mRNA expression did not vary in mesothelial cells 
incubated with different doses of TGF-β1 after 48 h of treatment (Figure 3.1B).  
Loss of epithelial morphology and acquisition of fibroblast-like form was evident 
when mesothelial cells were incubated with 5 and 10 ng/ml of TGF-β1 after 48 h of 
treatment (Figure 3.2). Nevertheless, most of the mesothelial and mesenchymal 
markers studied showed a threshold for statistical significance at 1 ng/ml. Importantly, 
(A) (B) 
Figure 3.1. TGF-β1 represses epithelial and induces mesenchymal markers in mesothelial cells in a 
concentration dependent fashion. Omentum-derived mesothelial cells were treated with TGF-β1 at 
the indicated concentrations during 48 h. (A) Epithelial markers: E-Cadherin, ZO-1, Occludin and 
Claudin-1. (B) Mesenchymal markers: Fibronectin, Collagen I, Snail and α-SMA. mRNA expression of 
all markers was analyzed by RT-qPCR and normalized to GAPDH mRNA expression. Data were analyzed 
by one-way ANOVA for matched samples followed by post-hoc Holm-Sidak’s test comparing each 
concentration mean with the control mean. Data represent the mean S.E.M. from three independent 
donor experiments. *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.005.  
85 
 
MMT reversibility has been shown to be feasible during, at least, the initial-phases of 
the process. Consequently, the identification of early MMT stages in PD patients 
together with the determination of molecules that revert MMT promoting 
mesenchymal-to-mesothelial transition (rMMT) must be a priority in the PD field. Along 
these lines, this research focused in key early changes during mesothelial cells 
conversion that would lead the MMT process associated to the treatment. The minimum 
concentration of TGF-β1 able to induce MCs molecular expression reprogramming was, 
consequently, chosen for subsequent time-course characterization. 
Time-course experiments were then carried out to investigate temporal 
variation downstream TGF-β1 gene regulation. Down-regulation of epithelial mRNA 
markers was observed from 48 h onwards (Figure 3.1A; Figure 3.3, A-D). The mRNA 
expression of epithelial markers ZO-1, Claudin and Occludin was affected by cell 
confluence and was most evident after 72 h of treatment (Figure 3.3, A-D). By contrast, 
Fibronectin, α-SMA and Collagen I mesenchymal transcript markers were induced by 12-
24 h, with Snail mRNA expression peaking at 2 h (Figure 3.3, E-H). Snail has been 
described to be involved in the alterations of intercellular adhesion during the MMT 
process, and its early activity here may contribute to the latter changes observed in 
epithelial markers (Figure 3.1A).  
Figure 3.2. Phenotypic time-course changes of HPMCs in culture after TGF-β1 treatment. Omentum-
derived mesothelial cells were treated with 0, 0.01, 0.1, 1, 5 and 10 ng/ml of TGF-β1 during 48 h. (0-1 
ng/ml of TGF-β1) Characteristic epithelial morphology of polygonal shape cells from a confluent 
monolayer, star indicated. (5 and 10 ng/ml of TGF-β1) Loss of epithelial morphology and acquisition 
of fibroblast-like form, arrow indicated. One representative experiment of three is shown. Zeiss 
Axiovert 135 microscope. Magnification: 200x.  
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Phenotypic changes were not seen before 24 h. Fibroblast-like architecture was 
visible around 48 h, and these changes were most evident after 72 h (Figure 3.4). In 
summary, these results demonstrated that in primary HPMCs from multiple donors, 1 
ng/ml of TGF-β1 induced changes consistent with an MMT process after 48 h. This study 
was consequently focused in early key changes in miRNA expression during mesothelial 
cells conversion that would lead the MMT process associated to the treatment.  
3.2.2. Mesothelial miRNA profile is altered by TGF-β1  
To elucidate the influence of TGF-β1 treatment on mesothelial cells miRNA 
expression profiles, cells isolated from four different donors incubated with TGF-β1, 1 
ng/ml for 48 h and control non-treated cells were compared. Global miRNA expression 
was quantified by hybridization array. Independent biological replicates displayed high 
consistency (Figure 3.5B). A total of 699 miRNAs were detected in at least three samples 
and were included in subsequent analysis. 
miRNAs were analyzed on the basis of baseline level of expression, fold change in 
response to TGF-β1, and statistical significance of the observed change (Figure 3.5A). 95 
of 699 miRNAs were differentially regulated by a fold change greater than 1.5 x. Of 
these, miR-21 and miR-31 were among the most highly expressed in HPMCs, and were 
induced by TGF-β1 treatment (Figure 3.5A). Additional miRNAs previously associated 
with peritoneal membrane transport change and fibrosis were detected at low signal 
intensity in this profile and did not change significantly in response to TGF-β1 (includes 
miRs -15a, -17, -30, -192, -377, -589). Therefore, subsequent analysis focused on miR-21 
and miR-31. 
 
Figure 3.3. TGF-β1 represses epithelial and induces mesenchymal markers in mesothelial cells in a 
time dependent fashion. Omentum-derived mesothelial cells were treated with TGF-β1 at the 
indicated times. Control - white bars, TGF-β1 (1ng/ml) - black bars. (A) E-Cadherin. (B) ZO-1. (C) 
Occludin 1. (D) Claudin-1. (E) Fibronectin. (F) Collagen I. (G) Snail. (H) α-SMA. mRNA expression of all 
markers was analyzed by RT-qPCR and normalized to GAPDH mRNA expression. Data were analyzed 
by two-way ANOVA for matched samples by both factors followed by post-hoc Holm-Sidak’s test 
between treatments at each time point. Data represent the mean S.E.M. from three independent 
donor experiments. *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.005; ****p ˂ 0.001. (See above page) 
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Figure 3.4. Phenotypic time-course changes of HPMCs in culture after TGF-β1 treatment. Omentum-
derived mesothelial cells were treated for 0, 1, 2, 4, 6, 12, 24, 48 and 72 h with TGF-β1 (1 ng/ml). (0-
24 h) Characteristic epithelial morphology of polygonal shape cells from a confluent monolayer. (48 h) 
Loss of epithelial morphology and acquisition of fibroblast-like form. (72 h) Loss of epithelial 
morphology and acquisition of fibroblast-like phenotype with disruption of intercellular junctions 
characteristic of a migratory phenotype. One representative experiment of three is shown. Zeiss 
Axiovert 135 microscope. Magnification: 200x.  
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Figure 3.5. miRNA profiling in TGF-β1-stimulated HPMCs. (A) Three-dimensional scatter plot of 
miRNA expression following 1ng/ml of TGF-β1-treatment for 48 h (x axis: log
2
 fold change of the 
normalized miRNA signal (mean of at least three replicates); y axis: -log
10
 p value obtained from one-
way ANOVA followed by Fisher’s least significant difference (LSD) post hoc analysis; z axis: log
10
 of the 
level of baseline expression in mesothelial cells). miR-21 (red), miR-31 (blue). (B) Scatterplot of 2 
technical replicates showing correlation for all miRNA probes. 
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Up-regulation of miR-21 and miR-31 in primary HPMCs was then validated using 
miRNA-specific Taqman RT-qPCR assays (fold change: miR-21, 1.8 x, p=0.012; miR-31, 
1.7 x, p=0.004) (Figure 3.6A). Induction of expression of these miRNAs was further 
confirmed by TGF-β1 dose-response analysis (Figure 3.6, B-C).  
 
 
 
 
 
 
 
 
 
Figure 3.6. TGF-β1 significantly induces miR-21 and miR-31 expression in HPMCs after 48 hours of 
treatment. Omentum-derived mesothelial cells were treated with 1 ng/ml of TGF-β1 (A) or 0, 1, 5 and 
10 ng/ml of TGF-β1 (B-C) for 48h. Expression of miR-21 and miR-31 was analyzed by RT-qPCR and 
normalized to miR-191 expression. Data were analyzed by paired, two tail, t test or one-way ANOVA 
for matched samples followed by post-hoc Holm-Sidak’s test comparing each condition mean with the 
control omentum-derived mean. Data represent the mean S.E.M. from five (A) or three (B-C) 
independent donor experiments. *p ˂ 0.05; ***p ˂ 0.005.  
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3.2.3. PDF-treated MCs display morphological changes and 
supernatant miRNA release 
Previous research has linked HPMCs exposure to different PD fluid compounds 
with mesothelial cells MMT, sterile peritoneal inflammation and peritoneal membrane 
mesothelial cell loss. Therefore, whether HPMCs treated with different PD fluids could 
alter their phenotype and, most importantly, up-regulate the miRNAs of study at both, 
cellular and supernatant levels was analyzed.  
The characteristics of the PD solutions used for this study are summarized in 
Table 3.1. After treatment optimization (see 2.2.2.) HPMCs where incubated with 50% 
PDF in 1% FBS medium or control HPMCs medium for 48 h. Loss of epithelial MCs 
monolayer and different extent of morphological changes and acquisition of fibroblast-
like phenotype was observed when control and PBS conditions where compared with 
glucose 2.3% and different PD fluid conditions (Figure 3.7A). Due to the high number of 
different conditions compared and the variability between donors significant 
differences in miRNA expression at cellular or supernatant level could not be identified 
(Figure 3.8). Nevertheless, miR-21 showed a trend to increase with PDF treatment and 
PBS dilution at cellular level while being differentially released into the supernatant only 
with PDF exposure (Figure 3.8, A-B). On the other hand, miR-31 showed a trend to 
increase with PDF treatment at both cellular and supernatant level (Figure 3.8, C-D). The 
PDF inducing the highest miR-21 release to the supernatant were BicaVera 2.3% = 2.818 
(-3.331 to 8.968), Physioneal 2.27% = 2.514 (-2.368 to 7.396), Balance = 1.632 (0.2114 
to 3.053) and Nutrinil = 1.584 (-1.123 to 4.290) while for miR-31 these were BicaVera 
1.5% = 2.299 (-1.812 to 6.409), Physioneal 2.27% = 1.935 (-0.1909 to 4.060), Extraneal = 
1.673 (-0.348 to 3.695) and Nutrinil = 1.597 (-0.268 to 3.462) (95% confidence interval). 
Three of the four PD solutions that induced higher miR-21 release to the supernatant 
contain also the highest glucose percentages (BicaVera 2.3%, Physioneal 2.27% and 
Balance 2.3%); nevertheless CAPD4 also holds 2.3% of glucose and was between the 
fluids that less induced miR-21. Surprisingly, three of the four PD solutions that better 
increased miR-21 also own the higher pH (BicaVera 7.4, Physioneal 7.4 and Balance 7.0) 
while no trend was detected between the buffer of use and higher miR-21 release in 
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HPMCs. No pattern was found between miR-31 up-regulation in MCs supernatant and 
PD fluid composition. In common, PD fluid exposure resulted in a decrease in cell 
viability to a higher extent than medium dilution and/or glucose 2.3% incubation (Figure 
8E). Higher levels of compromised cell viability were found with Extraneal = 49.98% 
(9.226% to 90.74%), Physioneal 2.27% = 59.62% (31.05% to 88.18%), Nutrineal = 63.85% 
(37.30% to 90.40%) and BicaVera 2.3% = 64.92% (44.42% to 85.42%) (95% confidence 
interval). Three of the four PD solutions that induced lower cell viability also showed 
higher miR-21 and miR-31 levels at the supernatant but no trend was detected within 
viability and PD solution composition. These results demonstrate that HPMCs treated 
with PDF can differentially release miRNAs to the supernatant and encouraged the study 
of further models of peritoneal membrane deterioration and MMT associated to PD 
therapy.    
The 
characteristics 
pH Chambers 
Osmotic 
agent 
Buffer GDPs Disadvantages 
Nutrineal
®
 
(Baxter) 
5.5 Single 
1.1% 
Amino 
Acids 
Lactate 40 
mmol/L 
No 
Contains lactate; low 
pH; single daily 
exchange 
Balance
®
 
(Frasenius) 
7.0 Double 
2.3% 
Glucose 
Lactate 35 
mmol/L 
Low 
Contains lactate and 
glucose; no-neutral pH  
CAPD4
®
 
(Frasenius) 
5.5 Single 
2.3% 
Glucose 
Lactate 35 
mmol/L 
Medium 
Contains lactate and 
glucose; low pH 
Extraneal
®
 
(Baxter) 
5.6 Single 
7.5% 
Icodextrin 
Lactate 40 
mmol/L 
Low 
Contains lactate; low 
pH; single daily 
exchange 
BicaVera
®
 
(Frasenius) 
7.4 Double 
1.5% 
Glucose Bicarbonate  
34 mmol/L 
Low Contains glucose 
2.3% 
Glucose 
Physioneal
®
 
(Baxter) 
7.4 Double 
1.36% 
Glucose 
Lactate 10 
mmol/L and 
Bicarbonate  
25 mmol/L 
Low 
Contains glucose; low 
lactate exposure 2.27% 
Glucose 
 
 
 
Table 3.1. Peritoneal dialysis solutions selected for study. Data summarized from package product 
information and García-López et al. 2012.  
93 
 
Figure 3.7. Phenotypic changes of cultured HPMCs after treatment with different PD fluids. 
Omentum-derived mesothelial cells were treated for 48 h with 50% of the specified PD fluids. (Control 
and PBS) Characteristic epithelial morphology of polygonal shape cells from a confluent monolayer, 
star indicated. (Glucose 2.3% and PD fluids) Loss of epithelial MCs monolayer and different extent of 
morphological changes and acquisition of fibroblast-like phenotype, arrow indicated. One 
representative experiment of four is shown. Zeiss Axiovert 135 microscope. Magnification: 200x.  
Figure 3.8. miR-21 and miR-31 profiling in HPMCs and cellular supernatant after treatment with 
different PD fluids. Omentum-derived mesothelial cells were treated for 48 h with 50% of the 
specified PD fluids or control HPMCs medium. (A) cellular miR-21. (B) supernatant miR-21. (C) cellular 
miR-31. (D) supernatant miR-31. (E) AlamarBlue cell viability assay over a period of 48 h. Expression 
of miR-21 and miR-31 was analyzed by RT-qPCR and normalized to miR-191 expression. Data were 
analyzed by one-way ANOVA for matched samples followed by post-hoc Holm-Sidak’s test comparing 
each condition mean with the control omentum-derived mean. Data represent the mean S.E.M. from 
four independent donor experiments. (See following page). 
* * 
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3.2.4. PDE-derived MCs have increased levels of miR-21 and miR-31 
Ex vivo MCs cultured from PDE from PD patients have a diverse range of 
morphologies, ranging from cuboidal form, comparable to those observed from 
omentum-derived MCs, to fibroblast-shaped cells. Yáñez-Mó et al. 2003, characterized 
this PDE-derived MCs model by the study of cellular morphology and expression of key 
molecular markers that suggested an MMT process (Yáñez-Mó et al, 2003). Therefore, 
miR-21 and miR-31 were evaluated in PDE-derived HPMCs cultured ex vivo, divided as 
previously described (Yáñez-Mó et al, 2003) into those exhibiting phenotypic changes 
consistent with early MMT (E: epithelial phenotype) or late MMT (NE: non-epithelial 
phenotype) (Figure 3.9A). RNA from this model was kindly provided by Dr Manuel Lopez-
Cabrera and used for analysis. Non-epithelial PDE-derived cells showed increased miR-
21 and miR-31 expression compared with control omentum-derived HPMCs (Figure 3.9, 
B-C). These data support the potential of miR-21 and miR-31 to act as sentinels for PD-
induced peritoneal membrane deterioration in PD patients.  
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Figure 3.9. miR-21 and miR-31 profiling in a model of progressive peritoneal membrane 
deterioration. (A) Peritoneal effluent derived (PDE) cells diagram, a model of progressive peritoneal 
membrane deterioration. Relative expression of miR-21 and miR-31 in control omentum-derived 
mesothelial cells (HPMCs), TGF-β1 treated (1ng/ml, 48h) and cultured peritoneal effluent derived 
(PDE) cells with epithelial (E) and non-epithelial (NE) phenotype. (B) miR-21 expression. (C) miR-31 
expression. Expression of miR-21 and miR-31 was analyzed by RT-qPCR and normalized to miR-191 
expression. Data were analyzed by one-way ANOVA followed by post-hoc Holm-Sidak’s test comparing 
each condition mean with the control omentum-derived mean. Data represent the mean S.E.M. from 
five independent donor experiments. *p ˂ 0.05.  
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3.2.5. PM thickness and miR-21 follow the same pattern of expression 
in a uraemic PD mouse model 
A uraemic PD mouse model was next analyzed to elucidate whether changes in 
PM thickness were associated with differential miRNA expression in vivo. In order to 
evaluate the effects of PD therapy in a clinically relevant model, a newly designed mouse 
model by ESR Evelina Ferrantelli combining long-term PD exposure and uraemia was 
chosen. Peritoneal membrane from mice undergoing PD with and without 5/6 
nephrectomy (Nx) were kindly provided by ESR Evelina Ferranteli and examined, and 
compared with uraemic controls (n=7 per group, 12-14 weeks + 10 weeks of experiment) 
(Figure 3.10A). 5/6 Nx PDF treated group showed a significant increase in PM thickness 
compared to the 5/6 Nx control group (mean thickness 21.970 (7.053 to 36.890) vs 9.115 
(4.779 to 13.450); 95% confident interval; p<0.05) (Figure 3.10C). The mesothelial and 
submesothelial compact zone of H&E FFPE samples were LCM micro-dissected for 
miRNA analysis (Figure 3.10B). Similarly, the examination of PM miRNA expression 
showed a trend to up-regulate PM miR-21 in the 5/6 Nx PDF treated group compared to 
the 5/6 Nx control group (Figure 3.10D). Nevertheless, this trend was not reproduced 
when miR-31 was analyzed (Figure 3.10E). Of note, although miR-31 seed sequence is 
conserved between human and mouse the full miRNA sequence is not exactly the same. 
The implications of this will be further discussed below. The results shown here 
demonstrate that PD treatment causes a peritoneal membrane thickening that is 
aggravated by the uraemic condition, and that miR-21 may be a miRNA especially suited 
to monitor peritoneal membrane changes in PD patients.  
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Figure 3.10. miR-21 and miR-31 profiling in an uraemic PD mouse model. (A) Uraemic PD mouse 
model diagram. (B) Formalin-fixed paraffin embedded (FFPE) samples were H&E stained and LCM 
micro-dissected to measure relative miRNA expression. Mesothelial and submesothelial compact zone 
was specifically micro-dissected by LCM selection (left panel) and specific removed are (right panel). 
Scale bar, 50 µm. (C-E) PD mouse model study in which the following groups where comapared 5/6 
nephrectomy (Nx + none), 5/6 nephrectomy + daily PD treatment during 56 days (Nx + PD) and PD 
treatment during 56 days (PD control). (C) Peritoneal membrane thickness. (D) miR-21 expression. (E) 
miR-31 expression. Expression of miR-21 and miR-31 was analyzed by RT-qPCR and normalized to miR-
191 expression. Data were analyzed by one-way ANOVA followed by post-hoc Holm-Sidak’s test 
comparing all condition means. Data represent the mean S.E.M. from seven independent samples. *p 
˂ 0.05.  
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3.2.5. Supernatant from TGF-β1-treated MCs have increased levels of 
miR-21 and miR-31 
To assess the potential of miR-21 and miR-31 as biomarkers to monitor 
peritoneal mesothelial MMT and the maintenance of the structural integrity of the 
peritoneal membrane in PD patients, miRNA expression was analyzed in supernatant 
from TGF-β1-treated MCs in vitro. For this aim, HPMCs where carefully washed 3 x with 
PBS before serum starvation and TGF-β1 incubation, in order to avoid possible 
contamination with FBS miRNAs (Figure 3.11A). Both miRNAs showed a trend to 
increase in HPMC supernatant after 72 h of TGF-β1 stimulation (Figure 3.11, B-C). These 
results demonstrated that in a well characterized in vitro model of TGF-β1-induced MMT 
in HPMCs, miR-21 and miR-31 up-regulation can not only be monitored at cellular level 
but also at the supernatant.  
Figure 3.11. miR-21 and miR-31 profile in supernatant of HPMCs after TGF-β1 treatment. Omentum-
derived mesothelial cells were treated with 1 ng/ml of TGF-β1 for 72 h. (A) Experimental model 
diagram. (B) Supernatant miR-21. (C) Supernatant miR-31. Expression of miR-21 and miR-31 was 
analyzed by RT-qPCR and normalized to miR-191 expression. Data were analyzed by paired, two tail, t 
test. Data represent the mean S.E.M. from three independent donor experiments.  
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3.3. Discussion 
The peritoneal membrane has a complex structure, and includes cells of multiple 
lineages. The mesothelial cell layer forms the interface between dialysate and 
membrane, and plays an important role in determining changes associated with PD 
therapy failure (Selgas et al, 2006). Of the wide range of cytokines and factors that are 
deregulated during the complex process of PD treatment-driven membrane alterations, 
TGF-β1 plays a pivotal role (Loureiro et al, 2011). Indeed, PD patients have a high basal 
inflammatory state at the peritoneal cavity that includes increased TGF-β1 levels. This 
cytokine induces early changes (Snail expression, Figure 3.3G) that could partially 
explain a future peritoneal MCs MMT process (mesothelial markers down-regulation 
after 48 h, Figure 3.1A; and mesenchymal markers up-regulation between 24-72 h, 
Figure 3.3, E-F and H) and, ultimately, lead to fibrosis and ultrafiltration failure.  
This research focused on the minimum TGF-β1 concentration and time able to 
induce mesothelial and mesenchymal changes during characterization analysis for 
following studies (1 ng/ml, 48 h). Of note, gross phenotypical changes were not 
observed under the TGF-β1 concentration and time selected, and were only apparent 
with higher concentrations or longer time-exposures (Figure 3.2 and 3.3). These 
decisions were based on the aims and background of the research including (i) evidence 
of MMT reversibility has been shown only during the early-MMT stages; (ii) miRNAs 
could be used as diagnostic tools to indicate the initial-phases of the MMT process; and 
(iii) early-MMT miRNA changes may be direct therapy targets. However, it is important 
to consider that higher doses of TGF-β1 and, particularly, coordinated effects of TGF-β1 
together with other important inflammatory and pro-fibrotic stimuli, may have 
additional effects important to the processes underlying peritoneal fibro-genesis, and 
that miRNAs are likely also to play important roles in these processes. 
Since the start of this project in September 2012, there has been a large increase 
in published findings describing miRNAs in many contexts, reflecting the wide current 
interest in this class of regulator molecules. Papers addressing miRNAs in the context of 
PD remain more limited. Those that were published during my studies are tabulated in 
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the general discussion (Table 6.1) and provide some additional evidence for miRNAs as 
regulators of key molecular pathways driving peritoneal membrane alterations leading 
to PD failure. Nevertheless, most PD-related miRNA studies have taken a literature-
based approach to identify candidate miRNAs for further analysis (Table 6.1) (Bao et al, 
2015; Chen et al, 2012a; Yu et al, 2014; Zhang et al, 2013). Thus, miRNAs implicated in 
epithelial-to-mesenchymal transition (EMT) in other contexts have been associated with 
mesothelial cells MMT during PD therapy in the last years (Yu et al, 2014; Zhou et al, 
2013). However, it is commonly recognized that EMT processes may greatly differ 
depending on specific cell population and context. Therefore, extrapolation of miRNAs 
related to the EMT process in different research areas into the peritoneal fibrosis field 
is suboptimal, and miRNA expression profiling techniques are a better approach. 
Animal models offer a useful approach to study PD therapy, but models that 
come close to mimicking the processes occurring in patients are necessarily complex 
(González-Mateo et al, 2009; Lameire et al, 1998). The use of intraperitoneal injection 
of dialysate as PD model has many advantages including low cost, high practicality and 
low infection risk (Lin et al, 2015; Liu et al, 2014; Liu et al, 2015; Morishita et al, 2016; 
Yu et al, 2014; Zhou et al, 2013). Nevertheless better PD models, in which a catheter is 
permanently inserted into the peritoneal cavity of the animals, have been described 
(González-Mateo et al, 2009). It is also important to remember that miRNA sequences 
are not always conserved between humans and animals (Kozomara & Griffiths-Jones, 
2014), and analyzing their relevance in humans is, therefore, highly important (Table 
6.1) (Lin et al, 2015; Liu et al, 2014; Liu et al, 2015; Morishita et al, 2016).   
Several articles published during the development of this research have based 
their miRNA microarray analysis on total peritoneal RNA samples (Table 6.1) (Lin et al, 
2015; Liu et al, 2014; Liu et al, 2015; Morishita et al, 2016; Zhou et al, 2013). 
Nevertheless, it is well accepted that PD treatment induces several structural and 
functional changes at the peritoneal cavity including changes in the percentages of 
constituent cell types and phenotype (Fernandez de Castro et al, 1994). miRNA 
expression profiles will change with each defined cell phenotype and context. Therefore, 
the study of miRNAs from total peritoneal samples has important associated challenges 
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defining the specific cell-type contribution and validating the changes in different, cell-
specific models.  
Indeed, CAPD patient PDE cell populations have been previously described as 
composed principally of macrophages (78%), followed by lymphocytes (12.3%), 
neutrophils (4.9%), eosinophils (2.6%), mesothelial cells (1.9%) and mast cells (0.3%) 
(Bos et al, 1991). Therefore, although the study patients would be free of peritonitis, 
macrophages will still have an important contribution to the miRNA profile measured by 
total PDE-derived cells miRNA array. Consequently, miRNA arrays based on all PDE-
derived cells and/or full membrane digests (Lin et al, 2015; Liu et al, 2014; Liu et al, 2015; 
Morishita et al, 2016; Zhou et al, 2013) may not be a good model for mesothelial cell 
changes associated to PD therapy as suggested by some of the published articles in the 
field. Similarly, when the studied miRNAs are selected from the existing literature, the 
choice of an appropriate model of study remains essential (Bao et al, 2015; Chen et al, 
2012a; Yu et al, 2014).  
In vitro models, although more simplistic, may be critical to understand the 
specific pattern of miRNA expression in response to a known stimulus in a specific cell-
type where mechanistic research can be pursued. Therefore, in this research, primary 
human mesothelial miRNA expression and responses to TGF-β1 were defined. This 
approach was chosen not only to identify candidate miRNAs that may act as biomarkers 
and/or important contributors during the early MMT process but also a cellular model 
in which consequent mechanistic effects could be subsequently investigated (Figure 
6.1C, Table 6.1). miRNA data was examined here considering three important 
parameters for research (i) baseline level of expression, (ii) fold change in response to 
TGF-β1, and (iii) statistical significance of the observed change (Figure 3.5A). 
Hybridization array data is often presented purely on the basis of fold change and 
significance level. However, this approach may lead to focus on less abundant 
transcripts, potentially a problem for future biologically relevant research given that 
miRNAs’ function as negative regulators of mRNAs is sensitive to the stoichiometry of 
miRNA:mRNA (Ebert & Sharp, 2012; Hansen et al, 2013; Salmena et al, 2011). Two 
abundant miRNAs, miR-21 and miR-31, the expression of which was increased when 
MCs were incubated with TGF-β1, were selected for subsequent study. Nevertheless, 
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alternative approaches including the study of miRNAs that where not present at baseline 
level but up-regulated following TGF-β1 exposure could have been taken. 
Ongoing efforts are being made to improve PD biocompatibility, but controversy 
remains regarding downstream effects of PD fluids on mesothelial cell MMT and long-
term benefits of biocompatible solutions (Blake et al, 2013; Johnson et al, 2012). Recent 
improvements introduced in PD solutions include (i) glucose degradation product 
reduction via physical glucose (low pH) separation from the buffer during sterilization 
and storage, (ii) partial replacement of glucose by icodextrin, or (iii) amino acids, and (iv) 
lactate buffer replacement by bicarbonate (see 1.3.2). PD fluids used in this chapter for 
research varied regarding osmotic and buffer compounds, pH and glucose degradation 
products (GDPs) (Table 3.1). Global phenotypic changes in MCs and levels of miRNAs of 
interest in both cells and cell supernatant were assessed after PDF treatment (solution: 
medium 1% FBS supplemented, 1:1) for 48 h. Although a general pattern of miRNA up-
regulation induced by PDF treatment could be observed at the cellular level, miRNA 
measurement seemed more likely to be solution-dependent when measured in cell 
supernatant (Figure 3.8). miRNAs have been recently shown to better correlate on 
supernatant rather than at the cellular component in other models and contexts. For 
instance, Hansen et al. 2014 showed that miR-888, let-7c and miR-200b correlated with 
disease status more closely with the supernatant from prostatic secretions in urine 
rather than using the pellet fraction (Hansen et al, 2013). Nevertheless, due to the high 
variability observed between primary MCs from different donors and the amount of PD 
solutions selected for study no significant changes could be identified. Therefore, future 
study is necessary for conclusive results regarding the differential levels of miRNAs 
measured in HPMCs and cell supernatant after exposure to PD fluids. It would also be 
interesting to study TGF-β1 expression as well as the epithelial and mesenchymal 
markers used in this chapter to characterize HPMCs MMT process driven by PD solutions 
in vitro and possible autocrine TGF-β1 response. Finally, it would be especially 
interesting, using a higher experimental number, to compare miRNA expression with the 
expression of other molecules that are used as markers for MCs damage, for example 
CA-125 and IL-6 (Lopez-Anton et al, 2015).  
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Of note, although miRNAs can be actively released from cells (Chen et al, 2012b; 
Schwarzenbach et al, 2014), supernatant miRNA measured here may only be indicative 
of cell injury and death due to treatment (Figure 3.7 and 3.8E). This raises two important 
questions regarding (i) the need to reconsider the term biocompatible for PD solutions 
which may be too hopeful and induce patient misconception by other terms like less 
non-biocompatible or more-biocompatible, and (ii) regarding miRNA stability and/or 
protection of the cell-free miRNAs measured in this context, which would be further 
discussed during the following Chapters 4 and 6.  
Although a general pattern was difficult to observe in supernatant miRNA 
expression of HPMCs treated with different PD fluids, there was an observable trend 
indicating that solutions with higher glucose concentrations induced higher miR-21 
expression (Figure 8B). Different studies have described a raise in PMCs TGF-β1 
expression after PD solution exposure and, especially, after glucose-containing fluid 
exposure, which would explain subsequent increase in miR-21 expression. Mizuri and 
co-workers detected an increase in TGF-β1 expression in rat PMCs exposed to glucose-
containing PDF (Mizuiri et al, 2009). Indeed, HPMCs incubation with glucose and sodium 
lactate, either alone or in combination, enhanced TGF-β1 mRNA expression and protein 
secretion (Wong et al, 2003). Ha et al. 2001 compared the effect of Dianeal (1.5% and 
4.25% glucose and 40 mmol/L lactate buffer) with Physioneal (1.5% and 4.25% glucose, 
15 mmol/L lactate and 25 mmol/L biocarbonate buffers) and Extraneal (7.5% icodextrin 
and 40 mmol/L lactate buffer) 1:2 diluted in serum-free media for 48 h (Ha et al, 2002). 
They observed TGF-β1 secretion was significantly increased by Dianeal 4.25% and 
Extraneal; with icodextrin increasing TGF-β1 secretion in a dose-dependent manner (Ha 
et al, 2002). This last interesting observation regarding icodextrin would be further 
discussed during next chapter.   
PDE-derived MCs used in this chapter were previously characterized by Dr 
Manuel López-Cabrera group following established protocols (López-Cabrera et al, 2006; 
Yáñez-Mó et al, 2003). PDE proliferative MCs displayed high ICAM-1 and CA-125 
expression, which is negative in omentum-derived fibroblasts and suggests a 
mesothelial MMT origin of non-epithelioid MCs (López-Cabrera et al, 2006; Yáñez-Mó et 
al, 2003). Cytokeratins and E-cadherin are epithelial markers highly expressed in 
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omentum-derived MCs and gradually decreased in epithelioid and non-epithelioid PDE-
derived MCs. Although, only a minor non-epithelioid population remained cytokeratin 
and E-cadherin positive, omentum-derived fibroblasts did not express these markers 
(López-Cabrera et al, 2006; Yáñez-Mó et al, 2003). The study of particular mesenchymal 
markers including Snail, N-cadherin, Fibronectin, Collagen I, α-SMA, and fibroblast 
specific protein-1 (FSP-1), which were progressively increased in epithelioid and non-
epithelioid PDE-derived MCs confirmed PD-induced MCs MMT changes in this model 
(López-Cabrera et al, 2006; Yáñez-Mó et al, 2003). Further experiments found increased 
miR-21 and miR-31 in PDE-derived mesothelial cells with mesenchymal characteristics. 
These results associate miR-21 and miR-31 to a progressive peritoneal mesothelial cell 
deterioration during PD treatment that was previously shown ex vivo to define an 
adverse response to PD (Yáñez-Mó et al, 2003).  
Different PD animal models have been established during recent years. Among 
them, the thickening and miRNA expression in the mesothelial and sub-mesothelial 
compact zone from a uraemic PD mouse model was specifically studied. Precise 
peritoneal mesothelial and sub-mesothelial compact zone micro-dissection was possible 
via LCM and histopathology expert guidance. Peritoneal membrane thickening 
increased with PD therapy and followed the same pattern as miR-21 expression (Figure 
3.10, C-D). Nevertheless, miR-31 did not follow the expected pattern of expression. Of 
note, both miRNAs are highly conserved in mammals and miR-31 has been studied 
successfully in other mouse models of human disease. miR-21 and miR-31 are 
independently transcribed and will, therefore, be regulated by different factors that may 
not be fully conserved between species. Further research would be needed to clarify 
these possible alternatives. Of note, here Dianeal was used to treat uraemic mice, which 
is a PD solution that was not included between the analyzed in vitro fluids shown above 
(Figure 3.7 and 8, Table 3.1). Dianeal® (Baxter) uses glucose 3.86% as osmotic agent and 
lactate 40 mmol/L as a buffer in a single chamber under low pH 5.2 and contains, 
therefore, a high amount of GDPs being poorly-biocompatible but adequate for the 
model of study (García-López et al, 2012). The trend of use of this solution will probably 
be reduced during the following years and therefore was not considered for these in 
vitro study of PD fluids. Instead, CAPD4, which also uses glucose 2.3% and lactate 35 
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mmol/L in a single bag and at a low pH 5.5, was used as a medium-GPDs solution for 
study. Nevertheless, it would be interesting to know miRNA regulation in HPMCs 
following Dianeal exposure. Additionally, to include a control non-uraemic non-PD 
animal group to know the basal thickness of the PM as well as the basal levels of miRNA 
expression would add valuable information to this model highlighting any effects due to 
uraemia.      
Finally, the fact that this research was able to measure both miRNAs in the 
supernatant from TGF-β1-treated MCs where they displayed, in both cases, a trend to 
increase, suggested that they could be used as MMT biomarkers for PD therapy. It is 
important to note that although both miRNAs are up-regulated by TGF-β1 in most of the 
models developed during the chapter, they will probably have different specific roles 
during the MMT process (see Chapter 5). A given miRNA can regulate the expression of 
hundreds of mRNAs. Moreover, target mRNAs are likely to be simultaneously controlled 
by multiple miRNAs rather than by the action of a single miRNA alone. Alternatively, 
miRNAs may be actively synthesized and secreted not only to modulate intra-cellular 
pathways but also to influence the behavior of neighboring cells in a paracrine fashion 
(Chen et al, 2012b). This creates a complex network in which several miRNA-regulated 
pathways cooperate to promote profound and specific effects in MCs phenotype and 
function but also potentially modulating the whole peritoneal cavity during the 
progression of PD therapy. 
miRNAs have been shown to be promising as biomarkers in patients with kidney 
disease (Beltrami et al, 2012; Bowen et al, 2013) but there has been limited study to 
date in PD patients. During this chapter miR-21 and miR-31 level of expression was 
shown to be increased in different, well-established models associated with structural 
and functional alterations of the peritoneal membrane during peritoneal dialysis. These 
MMT models included (i) in vitro MCs TGF-β1 stimulated, (ii) MCs treated with different 
PD solutions in vitro, (iii) ex vivo MCs with epithelial and non-epithelial phenotype, and 
(iv) in vivo uraemic PD mouse model. Therefore, these results suggested to consider the 
possibility of measuring miR-21 and miR-31 in PDE from PD patients and to correlate 
their levels of expression with different clinical parameters associated with peritoneal 
membrane deterioration and worse PD outcome (see Chapter 4).
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Chapter 4 – Evaluation of miRNAs as biomarkers in  
PD effluent from patients
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4.1. Introduction 
Continuous dialysis fluid exchange allows easy access to monitor peritoneal cells 
and miRNA expression in PD effluent (PDE). This presents the enticing possibility of 
monitoring peritoneal cavity homeostasis during PD treatment. Nevertheless, no PDE-
derived biomarker is currently used in clinical routine to monitor the homeostatic 
maintenance of the peritoneal cavity. miRNAs have shown a sound potential as 
biomarkers in several fields. Thus, PDE-derived miRNAs may be particularly suitable as 
biomarkers due to their specific pattern of expression, easy detection, stability, and 
reliability in other contexts (Akat et al, 2014; Di Leva et al, 2014; Liang et al, 2007; 
Lorenzen et al, 2012). Although, PD-miRNA research is in an early stage there is a 
particular interest regarding miRNA as biomarkers to help individualizing PD treatment. 
However, until now, no one has examined PDE extracellular miRNAs and their utility as 
PDE biomarkers remains to be established. 
To date, research on miRNA expression associated with PD therapy has been 
limited in scale and has primarily chosen a literature-based miRNA-candidate 
methodology or had other significant design weaknesses (See 1.6.3 and Chapter 6). In 
this chapter, the potential of miRNAs as MMT biomarkers during PD therapy was 
investigated. This research (i) developed a new method for miRNA extraction and RT-
qPCR measurement in 4 h PDE samples, (ii) evaluated the correlation of miR-21 and miR-
31 in PDE with clinical parameters associated with peritoneal membrane MMT and 
treatment stability, in a cohort of 230 patients taken from the Global Fluid Study; and 
(iii) measured miR-21 and miR-31 expression as well as TGF-β1 pathway activation in 
peritoneal membrane biopsies from PD patients.  
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4.2.  Results 
4.2.1.  Stability of PDE miRNAs at room temperature 
Before studying samples from the Global Fluid Study (GFS), a careful analysis of 
PDE miRNA stability was performed. The GFS is an international, multicenter, 
prospective, observational cohort study of 959 patients (Lambie et al, 2013). Sample 
collection and storage methodology was standard but variability between sample 
processing times cannot be completely dismissed, due to the different handling of 
subjects and to possible complications. PDE from the GFS was, in all cases, spun and kept 
at -80ºC within the following 6 h after withdrawal from the peritoneal cavity. PDE miRNA 
stability was studied during incubation at room temperature at time points up to 24 h, 
to evaluate sample adequacy for this research within a reasonable processing timescale. 
Samples for this work were obtained from the Wales Kidney Tissue Bank (WKTB).  
Fresh overnight PDE samples from three different control patients were 
collected for the study. PDE was aliquoted into two 50 ml falcon tubes. One tube was 
spun during 20 min at 400 x g and room temperature (RT), while the other was kept at 
RT. 1 ml aliquots from each sample were collected after 0, 4, 8 and 24 h, and spun during 
20 min at 400 x g and RT (Figure 4.1A). 500 µl of PDE supernatant were taken, RNA 
extracted and RT-qPCR analyzed. Results were analyzed by two-way ANOVA with 
matched values for both factors (method and time). Multiple comparisons were 
performed by post-HOC Holm-Sidack’s test comparing each time mean with the control 
(0 h) mean. Samples were stable at room temperature for the miRNAs of study 
independently if they were spun/not spun when collected (Figure 4.1, B-D). miRNAs 
were stable within a reasonable time-scale (less than 8 h) and differences in their 
expression compared with control-time (0 h) were only observed for miR-21 after 24 h 
of room temperature (Figure 4.1, B-D). The miRNAs of study (miR-21, -31 and -191) and, 
likely, other miRNAs, are stable in PD fluid without need of a special handling within a 
reasonable time-scale (less than 8 h). Therefore, PDE samples from this biobank are 
adequate for the measurement and study of selected miRNAs. 
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Figure 4.1. Stability of PDE miRNAs at room temperature. (A) Experiment diagram. Fresh overnight 
PDE samples were aliquoted into two 50 ml falcon tubes. One tube was spun during 20 min at 400 x g 
and RT while the other was kept on RT. 1 ml aliquots from each sample were collected after 0, 4, 8 and 
24 h, and spun during 20 min at 400 x g and RT. 500 µl of PDE supernatant were taken for experiment. 
(B-D) Expression of all miRNAs was analyzed by RT-qPCR and expressed as 40-Ct. (B) miR-21. (C) miR-
31. (D) miR-191. Data were analyzed by two-way ANOVA for repeated measures by both factors, 
followed by post-hoc Holm-Sidak’s test comparing each time mean with the control (0 h) mean. Data 
represent the mean S.E.M. from four independent donor experiments. **p ˂ 0.01. 
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4.2.2.  Optimization of extraction of overnight PDE miRNAs 
Overnight PDE from patients was suitable for miRNA measurement with mean 
Ct values lower than 35, which is the established limit of qPCR detection. Mean 
(minimum-maximum) Ct values were miR-21, 27.16 (26.01-28.90); miR-31, 31.97 (30.56-
33.28) and miR-191, 31.54 (30.41-32.11) (Figure 4.2, A-B). GFS dialysate sampling was 
from a 4 h peritoneal equilibration test (PET) and no amplification plot was detected 
following this protocol in a first, preliminary measurement. There were two possible 
manners of improving the RT-qPCR miRNA measurement from PDE of the GFS: (1) to 
optimize the RNA isolation process and/or (2) to optimize the RT and qPCR reaction.  
 
Figure 4.2. Peritoneal dialysis effluent (PDE) RNA extraction optimization. (A) Overnight PDE miRNA 
expression using miRNAeasy Mini Kit. (B) Overnight PDE miRNA expression statistics. (C) miRNAeasy 
Mini Kit PDE-RNA isolation optimization using handbook protocol, increased sample (4x), increased 
MS2 carrier (4x) or no MS2 carrier. (D) PDE-RNA isolation comparison between miRNAeasy Mini and 
mirVana PARIS kit using the three different protocols detailed by the kit (see Figure 4.3). Data were 
analyzed by one-way ANOVA for matched samples followed by post-hoc Holm-Sidak’s test comparing 
each protocol mean with the control mean. Data represent the mean S.E.M from three independent 
donor experiments. *p ˂ 0.05; ****p ˂ 0.001. 
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4.2.3.  PDE miRNA isolation optimization 
To improve the miRNA isolation step, this research attempted to enhance miRNA 
quantity obtained with the miRNeasy Mini kit (QIAGEN). Handbook protocol, previously 
used for overnight PDE, was compared with extractions including increased sample 4 x, 
increased MS2 RNA carrier 4 x and no MS2 RNA carrier used. miR-21 measurement by 
RT-qPCR was performed for evaluation. None of the modifications introduced to the 
protocol increased the efficiency of the original extraction protocol (Figure 4.2C). Burgos 
et al. 2013, recently evaluated different RNA isolation kits for very diluted samples of 
cerebrospinal fluid and indicated high isolation efficiency with mirVana PARIS kit (Burgos 
et al, 2013). The mirVana PARIS handbook protocol offers two isolation alternatives: 
Total RNA (1.25 volumes of ethanol and a single column) and using two consecutive 
columns: first column (A) recommended for large RNAs, >200 nt (1/3 volume of ethanol), 
which effluent is filtered by a second column (B) suggested for small RNAs <200 nt (2/3 
volume of ethanol) (Figure 4.3A). RNA from overnight PDE was extracted using 
Handbook protocol for miRNeasy Mini kit and the three isolation alternatives of mirVana 
PARIS kit. miR-21 was measured in all samples by RT-qPCR for evaluation. miRNeasy Mini 
kit performance was similar to mirVana PARIS kit (A) while (Total) and (B) extraction 
were less efficient (Figure 4.2D). mirVana PARIS RNA elution volume recommended by 
Handbook protocol is double the amount of that suggested by miRNeasy Mini kit. 
Therefore, total RNA eluted from mirVana PARIS (A) was estimated to contain an 
amount of miRNAs near twice of that eluted by miRNeasy, and was selected for future 
optimization. 
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Figure 4.3. PDE miRNA isolation optimization. (A) mirVana PARIS handbook protocol diagram for RNA 
isolation alternatives. mirVana PARIS handbook protocol recommends three isolation alternatives 
including total RNA, large RNAs, >200 nt and small RNAs <200 nt. Second extraction (E2) step in which 
the remaining interphase and organic layer were re-hydrated and re-isolated with water is labeled and 
further described at the text. (B-D) mirVana PARIS PDE miRNA isolation optimization. (B) Isolation 
optimization: second extraction with water (E2), Speed-Vac step (SV). (C-D) Isolation optimization: 
MS2 RNA carrier is not necessary for the extraction. Data were analyzed by paired, two tail, t-test or 
one-way ANOVA for matched samples followed by post-hoc Holm-Sidak’s test comparing each 
protocol mean with the control mean. Data represent the mean S.E.M. from three independent donor 
experiments. *p ˂ 0.05; ****p ˂ 0.001. 
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The organic phase division for nucleic acid extraction entails the upper aqueous 
layer, confining the RNA, being prudently taken, avoiding contamination from the 
interphase and the organic phase below. With the intention of isolating the aqueous 
phase with the smallest volume of impurities from the matter below, part of the RNA-
comprising aqueous layer is left behind. To increase RNA recovery, mirVana PARIS 
handbook protocol for isolation (A) was subsequently improved by adding a second 
extraction (E2) step in which the remaining interphase and organic layer were re-
hydrated and re-isolated with water (Figure 4.3A). An equal volume of ‘removed-
aqueous phase’ of water was added to the acid-phenol chloroform extract, vortexed for 
30 - 60 sec to mix and centrifuged for 5 min at maximum speed (10,000 x g) at room 
temperature to separate again the aqueous and organic phases. The aqueous phase was 
carefully removed and processed with the previously extracted aqueous phase. Finally, 
a 40 min, cold, Speed-Vac (SV) step was introduced to concentrate the final eluted 
samples in silicone coated eppendorfs. E2 increased the final eluted RNA concentration 
by 1.44 Cts while the addition of E2+SV enhanced the measurement by 3.14 Cts (Figure 
4.3B). Addition of MS2 carrier RNA did not improve miRNA isolation using either 
mirVana PARIS kit (A) and (B) handbook isolation protocol neither greating increasing 
MS2 by four times (Figure 4.3, C-D). In short, after PDE miRNA isolation optimization, 
miRNA concentration was increased by 3.144 Cts. Given that 1 Ct difference 
approximates to a doubling of miRNA signal, this represents a substantial optimization 
in signal. Subsequently, this research was focused on the optimization of the RT and 
qPCR reaction.  
4.2.4.  Reverse Transcription Chemistry Evaluation 
To improve miRNA RT the possibility of eliminating the water of this reaction and 
subsequently adding the remaining extra volume as additional isolated RNA was 
investigated. TaqMan miRNA RT assays are tested and amplification efficiency values 
range from 100% (±10%) when measured samples are free of PCR inhibitors. PCR 
performance may be affected by different substances. miRNAs have never been 
previously extracted from 4 h PDE and it is important to consider the possibility of 
carrying different inhibitors from the PD fluid. Sample dynamic range testing is based on 
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serial dilution and was limited due to the high dilution of the initial sample. To overcome 
this issue 1 µl of 10 ng RNA from HPMC cells was spiked into each of the testing samples. 
3, 6 and 9 µl of PDE-RNA were miR-21 reverse transcribed using the same total volume 
and 4 µl of serial RT dilutions were used to evaluate the RT performance by qPCR (Figure 
4.4D).  
 
 
 
 
 
Exceeding the capacity of the reaction was not an issue, as the analyzed samples 
were highly diluted. Nevertheless, the linearity of the reaction, with a potential increase 
in sample volume and, a subsequent potential increase in inhibitors from the PDE, was 
important. The linearity of the reverse transcription is called efficiency (E) and can be 
calculated as: E = (10-1/Slope-1) × 100 
The efficiency of 3, 6 and 9 µl of reverse transcribed PDE-RNA was in all cases 
90.25, and, therefore, within the values range guaranteed by the supplier (Figure 4.4, A-
C). R2=0.9979 and 0.9976 indicated there were no potential precision issues that could 
drastically affect low-fold change variations in target expression (Figure 4.4, A-C). PCR 
inhibition due to potential chemical contaminants isolated from the PDE together with 
Figure 4.4. Reverse Transcription Chemistry Evaluation. (A-C) Serial dilutions from RT product 
standards of 3, 6 and 9 µl of PDE isolated RNA were qPCR independently evaluated for miR-21. (A) 
miR-21 expression for 3 µl PDE isolated RNA. (B) miR-21 expression for 6 µl PDE isolated RNA. (C) miR-
21 expression for 9 µl PDE isolated RNA. (D) miR-21 qPCR amplification plot comparing serial dilutions 
of RT product from 3, 6 and 9 µl of PDE isolated RNA from a single donor. Data were RNA mass log 
transformed and analyzed by linear regression. Data represent serial dilutions from five independent 
donor experiments. 
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the RNA was also a matter of interest. PCR efficiency greater than 100% and low R2 
values are characteristics of a plot demonstrating PCR inhibition. These characteristics 
were absent, and, therefore inhibition was not a matter of concern for these samples 
and experimental conditions. Finally, RT protocol modifications by introducing a higher 
concentration of sample at the RT step was a good optimization approach, as this was 
not affecting the efficiency of the measurements.  
4.2.5.  qPCR Chemistry Evaluation 
Similarly, to improve miRNA qPCR the possibility of eliminating the water of this 
reaction and adding the remaining extra volume with isolated RNA was investigated. 
TaqMan miRNA qPCR assays are also tested and amplification efficiency values range 
from 100% (±10%) when measured samples are free of PCR inhibitors. Nevertheless, a 
careful evaluation of this optimization process was needed for the reasons named 
above. 9 µl of 4 h PDE-RNA were reverse transcribed with 1 µl of 10 ng RNA from HPMC 
cells spiked-into each of the testing samples and 3, 6 or 9 µl of serial RT dilutions were 
used to evaluate the qPCR performance using the same total volume (Figure 4.5D).  
 
 
 
Figure 4.5. qPCR Chemistry Evaluation. (A-C) Serial dilutions from 9 µl of PDE isolated RNA RT product 
were qPCR independently evaluated using 3, 6 and 9 µl of diluted RT product for miR-21. (A) miR-21 
expression for 3 µl of RT product. (B) miR-21 expression for 6 µl of RT product. (C) miR-21 expression 
for 9 µl of RT product. (D) qPCR amplification plot comparing serial dilutions of 9 µl of PDE isolated 
RNA RT product independently qPCR evaluated using 3, 6 and 9 µl of diluted RT product for miR-21 
from a single donor. Data were RNA mass log transformed and analyzed by linear regression. Data 
represent serial dilutions from five independent donor experiments. 
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Newly, exceeding the capacity of the reaction was not an issue. Nonetheless, the 
linearity of the reaction with a potential increase in RT mass was important. The 
efficiency of 3, 6 and 9 µl of PCR PDE-RT was 84.54, 87.56 and 88.34 and, therefore, 
similar to the values ranges guaranteed by the supplier in standard conditions (Figure 
4.5, A-C). R2=0.9897, 0.9976 and 0.9988 indicated there were no potential precision 
issues that could drastically affect low-fold change variations in target expression (Figure 
4.5, A-C). Indeed, higher volumes gave us better efficiency due to the high dilution of 
the samples reaching the RT-qPCR limit of detection. PCR inhibition caused by potential 
chemical contaminants isolated from the PDE, together with the RT mass, was also a 
matter of interest in this case. PCR efficiency was not greater than 100% and R2 values 
were high. Therefore, PCR inhibition should, thus, not be an issue for these samples. 
Finally, PCR protocol modification performed by introducing a higher concentration of 
RT sample at the PCR step, was a good optimization approach, as greater concentrations 
of PDE-RT product represented a tighter and greater efficiency. This was neither 
inhibiting the PCR reaction nor affecting the accuracy of the measurement. 
4.2.6.  RT and qPCR reaction optimization, PDE GLOBAL samples 
To improve miRNA RT and qPCR step, the possibility of eliminating the water of both 
reactions and adding the remaining extra volume with isolated RNA (+RT) or diluted RT 
(+PCR) product respectively was investigated. +RT showed that 4 h PDE met the cycle 
threshold for RT-qPCR detection earlier for miR-21 mean ± SD, (1.33 ± 0.5555 Ct earlier 
detection); miR-31, 2.039 ± 1.4918 Cts and miR-191, 1.919 ± 0.3745 Cts while the 
addition of +RT+PCR enhanced the measurement for miR-21, 2.75 ± 0.5632 Cts; miR-31, 
3.81 ± 1.4758 Cts and miR-191, 2.961 ± 0.5387 Cts compared with the control sample 
following RT and qPCR handbook protocol (Figure 4.6, A-C). Subsequently, miR-21 was 
measured for three independent overnight and 4h PDE samples from GLOBAL using the 
optimization approaches for RNA extraction, RT and qPCR already established. As 
expected, 4h PDE had less miR-21 content compared with overnight PDE samples, 
consistent with the difficulty of measuring miRNAs in these samples without protocol 
optimization (Figure 4.6, D). Average 4h PDE miRNA measurement of miR-21, miR-31, 
miR-191 and a spiked in cel-miR-39 were in all cases lower than 35 Cts: miR-21, 32.18 ± 
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0.4290 Cts; miR-31, 34.64 ± 1.035 Cts; miR-191, 34.46 ± 0.2940 and cel-miR-39, 32.95 ± 
0.4476 (Figure 4.7, A-B). cel-miR-39 was spiked into these samples in order to study the 
final consistency and uniformity of the results obtained between samples. The 
coefficient of variation (CV) is the standard deviation of a sample divided by the mean 
and is used as a measure of sample variability. CV (cel-miR-39) = 0.02, and therefore, the 
consistency of the process was considered to be sufficient to continue with the study 
(Hellemans et al, 2007). miR-31 and miR-191 were close to the 35 Ct limit of reliable 
qPCR detection due to high level of Ct variation when target quantities approach a single 
copy (Poisson distribution). Nevertheless, protocol optimization was adequate to 
measure miRNAs in a large study of GLOBAL samples (4h PDE exchange) in which 
samples reaching 35-40 Ct values would be eliminated from the analysis. Before further 
research was undertaken, optimization suitability of this protocol was confirmed by Dr 
Wim Reidt, an expert from ThermoFisher Scientific technical support.  
 
Figure 4.6. Final 4 h PDE-RNA extraction, RT and qPCR reaction optimization, GLOBAL PDE samples. 
(A-C) miRNA quantification using manufactures adapted protocol developed in figures 1-3 (Control), 
with additional diluted RNA added at the RT (+RT) and with additional diluted RT added at the PCR 
(+PCR) respectively. (A) miR-21. (B) miR-31. (C) miR-191. (D) GLOBAL, 4h exchange PDE miRNA 
expression after extraction, RT and qPCR reaction optimization compared with O/N PDE for miR-21. 
Data were analyzed by unpaired, two-tail, t-test or one-way ANOVA for matched samples followed by 
post-hoc Holm-Sidak’s test comparing each protocol mean with the control mean. Data represent the 
mean S.E.M. from three independent donor experiments. *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.005. 
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4.2.7.  miR-21 and miR-31 expression correlate with clinically 
important parameters 
To assess the potential of miR-21 and miR-31 as biomarkers to monitor the 
maintenance of the structural integrity of the peritoneal membrane, miRNA expression 
was analyzed in samples from a cohort of 230 patients from the GFS. A gene 
maximization approach was used to design the plate layout for experiment and, 
therefore, the amount of samples/plate was limited by the amount of miRNAs 
measured. Due to the relatively high sample size of the experiment, inter-run calibrators 
(IRCs) were used to quantify differences between qPCR plates (Derveaux et al, 2010; 
Hellemans et al, 2007). IRCs comprised three independent RT-PDE samples, pre-
aliquoted at the start of the analysis and present in each of the qPCR plates run in this 
Figure 4.7. miRNA measurements in GLOBAL PDE, 4h exchange. GLOBAL, 4h PDE exchange miRNA 
expression after extraction, RT and qPCR reaction optimization. (A) miRNAs -21, -31, -191 and cel-
miR39 quantification using manufactures adapted protocol developed in Figures 1-6. Threshold limit 
for RT-qPCR detection Ct=35 (dot line). (B) Statistical description of miRNAs selected for study. Data 
represent mean S.E.M. from three independent donor experiments.  
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study. A non-template control (NTC) was also present in all plates for all miRNAs of this 
study. 0.5 pM of a synthetic exogenous small RNA Caenorhabditis elegans (cel-miR-39) 
was spiked into each sample (after denaturing solution addition to avoid degradation by 
PDE RNAses (Mitchell et al, 2008). cel-miR-39 provided an internal positive control for 
RNA isolation, cDNA synthesis and PCR amplification. miR-191 CV across the study was 
determined to show its stability and, therefore, its suitability as a reference miRNA 
(Hellemans et al, 2007). The goal for any reference gene is to have the smallest CV 
possible and, generally, a variability of less than 10-15% is acceptable. CV (miR-191) = 
0.0534 (0.0539 before IRC correction) and is, therefore, a suitable reference miRNA for 
this study.  
Table 4.1 displays baseline clinical characteristics of the patients whose samples 
are included in this analysis. When measured in effluent of prevalent PD patients, or 
more than 9 months under therapy, detection of miR-21 and miR-31 was significantly 
higher in comparison with incident cases (fold difference: miR-21, 3.26 x, p=0.0015; miR-
31, 1.84 x, p=0.0007) (Figure 4.8, A-B). The study of expression of both miRNA according 
to different semesters showed a significant increase between 12-18 months of therapy 
compared with control, 0-6 months and a trend to increase with time (fold change: miR-
21, 4.35 x, p<0.0001; miR-31, 0.93 x, p=0.0005) (Figure 4.8, C-D).  
To investigate the potential relationship between miR-21 and miR-31 with 
parameters associated with poor PD outcome, an exploratory correlation analysis was 
performed (Table 4.2).This analysis was undertaken by Dr Mark Lambie and showed that 
both miRNAs correlated with each other R=0.26, although miR-21 better correlated with 
parameters associated with an inflammatory condition. Notably, miR-21 was found to 
correlate with IL-6 R=0.28, icodextrin use R=0.28, miR-31 R=0.26, peritonitis count 
R=0.25, urine volume R=-0.19, 4 hour D/P creatinine R=0.16, BMI R=0.15 and PD 
duration R=0.13. miR-31 better correlated with urine volume R=-0.24, dialysate glucose 
concentration R=0.22, PD duration R=0.19, peritonitis count R=0.18, and BMI R=0.16.  
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Table 4.1. Descriptive characteristics of 230 patients selected as a study population are summarized 
at the table above. Patients were selected from a single center (Stoke PD fluid) part of the GLOBAL 
fluid registry. Center selection was done based on better patient information registry. Data are 
presented as the mean ± SD, median (interquartile range), or as percentage. Data prepared by Dr Mark 
Lambie, responsible of Stoke PD fluid data registry. 
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In order to understand the relevance of these variables for the described up-
regulation of miR-21 and miR-31, Dr Mark Lambie performed a multivariable linear 
regression with backwards stepwise variable selection for all parameters included in 
Table 4.2 and each miRNA (Table 4.3 and 4.4). Consequently, stepwise variable selection 
determined a group of tighter risk factors that associated with each miRNA in predicting 
PD outcome. miR-21 better associated with dialysate icodextrin usage R=0.52, (95% 
confidence intervals 0.20, 0.84), peritonitis count R=0.16, (0.03, 0.29), miR-31 R=0.52 
(0.15, 0.90) and dialysate cytokines (Table 3). On the other hand, miR-31 showed little 
associations with biocompatible solution use R=0.18 (-0.04, 0.40), use of CAPD vs APD 
R=0.14 (0.02, 0.25), miR-21 R=0.087 (0.038, 0.136), peritonitis count R=0.052 (0.006, 
Figure 4.8. Up-regulation of miR-21 and miR-31 expression in peritoneal dialysis effluent (PDE) from 
PD patients (n=230). RNA from 230 PDE samples was isolated and RT-qPCR analyzed. Relative 
expression of miR-21 and miR-31 was normalized to miR-191 expression. (A-B) Prevalent PD compared 
with incident cases (n=230). (A) miR-21 up-regulation versus incident patients. (B) miR-31 up-
regulation versus incident patients. (C-D) Variation in miR-21 and miR-31 expression according to 
different time in PD. (C) miR-21 expression versus 0-6 months. (D) miR-31 expression versus 0-6 
months. Data were analyzed by unpaired, Mann-Whitney test and Kruskal-Wallis non-parametric test 
followed by post-hoc Dunn’s test comparing the mean of each column with the mean of a control ‘0-
6 mth’ column.  Data represent the mean S.E.M. from detailed n samples. *p < 0.05; **p < 0.01; ****p 
< 0.001; and *****p < 0.0001. 
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0.098), plasma albumin R=0.0096 (-0.001, 0.020) and urine volume R=-0.0001 (-0.00017, 
-0.00003 (Table 4.4). These results indicate that both miRNAs correlate with clinical 
parameters that have been described to be important in triggering the MMT process 
associated with PD therapy.  
 Table 4.2. PDE miR-21 and miR-31 correlation with clinically important parameters (n=230). 
Preliminar exploratory correlation analysis. Both miRNAs correlate with each other, although miR-21 
seemed to better correlate with parameters associated with an inflammatory condition which 
encouraged us to perform a deeper statistical analysis. Statistical analysis was conducted by Dr Mark 
Lambie, responsible of Stoke PD fluid data registry. 
a
p<0.05, 
b
p<0.01, 
c
p<0.001. 
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Table 4.3. Multivariable Regression of miR-21 (n=230). To understand the relevance of all parameters 
included in Table 2 for the described up-regulation of miR-21 multivariable linear regression with 
backwards stepwise variable selection was performed. Stepwise variable selection determined a 
group of tighter risk factors that associated with miR-21 in predicting PD outcome that are detailed at 
the table above. The predicted variable, miR-21, was log transformed. Statistical analysis was 
conducted by Dr Mark Lambie, responsible of Stoke PD fluid data registry.  
Table 4.4. Multivariable Regression of miR-31 (n=230). To understand the relevance of all parameters 
included in Table 2 for the described up-regulation of miR-31 multivariable linear regression with 
backwards stepwise variable selection was performed. Stepwise variable selection determined a 
group of tighter risk factors that associated with miR-31 in predicting PD outcome that are detailed at 
the table above.The predicted variable, miR-31, was square root transformed. Statistical analysis was 
conducted by Dr Mark Lambie, responsible of Stoke PD fluid data registry 
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4.2.8.  TGF-β1 signalling is activated, and miR-21 and miR-31 
expression is increased, in PD patient peritoneal membrane biopsies  
Next, whether changes in activation of TGF-β1 signalling and miR-21 and miR-31 
expression could be observed in the mesothelial cell layer of patients undergoing PD 
was analyzed. In order to evaluate the effects of the therapy, distinct from associated 
vascular pathology or other comorbidity that may be present in biopsies from adult 
patients, samples from the International Pediatric Membrane Biopsy Registry were 
kindly selected by ESR Maria Bartosova and studied in collaboration with her. Children 
undergoing PD with conventional and with biocompatible fluids were examined, and 
compared with uraemic and non-uraemic controls (n=11 per group, mean age at biopsy: 
PD conventional 9.1 years, PD biocompatible 8.9 years, control uraemic 9.6 years, 
control non-uraemic 8.0 years; mean duration of PD: PD conventional 30 months, PD 
biocompatible 31 months). SMAD2 and SMAD3 phosphorylation was determined, as a 
measure of TGF-β1 activity. Phospho-SMAD2/3 staining of formalin-fixed paraffin 
embedded (FFPE) samples were measured using Aperio Precision Image Analysis 
Software and a count algorithm for positive pixel detection (Figure 4.9A). The 
mesothelial and submesothelial compact zone of PD patients displayed enhanced TGF-
β1 pathway activation compared with controls and uraemic (Figure 4.9, A-B). Significant 
p-SMAD2/3 enhanced expression was observed in the mesothelium of PD patients 
under conventional PD fluid treatment compared with healthy controls (Figure 4.9B). 
miRNA analysis of manually micro-dissected FFPE samples also showed an increase in 
miR-21 expression at the mesothelium of PD patients compared with healthy and 
uraemic controls (Figure 4.9C). Due to a high variability between samples in the control 
group, no difference was seen between healthy controls and PD patients in miR-31 
peritoneal membrane expression. However, a trend of up-regulation in miR-31 
expression was observed between uraemic controls and PD patients (Figure 4.9D). 
These results demonstrate that PD therapy is associated with TGF-β1 signalling pathway 
activation, as well as the expression of miR-21 and miR-31, in the peritoneal membranes 
of PD patients.  
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Figure 4.9. Expression of p-SMAD2/3, miR-21 and miR-31 in 44 biopsies from the International 
Pediatric Membrane Biopsy Registry. Formalin-fixed paraffin embedded (FFPE) samples were p-
SMAD2/3 stained and manually macro-dissected to measure relative miRNA expression. miR-21 and 
miR-31 expression was analyzed by RT-qPCR and normalized to miR-191 expression. Histological image 
analysis using Aperio Precision Image Analysis Software. (A) Mesothelial and submesothelial compact 
zone selection (upper panel) and p-SMAD2/3 detection of the area of interest by the Aperio positive 
pixel count algorithm (lower panel). Negative background is showed in blue and positive p-SMAD2/3 
detection is showed in yellow-orange. Scale bar, 300 μm. (B) Level of p-SMAD2/3 staining was defined 
using a count algorithm for positive pixel detection. Conventional PD P-SMAD2/3 was up-regulated 
versus healthy controls and uraemic controls. (C) Conventional and biocompatible PD miR-21 was up-
regulated when compared with control and uraemic patients. (D) miR-31 up-regulation was ns. Data 
were analyzed by one- way ANOVA followed by post-hoc Holm-Sidak’s test. Data represent mean 
S.E.M. from eleven age-matched samples and equal average PD duration between PD groups. 
***p<0.005; ****p<0.001 and *****p<0.0001. 
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4.3. Discussion 
PD is an effective form of renal replacement therapy. Unfortunately, it is often 
limited by deterioration in the structural and functional characteristics of the peritoneal 
membrane. New biomarkers are needed, to help individualize PD therapy, to serve as 
appropriate surrogates in clinical trials, and to guide the development of innovations in 
the therapy. These data showed that miR-21 and miR-31 level of expression are 
increased in different, well-established models associated with structural and functional 
alterations of the peritoneal membrane during peritoneal dialysis (see Chapter 3). 
Moreover, both miRNAs can be measured in the peritoneal dialysis effluent from PD 
patients where they correlate with valuable clinical parameters indicating poor PD 
outcome. 
An important challenge of measuring miRNAs by RT-qPCR from PDE was the high 
dilution of the miRNA contained in the sample. The first research objective approached 
was, therefore, to develop an optimal approach for RNA purification to maximise the 
recovered miRNA fraction. An approach based on use of the mirVana PARIS kit for 
miRNAs purification, using four steps of optimisation was established and included (i) 
total RNA eluted from mirVana PARIS kit (column A) which contained a miRNA amount 
nearly twice of that eluted by miRNeasy, (ii) interphase/organic-phase re-hydration and 
phenol-chloroform re-extraction of the sample which increased the eluted miRNA 
concentration by 1.44 Cts, (iii) a 40 min, cold, Speed-Vac (SV) step which enlarged the 
miRNA fraction by 1.7 Cts; while (iv) addition of MS2 RNA carrier RNA did not further 
improve the yield. Surprisingly, the highest miRNA eluted from mirVana PARIS kit was 
found in column A, which according to the handbook protocol is better at recovering 
large RNAs (>200 nt) rather than in column B, which is meant to collect small RNAs (<200 
nt) (Figure 4.2D and 4.3A). This issue was discussed with Dr Wim Reidt, a technical 
support specialist from ThermoFisher scientific, who explained that this result was 
probably due to the pH and the nature of the samples used for experiment. This theory 
could be validated performing a re-extraction of the samples using the two columns’ 
protocol recommended by the manufacturer, and would expect to find higher miRNA 
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levels at the column B. Nevertheless, this question was finally considered to be beyond 
the purposes of this thesis and that line of investigation did not continue. 
An additional limitation of optimizing Qiagen miRNeasy for miRNA purification is 
its size exclusion of miRNA species lower than 18 nt. This restriction would not affect the 
study developed in this thesis as miRNA species of interest are: miR-21 (22 nt), miR-31 
(21 nt) and; miR-191 (23 nt). Nevertheless, an examination of human miRNAs described 
demonstrated that ~ 68 human miRNAs are smaller than 18 nt, constituting ~ 3% of all 
mature miRNA catalogued until now (miRBase; October 2012). Current research held at 
the department uses the PD effluent RNA extraction method developed in this chapter 
to address new experimental questions (see Chapter 6). Future research may include 
the measurement of miRNA species lower than 18 nt and, therefore, optimizing Qiagen 
miRNeasy was discarded as alternative.  
Further protocol optimizations were introduced at the RT and qPCR step by 
eliminating the water and adding the remaining extra volume with isolated diluted RNA 
and diluted RT respectively. TaqMan miRNA assays were evaluated for amplification 
efficiency performance after adding an extra volume of isolated RNA and an extra 
volume of PDE-RNA transcribed to the PCR step. The changes introduced showed not to 
inhibit the PCR reaction neither to affect the accuracy of the measurements. Indeed, 
PCR efficiency was found to be better when higher volumes of RT product were added 
to the PCR reaction (88.34% PCR efficiency with 9 µl while 84.54% with 3 µl). This was 
due to better chemistry performance when samples are farther from the limit of RT-
qPCR detection (Figure 4.5). After protocol optimization 4 h PDE miRNA measurement 
were in all cases lower than 35 Cts and, therefore, adequate to measure miRNAs in a 
large study comprising GLOBAL samples. The possibility of studying PDE miRNA 
expression in an animal model of the disease in which 5/6 nephrectomy was combined 
with PD in mice has also drawn attention during this project (see Chapter 2 and 3). 
Nevertheless, PDE samples are further limited when acquired from mice models. PDE 
obtained from the last PD exchange was, in all cases about 100 µl in the mice model and, 
unfortunately, did not allow us to get a reliable miRNA measure below the limit of qPCR 
detection.  
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PDE samples from the GFS were frozen down and conserved at -80° C (see 
Chapter 2). The GFS kept no record regarding the number of thawing-refreezing cycles 
the samples suffered. This issue has been reported to the manager of the study and it is 
now recorded and considered to be an important factor. For this study, the highest filled 
aliquots were chosen for each of the PDE samples needed. An estimation of 2-3% of the 
samples used for the study had probably been defrosted before. Extracellular miRNAs 
have been shown to be very stable along numerous thawing-refreezing cycles in 
different body fluids and, together with the small numbers that these samples 
represented, this factor was not considered a major limitation for this study (Mitchell et 
al, 2008). Nevertheless, fresh frozen PDE from different patients has been collected, 
frozen down and conserved at -80° C. This was done in case future studies using PDE 
samples from the GFS require an analysis of the specific effect of different thawing-
refreezing cycles on these samples. Considering that the aim of this study was to 
evaluate the possibility of using PDE derived miRNAs to monitor peritoneal membrane 
MMT during PD therapy, a more clinically relevant parameter to analyse was PDE miRNA 
stability at room temperature. Newly, extracellular miRNAs have already been proven 
to be very stable at room temperature, for up to 24 h, in different body fluids (Mitchell 
et al, 2008). This analysis was important for us for two reasons: (i) to confirm that PDE 
from the GFS was collected within a reasonable processing timescale for miRNA 
detection and; (ii) to validate the bedside feasibility of the technique. The miRNAs of 
study and, likely, other miRNAs, were stable in PDE without need of a special handling 
within a reasonable time-scale of < 8 h.  
The population under study presented here was designated with Dr Mark 
Lambie, and the sample size analyzed was the maximum feasible by the chosen registry 
(n=230). The samples analyzed were in all cases the first sample collected from each 
patient and a single institute was used to exclude centre effects. Van de Luijtgaarden et 
al. 2011 analyzed PD population characteristics in seven European renal registries (van 
de Luijtgaarden et al, 2011). PD population baseline characteristics reported (BCR) by 
van de Luijtgaarden et al. 2011 recalculated from their paper and compared with the 
population of study (PS) here are: age, mean ± SD (BCR, 58±16; PS, 54.3±16.2); males, % 
(BCR, 63; PS, 54.30) and comorbidity count, median (interquartile range) (BCR: 1 (0,1); 
129 
 
PS, 1 (0,1). In general, PS population was 4 years younger and had 8.7% less males while 
comorbidity score remained the same than BCR. Education, clinical guidelines and 
transplant activity may be factors explaining these divergences, which were considered 
minor for this study. Of note, excluding Sweden, the remaining European countries 
studied by van de Luijtgaarden et al. 2011 were less prone to choose PD as a therapy 
compared to the UK (van de Luijtgaarden et al, 2011).  
An important robustness of this research is that it is founded on an extensive PD 
population combining both, incident and prevalent patients, from a deep-seated, high 
quality cohort. There were, nevertheless, some limitations. A randomized clinical study 
reporting the outcomes of PD therapy is not only unfeasible but also unethical (Korevaar 
et al, 2003). Despite this, randomized trials are the only system to elude confounding by 
prescription, which happens when specialists choose patients for a single therapy due 
to particular arguments. In this investigation, additional data potentially relevant for us 
like TGF-β1 dialysate cytokine levels was lacking. The dialysate cytokine levels used for 
the correlations reported here were those previously measured in Lambie et al. 2013 by 
electrochemiluminescence and did not include TGF-β1 (Lambie et al, 2013). Of note, 
active TGF-β1 dialysate cytokine levels may highly differ from those read by HPMCs due 
to multiple variables including (i) level of TGF-β1 expression, (ii) ligand trapping 
molecules that control the formation of molecule gradients, (iii) mediators of ligand 
traps release, (iv) antagonistic ligands, (v) ligand-receptor TGF-β1 presentation via 
accessory proteins, and (vi) the combination of expressed signalling receptor molecules. 
Indeed, there have been few attempts to measure TGF-β1 from PD effluent samples 
from patients (Gangji et al, 2009; Jones et al, 2001; Kinashi et al, 2013; Lai et al, 1999; 
Zweers et al, 1999). Overall, the number of patients included in these studies are low 
and TGF-β1 concentrations reported are not consistent between groups. Nevertheless, 
TGF-β1 levels are, in all cases, increased in long term PD patients. Instead, mesothelial 
and submesothelial TGF-β1 pathway activation in an independently matched cohort of 
peritoneal biopsies from the International Pediatric Membrane Biopsy Registry was 
studied, and TGF-β1 pathway activation was associated with miRNA expression (Figure 
4.9B). Of note, peritoneal mesothelial and sub-mesothelial pSMAD2/3 was not 
measured here in combination of further HPMCs markers and may indicate TGF-β1 
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pathway activation in cells from different origin including activated fibroblasts and 
macrophages.  
The existence of extracellular miRNAs in 4 h PDE samples and miRNA correlations 
with important clinical parameters associated to the progression of the MMT process 
may represent a golden goose of non-invasive biomarkers in PD therapy. Considering 
that miRNA deregulation is an early episode in the MMT associated to PD (Figure 3.9), 
the determination of PDE miRNA levels may be valuable in unmasking peritoneal MMT, 
which can help to individualize PD therapy. This research showed for the first time that 
miR-21 and miR-31 expression was up-regulated in PDE from prevalent compared to 
incident PD patients (Figure 4.8, A-B). When miRNA expression was plotted by semesters 
the results were consistent with those previously described by Del Peso et al. 2008 
reporting an increase in prevalence of submesothelial fibrosis and MMT according to 
different semesters (Del Peso et al, 2008). It is noteworthy that the fourth semester, in 
which MMT was remarkable higher in Del Peso et al. 2008 studies, has not been included 
here due to low sample size (n=2).  
Multivariable linear regression with backwards stepwise variable selection for all 
parameters included in Table 4.2 and each miRNA was performed to understand the 
relevance of miRNA correlations with parameters associated to the MMT process. Both 
miRNAs showed to correlate with each other. miR-21 expression was associated with 
peritonitis count and dialysate IFN-γ, as well as with IL-6, TNF-α and IL-1β. IFN-γ has been 
shown to regulate the secretion of IL-6 by mesothelial cells (McLoughlin et al, 2003), 
which are the major producers of IL-6 within the peritoneal cavity (Topley et al, 1993; 
Witowski et al, 1996). It is also known that TNF-α or IL-1β stimulation of HPMCs results 
in a time and dose dependent increase in IL-6 production (Topley et al, 1993). IL-1β 
stimulation of HPMCs can also be synergistically enhanced by the simultaneous 
presence of IFN-γ (McLoughlin et al, 2003). In vivo, although IFN-γ alone had no 
significant effect on intraperitoneal IL-6 secretion, co-administration with IL-1β resulted 
in synergistic increase of intraperitoneal IL-6 levels (McLoughlin et al, 2003). IL-6-type 
cytokines endeavor their response via gp130, which is their universal signal-transducing 
receptor subunit (Ernst & Jenkins, 2004; Heinrich et al, 2003). HPMCs lack expression of 
IL-6 receptor (IL-6R) and require soluble IL-6R (sIL-6R) to trigger IL-6 response, inducing 
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gp130 activation and selectively regulating STAT3 which is a transcription factor critical 
for transformation (McLoughlin et al, 2004). miR-21 is controlled by an upstream 
enhancer containing two, evolutionary conserved, STAT3 binding sites (Löffler et al, 
2007). Indeed, miR-21 induction by IL-6 has been reported to be strictly dependent on 
STAT3 in a broad range of models including multiple myeloma, mammary epithelium, 
hepatocellular carcinoma (HCC), oral squamous cell carcinoma and keratinocytes (Chen 
et al, 2015; Iliopoulos et al, 2010; Lu et al, 2015; Löffler et al, 2007; Zhou et al, 2014). 
STAT3 is, therefore, not merely an IL-6 effector, but combined with miR-21 and its 
multiple downstream tumour suppressor targets, is an important element linking 
inflammation to epigenetic changes and cell transformation.  
Ongoing efforts are being made to improve PD biocompatibility. Nevertheless, 
the long-term benefits of biocompatible solutions remain controversial (Blake et al, 
2013; Johnson et al, 2012). Icodextrin is a high molecular weight glucose polymer 
created as a substitute for dextrose as an osmotic agent during PD. Icodextrin levels of 
advanced glycation end products (AGEs) resulting from glucose degradation products 
(GDPs) are low compared with standard PDF. AGEs induce TGF-β1 expression among 
other cytokines via the receptor for advanced glycation end products (RAGE) and 
promote MMT transformation. Indeed, anti-RAGE blocked TGF-β1 up-regulation and 
submesothelial fibrosis in rat peritoneum (De Vriese et al, 2003). This research show that 
miR-21 expression in PDE correlates with icodextrin use and that TGF-β1 and miR-21 
expression are up-regulated in peritoneal biopsies from PD patients. This is also the case 
when using biocompatible PD solutions (Figure 4.9, A-C) indicating the necessity to 
further improve the solutions in use. Interestingly, this study have also shown a low 
correlation between miR-21 and BMI. miR-21 has also been involved in the regulation 
of adipogenic differentiation, is highly expressed in adipose tissue and positively 
correlates with BMI (Keller et al, 2011). Conversely, long-term inhibition of miR-21 has 
led to a reduction of obesity in db/db mice (Seeger et al, 2014).  
miR-31 also associates with biocompatible solution usage and peritonitis count. 
miR-31 is up-regulated in psoriasis and esophageal squamous cell carcinoma, two 
inflammatory associated diseases where regulates cytokine/chemokine expression by 
targeting STK40, a negative regulator of NF-κB signalling (Taccioli et al, 2015; Xu et al, 
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2013). It has been reported that APD has various advantages compared with CAPD 
comprising peritonitis incidence, greater solute clearance and lower hernia incidence 
(Rabindranath et al, 2007). In this regard, this study showed a correlation between miR-
31 expression and the use of CAPD versus APD. Rabindranath et al. 2007 described three 
randomized controlled trials (RTCs) comparing continuous ambulatory peritoneal 
dialysis (CAPD) with all forms of automated peritoneal dialysis (APD) (Rabindranath et 
al, 2007). APD showed significantly lower peritonitis rates compared to CAPD (two trials, 
107 patients, rate ratio 0.54 95% CI 0.35-0.83) and hospitalization rate (one trial, 82 
patients, rate ratio 0.60, 96% CI 0.39-0.93). In a more recent study comparing CAPD and 
APD outcomes; patient survival appeared to be higher in the latter group although this 
could not be explained by differences in infections episodes (Cnossen et al, 2011). 
Nevertheless, more studies are needed to address the controversy associated to the 
possibility of considering peritoneal modality itself as a risk factor for inflammation, 
peritonitis and technique survival. 
Different groups demonstrated that uraemic conditions lead to mesothelial 
thickening and moderate vasculopathy suggesting that uraemia causes inflammation 
and peritoneal membrane remodeling (Fusshoeller, 2008; Williams et al, 2002). Due to 
a high variability between samples, no difference was observed between healthy 
controls and uraemic patients when miR-31 peritoneal membrane expression was 
studied while miR-21 showed an expected trend to increase with uraemia (Figure 4.9, 
C-D). Both miRNAs displayed a trend of up-regulation in peritoneal membrane biopsies 
when uraemic and PD patients where compared (Figure 4.9, C-D). Although both 
miRNAs negatively correlated with urine volume in an exploratory correlation analysis, 
multivariable linear regression showed that miR-31 better correlated with urine volume 
when analyzed in PDE from patients. Vascular endothelial growth factor (VEGF) and 
inflammatory cytokines including interleukin (IL)-1β and tumor necrosis factor-alpha 
(TNF-α) are significantly up-regulated in uraemic patients and may cooperate 
deregulating local inflammatory microenvironment and leading to mesothelial 
thickening during PD.  
Fibro-proliferative changes have been determined in the peritoneal membrane 
of PD patients, together with minor changes in uraemic (pre-dialysis) patients 
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(Fusshoeller, 2008; Williams et al, 2002). Peritoneal vascular changes are also frequently 
evident in adult patients, which may make it difficult to separate therapy-induced 
alterations from those related to the propensity of individuals with CKD to accelerated 
cardiovascular disease. At the time of PD onset the pediatric peritoneal tissue is devoid 
of vascular alterations. In order to determine the ‘pure’ effects of the therapy, pediatric 
biopsy samples were examined, from the International Pediatric Peritoneal Biopsy 
Registry. TGF-β1 signalling was clearly evident in biopsies from PD patients compared to 
controls, and was associated with increased miR-21 and miR-31 in the mesothelial and 
submesothelial zones. Given recent fate mapping studies, which have delineated an 
important contribution of submesothelial fibroblasts to peritoneal fibrosis in mouse 
models (Chen et al, 2014), understanding the potential role of miRNAs including miR-21 
and miR-31 to submesothelial fibroblast phenotype may also be an important future 
area of study. 
It is important to note that although both miRNAs are up-regulated by TGF-β1 in 
this context, they may have different specific roles during the MMT process. A given 
miRNA can regulate the expression of hundreds of mRNAs. Moreover, target mRNAs 
may be simultaneously controlled by multiple miRNAs rather than by the action of a 
single miRNA alone. This creates a complex network in which several miRNA-regulated 
pathways cooperate to promote profound and specific effects in cell phenotype and 
function during the progression of the disease. In this research, the miRNAs under study 
correlated with different parameters associated with patient outcome during PD 
therapy (Table 4.3 and 4.4). It is likely that underlying this is a distinct regulatory 
contribution from each miRNA, and further study developed in Chapter 5 will help to 
define specific targets and pathways regulated by miRNAs in this context that may be 
important for the MMT process. 
Recently it was shown that exosomes participate in different biological functions 
including angiogenesis, cell proliferation, tumour cell invasion or immune response to 
neighboring or distant cells. It has also been shown that in diverse biological functions, 
protein, mRNA and miRNAs are transferred between cells in a selective way and 
functionally active extracellular miRNAs can be taken up and affect gene expression in 
the recipient cells. Interestingly, it was shown that the exosome RNA profile is different 
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from the RNA profile of the parental cells, suggesting that this packing is selective. Urine 
exosomal miRNAs have been previously studied at this laboratory by Dr Cristina 
Beltrami, nevertheless, due to time limitations during the development of this thesis 
exosomal miRNAs were not evaluated in PDE neither in urine from PD patients. 
There are no other PD-related miRNA studies up to date that had analyzed 
miRNAs at PD effluent supernatant although some authors measured miRNAs in total 
PDE or cells from patients (Chen et al, 2012a; Xiao et al, 2015; Zhang et al, 2012). In this 
study, miR-21 and miR-31 correlated with each other and with different clinically 
important parameters including residual renal function, icodextrin usage, dialysate 
cytokine levels, peritonitis count preceding sample collection and therapy modality. In 
conclusion, these data identify miR-21 and miR-31 as potential biomarkers to monitor 
the peritoneal membrane of patients undergoing PD therapy. 
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Chapter 5 – Determination of miRNAs function in  
peritoneal mesothelial MMT 
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5.1. Introduction 
The role of a given miRNA is determined through the mRNAs that targets as well as by 
its regulatory influence on their expression. Bioinfomatic target prediction algorithms are 
used to identify mRNAs containing miRNA-specific regulatory binding sites, but present 
techniques yield many putative targets, and lack precision. In silico putative target prediction 
approaches used for this study combine several characteristics to determine whether a 
miRNA can regulate certain mRNAs and are summarized in Table 2.7. Briefly, miRNA target 
algorithm features include (i) miRNA 5’ seed region (bases 2 – 8) sequence complementarity 
with mRNA target gene 3’UTR, (ii) sequence conservation, (iii) mRNA/miRNA thermal stability, 
(vi) site accessibility, and (v) number of target sites. Additional characteristics are 
contemplated by different algorithms and distinct weight may be attributed to similar 
parameters, meaning that different algorithms yield overlapping but distinct pools of 
predicted targets, and that combined analysis employing several algorithms may be effective. 
Accordingly, genuine knowledge on miRNA and gene sequence may be enough to 
predict a large number of targets. However, these approaches originate lists of candidate 
targets that contain a relatively high amount of false-positives, false-negatives and indirect 
targets while missing some real targets. Additionally, miRNA target expression regulation is 
dependent on several further factors comprising (i) miRNA:target pool ratio (Bosson et al, 
2014), (ii) miRNA:target site affinity pool ratio (Bosson et al, 2014), (iii) cell type specific UTR 
binding co-factors, and (vi) regulatory site elimination due to alternative cleavage and/or 
polyadenylation (Sandberg et al, 2008). Thus, the pure existence of a miRNA binding site is 
not enough for expecting mRNA regulation and determining mRNA targets to define specific 
miRNAs function is, undoubtedly, one of the most challenging parts of miRNA research.  
Consequently, the research developed in this chapter firstly studied (i) the possibility 
of involving previously characterized miR-21 and miR-31 targets as contributors in peritoneal 
mesothelial cells MMT process. Secondly the study performed here used (ii) putative target 
predictions in order to identify new targets for the identified miRNAs and context of interest. 
Finally, once miRNA:target interplays were selected for subsequent study, different methods 
were used to confirm in silico target predictions including (iii) miRNA:target measurement 
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and inverse correlation, (iv) miRNA:target deep sequence analysis, (v) use of miRNA mimic 
and inhibitor molecules, and (vi) differential 3’UTR reporter gene analysis for candidate 
sequences.  
5.2. Results 
5.2.1.  miR-21 may contribute to the MMT process by targeting PDCD4, 
SPRY1 and/or PTEN while miR-31 may participate by targeting LATS2 and 
STK40 in HPMCs 
TGF-β1 promotes EMT while up-regulating miR-21 in a wide spectrum of cell types. 
miR-31 may also be involved in this process. To understand the biological mechanism by 
which miR-21 and miR-31 up-regulation may lead to MMT and fibrosis in HPMCs the 
expression of putative target genes previously reported in the literature was studied. miR-21 
has been shown to down-regulate numerous targets in different contexts including (i) 
programmed cell death protein 4 (PDCD4) (Asangani et al, 2008; Brønnum et al, 2013; Yao et 
al, 2011), (ii) Sprouty homologue 1 (SPRY1) (Brønnum et al, 2013; Thum et al, 2008), (iii) 
phosphatase and tensin homolog (PTEN) (Dey et al, 2012; Meng et al, 2007) contributing to 
mesenchymal phenotype and stimulating cell motility, migration and invasion. On the other 
hand, it has been demonstrated that miR-31 can directly regulate (i) large tumour suppressor 
kinase 2 (LATS2) (Mitamura et al, 2014), and (ii) serine/threonine kinase 40 (STK40) (Xu et al, 
2013) stimulating transformation and invasion while up-regulating the production of 
inflammatory mediators. Bioinformatics prediction showed that the 3’UTRs of PDCD4, SPRY1 
and PTEN have a conserved target site for miR-21 while the 3’UTRs of LATS2 and STK40 
perfectly matched with the seed region of miR-31 (Figure 5.1). In addition, 3’UTR reporter 
activity has also been used in different cell lines for these genes PDCD4 (Asangani et al, 2008; 
Brønnum et al, 2013; Yao et al, 2011), SPRY1 (Brønnum et al, 2013; Thum et al, 2008), PTEN 
(Dey et al, 2012; Meng et al, 2007), LATS2 (Mitamura et al, 2014) and STK40 (Xu et al, 2013). 
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We first determined mRNA expression levels of PDCD4, SPRY1, PTEN, LATS2 and STK40 
in control HPMCs, TGF-β1 treated and PDE derived cells with epithelial (early-MMT) and non-
epithelial (late-MMT) (Figure 5.2, A-E) phenotype. In all cases, greater MMT conditions (late-
MMT), previously characterized by increased miR-21 and miR-31 expression (Figure 3.9, B-C), 
displayed decreased expression of these genes compared with control HPMCs (Figure 5.2, A-
E). Intermediate MMT conditions (TGF-β1 and early-MMT models); with lower miR-21, also 
showed transitional levels of PDCD4, SPRY1 and PTEN compared with the late-MMT model 
(Figure 5.2, A-C). Interestingly, miR-31 exhibited a greater expression when HPMCs were 
treated with TGF-β1 than in PDE derived cells with epithelial phenotype (Figure 3.9C) and the 
inverse pattern of expression was shown by LATS2 and STK40 targets (Figure 5.2, D-E). 
We further examined the association between miR-21, miR-31 and the specific targets 
of study across all patients and MMT conditions previously described (Figure 5.2, A’-E’). A 
significant negative association between miR-21 and PDCD4 (Figure 5.2A’, r=-0.464, P=0.039) 
and miR-31 with LATS2 (Figure 5.2D’, r=-0.443, P=0.050) and STK40 (Figure 5.2E’, r=-0.607, 
P=0.004) was found. Nevertheless, miR-21 correlation with SPRY1 and PTEN were not 
significant (Figure 5.2B’, r=-0.431, P=0.058; Figure 5.2C’, r=-0.266, P=0.258). These initial 
experiments suggested that miR-21 might negatively regulate PDCD4 while miR-31 might 
negatively regulate LATS2 and STK40 in HPMCs at post-transcriptional level. The weaker, not 
significant, association between miR-21 and SPRY1/PTEN may indicate that although their 
regulation is important during the MMT process in HPMCs this may not be only mediated by 
miR-21 but part of a more complex regulation. 
Figure 5.1. miR-21 and miR-31 3’UTR target site conservation for PDCD4, SPRY1, PTEN and LATS2, STK40 
respectively across different animals. (A-E) Target sequences were acquired using TargetScan and 
alignment was performed with mega 6. Human complementary nucleotide sequences and 10 nucleotides 
up- and down-stream are presented. Conserved human complementary nucleotides at the seed binding 
area are displayed in red and whole nucleotide conservation is indicated with stars. (A’-E’) mRNA-miRNA 
hybrid was predicted using Diana v5.0. Seed binding area is displayed in red while remaining nearby 
nucleotides are shown in black (mRNA) and blue (miR-21 and miR-31). (A, A’) PDCD4. (B, B’) SPRY1. (C, C’) 
PTEN. (D, D’) LATS2. (E, E’) STK40.  
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To test whether miR-21 and miR-31 indeed could regulate the levels of candidate 
target mRNAs in disease relevant cells, primary HPMCs were transfected with different 
concentrations of miR-21 and miR-31 mimic and inhibitor molecules. miR-21 manipulation 
selectively regulated PDCD4 but not SPRY1 and PTEN mRNA levels (Figure 5.3 and 5.4, A-C) 
while miR-31 regulated both, LATS2 and STK40 mRNAs in primary HPMCs (Figure 5.3 and 5.4, 
D-E). Taken together, these data demonstrated that knockdown of PDCD4 by miR-21 as well 
as LATS2 and STK40 by miR-31 may contribute to MMT, alteration of cellular adhesions and 
promotion of fibrosis in HPMCs. 
 
 
 
Figure 5.2. miR-21 and miR-31 contribute to the MMT process by targeting PDCD4, SPRY1, PTEN and LATS2, 
STK40 respectively in different models and may contribute to HPMCs MMT process. (A-E) Relative mRNA 
expression in control omentum-derived mesothelial cells (HPMCs), TGF-β1 treated (1ng/ml, 48h) and 
cultured peritoneal effluent derived (PDE) cells with epithelial (E) and non-epithelial (NE) phenotype (n=5 for 
each group). (A) PDCD4. (B) SPRY1. (C) PTEN. (D) LATS2. (E) STK40. (A’-E’) Scatter plot showing correlation of 
miR-21 and miR-31 with their respective target mRNA levels in HPMCs – black circle, TGF-β1 treated – light 
grey, and PDE cells with E – dark grey, and NE – pale grey, phenotype.(A’) PDCD4. (B’) SPRY1. (C’) PTEN. (D’) 
LATS2. (E’) STK40. Target gene and miR-21 expression was analyzed by RT-qPCR and normalized to GAPDH 
and miR-191 expression respectively. Data were analyzed by one-way ANOVA followed by post-hoc Holm-
Sidak’s test. Pearson’s correlation test was used for association (n=20). Data represent the mean S.E.M. from 
five independent donor experiments. *p ˂ 0.05; **p ˂ 0.01; ****p < 0.001.  
Figure 5.3. miR-21 and miR-31 target mRNA expression after miRNA mimic delivery in HPMCs (A-E) Target 
mRNA expression after 48h of miRNA mimic delivery (5pM, 10pM and 20pM) in HPMCs. miR-control – white 
bars, miR-21-mimic and miR-31-mimic – black bars and three independent donor experiments.(A) PDCD4. 
(B) SPRY1. (C) PTEN. (D) LATS2. (E) STK40. Target gene expression was analyzed by RT-qPCR and normalized 
to GAPDH expression respectively. Data were analyzed by matched factor two-way ANOVA followed by post-
hoc Holm-Sidak’s test. Data represent the mean S.E.M. from three independent donor experiments. *p ˂ 
0.05; **p ˂ 0.01; ***p ˂ 0.005.   
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5.2.2.  miR-21 contributes to the MMT process by targeting PDCD4 in 
HPMCs 
Previous data shown in Chapter 4 indicated that miR-21 better correlated with clinical 
parameters including icodextrin usage, peritonitis count and dialysate cytokines which are 
deregulated during the complex process of PD treatment-driving membrane alterations. 
Thus, this research was further focused on miR-21 contribution to the MMT process by 
targeting PDCD4 in HPMCs. miR-21 over-expression significantly decreased PDCD4 protein in 
primary HPMCs after 72h of transfection (Figure 5.5A). Peritoneal membrane biopsies 
showed a significant down-regulation in PDCD4 expression at the mesothelial and 
submesothelial compact zone of PD patients using both, biocompatible and non-
biocompatible solutions, compared with healthy controls (Figure 5.5, B-C). Previous literature 
has shown that PDCD4 down-regulation triggers an increase in Snail protein and a consequent 
decrease in E-cadherin expression which in turn, stimulates β-catenin/TCF dependent 
transcription (Figure 5.5D) (Asangani et al, 2008; Brønnum et al, 2013; Yao et al, 2011). Thus, 
Figure 5.4. miR-21 and miR-31 target mRNA expression after miRNA inhibitor delivery in HPMCs (A-E) 
Target mRNA expression after 48h of miRNA inhibitor delivery (5pM, 10pM and 20pM) in HPMCs. miR-
control – white bars, anti-miR-21 and anti-miR-31 – grey bars and three independent donor experiments.(A) 
PDCD4. (B) SPRY1. (C) PTEN. (D) LATS2. (E) STK40. Target gene expression was analyzed by RT-qPCR and 
normalized to GAPDH expression respectively. Data were analyzed by matched factor two-way ANOVA 
followed by post-hoc Holm-Sidak’s test. Data represent the mean S.E.M. from three independent donor 
experiments. *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.005.   
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miR-21 down-regulation of PDCD4 in HPMCs may not only contribute to the detachment of 
inter-mesothelial adhesions but also to the acquisition of a new molecular program dictating 
a distinct expression regulation characteristic of an MMT process (Figure 5.5D). 
Figure 5.5. miR-21 may contribute to the MMT process by targeting PDCD4 in HPMCs. (A) PDCD4 protein 
expression and quantification after 72h of 5 pM miRNA mimic delivery in HPMCs analyzed by western blot 
(n=6). (B-C) Formalin-fixed paraffin embedded (FFPE) samples were PDCD4 stained. (B) Histological image 
analysis using Aperio Precision Image Analysis Software. Mesothelial and submesothelial compact zone was 
selected as area of interest and PDCD4 staining was quantified by the aperio positive pixel count algorithm. 
(C) Positive PDCD4 detection (brown). Scale bar, 80 μm. (D) Schematic representation of TGF-β1 triggered 
MMT regulation via miR-21 up-regulation in HPMCs. TGF-β1 is up-regulated in PD patients and induce the 
expression of miR-21 in HPMCs. miR-21 directly targets PDCD4, up-regulating Snail protein and decreasing E-
cadherin expression which, in turn, stimulates β-catenin/TCF dependent transcription. Data were analyzed 
by paired t test or one- way ANOVA followed by post-hoc Holm-Sidak’s test. Data represent the mean S.E.M. 
from eleven age-matched samples and equal average PD duration between PD groups. *p ˂ 0.05.  
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5.2.3.  miR-21 and miR-31 in silico target prediction may identify new direct 
targets that contribute to the MMT process in HPMCs 
Initial algorithm target prediction was performed prior identification of miR-21 and 
miR-31 associations with clinical parameters from the GFS. Thus, in this analysis similar 
importance was given to both miRNAs (Figure 5.6, A-B). Independent target prediction using 
Diana (Paraskevopoulou et al, 2013; Reczko et al, 2012) (blue), miRDB (Wang & El Naqa, 2008; 
Wong & Wang, 2015) (brown), miRanda (Betel et al, 2010; Betel et al, 2008) (green) and 
TargetScan (Agarwal et al, 2015; Nam et al, 2014) (red) in silico algorithms for miR-21 (dark 
color) and miR-31 (light color) were performed (Table 2.7; Figure 5.6A). Venn diagrams were 
used to identify common target predictions for both miRNAs and each one of the above 
mentioned algorithms (Figure 5.6A). Diana algorithm identified 481 likely targets for miR-21 
and 574 for miR-31; 29 of these targets were commonly predicted for both miRNAs. Similarly, 
miRanda detected 492 possible targets for miR-21 and 306 for miR-31; 15 of which were joint 
plausible targets for these two miRNAs. miRDB distinguished 240 potential targets for miR-21 
and 407 targets for miR-31; 8 of which were found to be shared by both miRNAs. Finally, 
TargetScan recognized 307 feasible targets for miR-21 and 425 for miR-31; 23 of these were 
also coincident targets for these two miRNAs. miR-21 and miR-31 common targets predicted 
and identified in Figure 5.6A (Diana=29, miRanda=15, miRBD=8, and TargetScan=23) where 
further inter-crossed using Venn diagram to identify targets that were predicted by three or 
more algorithms (Figure 5.6B). Three different targets for both miRNAs were identified by 
three or more prediction tools including Zinc Finger SWIM-Type Containing 6 (ZSWIM6), PDZ 
domain-containing protein 2 (PDZD2) and Mitogen-Activated Protein Kinase Kinase Kinase 1 
(MAP3K1) (Figure 5.6B). 
This research was conducted synchronously with data analysis shown in Chapter 4 and 
indicating miR-21 associated most clearly with factors implicated in peritoneal membrane 
alterations driven by PD therapy. Therefore, a second in silico target prediction approach 
focusing on miR-21 was performed. This second time, only miR-21 target predictions using 
Diana (blue), miRDB (brown), miRanda (green) and TargetScan (red) displayed in Figure 5.6A 
(dark color) were inter-crossed using Venn diagram to identify targets that were predicted by 
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three or more algorithms (Figure 5.6C). A total of 147 candidate targets were identified by 
three or more prediction tools and used to generate a list called ‘miRNA#’ (blue) (Figure 5.6C).  
Figure 5.6. In silico target prediction to identify new miR-21 and miR-31 targets that may contribute to the 
MMT process in HPMCs. (A) Target prediction using Diana (blue), miRDB (brown), miRanda (green) and 
TargetScan (red) in silico algorithms for miR-21 (dark color) and miR-31 (light color). Venn diagram were used 
to identify common target predictions for both miRNAs. (B) miR-21 and miR-31 common target predicted and 
identified in (A) were further inter-crossed using Venn diagram to identify targets that were predicted by 
three or more algorithms. (C) Prediction of miR-21 targets alone was also analyzed using Diana (blue), miRDB 
(brown), miRanda (green) and TargetScan (red) inter-crossed using Venn diagram to identify targets that were 
predicted by three or more algorithms.  
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 In order to evaluate the feasibility of these predictions mRNA array data from an ex 
vivo model of mesothelial cell MMT associated to PD therapy was used. mRNA array data 
were kindly provided by Dr Manuel Lopez-Cabrera displaying results from control omentum 
HPMCs, PDE derived MCs with epithelial phenotype (early-MMT) and PDE derived MCs with 
non-epithelial phenotype (late-MMT). mRNA array changes were analyzed comparing (i) 
control omentum HPMCs and PDE derived MCs with epithelial phenotype (early-MMT, 
green), (ii) PDE derived MCs with epithelial phenotype and non-epithelial phenotype (late-
MMT, yellow), and (iii) control omentum HPMCs and PDE derived MCs with non-epithelial 
phenotype (whole-MMT, red) to generate three independent lists of mRNA changes under 
the conditions of study (Figure 5.7A). These array results showed that 274 transcripts were 
down-regulated in the early-MMT model (green) while 298 transcripts were less expressed 
during the late phase of the process (yellow) (Figure 5.7A). Overall, 774 genes were 
differentially down-regulated when comparing extreme phenotypes as a whole-MMT process 
model (red) (Figure 5.7A). Subsequently, ZSWIM6, PDZD2 and MAP3K1 were sought in the 
three lists of gene changes generated from the ex vivo model previously described. From 
these, PDZD2 mRNA was identified by the array data to be differentially down-regulated 
during both early and late MMT. Nevertheless, no changes were identified in ZSWIM6 and 
MAP3K1 gene transcription displayed by the array.  
Similarly, miR-21 targets predicted in Figure 5.6C (miRNA#, blue) were further inter-
crossed using Venn diagram with the mRNA array list changes identified in figure 5.7A (lists: 
green, yellow, red) (Figure 5.7B). Five miR-21 predicted targets were identified to be 
differentially down-regulated during early-MMT (Figure 5.7B’), two in the late-MMT course 
(Figure 5.7B’’) and ten when the whole-MMT was compared (Figure 5.7B’’’). miR-21 possible 
targets identified included Natriuretic Peptide B (NPPB), PDZD2, S100 calcium-binding protein 
A10 (S100A10), SAM And SH3 Domain Containing 1 (SASH1) and Metalloproteinase inhibitor 
3 (TIMP3) for early-MMT (Figure 5.7B’); PDZD2 and SASH1 for late-MMT (Figure 5.7B’’); and 
Absent In Melanoma 1-Like (AIM1L), CASK Interacting Protein 1 (CASKIN1), Dual Specificity 
Phosphatase 8 (DUSP8), Fibroblast Growth Factor 18 (FGF-18), Matrilin 2 (MATN2), Neural 
EGFL Like 2 (NELL2), PDZD2, (Ras Homolog Family Member B (RHOB), SASH1 and Sprouty RTK 
Signalling Antagonist 1 (SPRY1) for whole-MMT (Figure 5.7B’’’). Thirteen different possible 
147 
 
miR-21 direct targets identified above and likely to be important in the MMT process 
associated to PD treatment were selected for subsequent study.  
 Figure 5.7. mRNA array changes for early, late and whole MMT process associated to PD therapy in HPMCs. 
(A) Diagram displaying mRNA array changes comparing control omentum HPMCs and PDE derived MCs with 
epithelial phenotype (early-MMT, green), PDE derived MCs with epithelial phenotype and non-epithelial 
phenotype (late-MMT, yellow), and control omentum HPMCs and PDE derived MCs with non-epithelial 
phenotype (whole-MMT, red). (B) Diagram displaying miR-21 targets predicted and identified in Figure 5.6C 
(blue) further inter-crossed using Venn diagram with the mRNA array changes identified in (A; green, yellow, 
red). Common targets identified by Figure 5.6C and (A) inter-crossed lists are shown into squares with the 
respective MMT color (B’, early-MMT; B’’, late-MMT; B’’’, whole-MMT). 
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5.2.4.  Target prediction screening in HPMCs under MMT conditions 
Predicted miR-21 targets were screened in a model of progressive peritoneal 
membrane deterioration in which mRNA expression was measured in control omentum-
derived HPMCs, TGF-β1 treated and peritoneal effluent derived (PDE) cells with epithelial (E) 
and non-epithelial (NE) phenotype. Potential miR-21 target expression for each of the model 
conditions described above as well as association between miR-21 and specific potential 
targets of study across MMT conditions are shown in Figure 5.8. SPRY1 expression and 
association with miR-21 has been previously described and discussed in Figure 5.2B, B’. Eleven 
of thirteen possible miR-21 targets identified in silico followed a pattern of mRNA expression 
consistent with a direct and/or indirect regulation by miR-21 in a model of progressive 
peritoneal membrane deterioration (Figure 5.8). Plausible miR-21 regulated transcripts 
included PDZD2, S100A10, SASH1, AIM1L, CASKIN1, DUSP8, FGF-18, MATN2, NELL2 and SPRY1 
(Figure 5.8, B-D, B’-D’, F-M and F’-M’). Significant inverse association between miR-21 and 
four of these targets was found including S100A10 (Figure 5.8C’, r=-0.555, P=0.011), CASKIN 
(Figure 5.8G’, r=-0.468, P=0.038), DUSP8 (Figure 5.8H’, r=0.468, P=0.029) and NELL2 (Figure 
5.8K’, r=-0.463, P=0.040). NPPB, TIMP3 and RHOB were the only targets that did not follow 
the expected tendency in mRNA expression reduction in the model of study (Figure 5.8A, A’, 
E, E’, L and L’). Indeed, a significant positive association between miR-21 and NPPB (Figure 
5.8A’, r=0.763, P<0.0001) was found while positive association trends were identified 
between miR-21 with TIMP3 (Figure 5.8E’, r=0.173, P=0.465) and a mild association with 
RHOB (Figure 5.8L’, r=0.107, P=0.653). Of note, SPRY1 has previously been identified and 
confirmed to be miR-21 specific targets (Thum et al, 2008) and was, therefore, not considered 
for future research (Figure 5.8B, B’). Thus, target prediction screening in HPMCs under MMT 
conditions decreased the initial target selection to nine potentially miR-21 regulated 
transcripts including PDZD2, S100A10, SASH1, AIM1L, CASKIN1, DUSP8, FGF-18, MATN2 and 
NELL2.  
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miR-21 mimic delivery in HPMCs was used to further screening in silico target 
predictions of the nine remaining targets identified. Three different miR-21 and miR-control 
mimic concentrations (5 pM, 10 pM and 20 pM) were used for this study (Figure 5.9). Four of 
the nine targets studied were significantly down-regulated by miR-21 mimic delivery including 
PDZD2, S100A10, FGF-18 and MATN2 (Figure 5.9A, B, G and H). miR-21 inhibitor was also 
transfected in HPMCs to additionally screen the feasibility of the nine targets determined in 
silico. Three different miR-21 and miR-control inhibitor concentrations (5 pM, 10 pM and 20 
pM) were utilized for this purpose (Figure 5.10). Seven of the nine targets analyzed were 
significantly up-regulated by miR-21 inhibition comprising PDZD2, S100A10, CASKIN, DUSP8, 
FGF-18, MATN2 and NELL2 (Figure 5.10A, B, E, F, G, H and I). Targets that showed to be 
commonly regulated by miR-21 gain- and loss-of-function experiments were selected for 
further research including PDZD2, S100A10, FGF-18 and MATN2 (Figure 5.9 and 5.10A, B, G 
and H).   
Deep analysis on 3’UTR target site types and conservation for PDZD2, S100A10, FGF-
18, MATN2 and miR-21 and miR-31 across different animals is shown in Figure 5.11. PDZD2 
3’UTR showed to contain five different seed regions, two for miR-21 and three for miR-31, 
while the rest of the targets identified enclosed a single miR-21 seed region (Figure 5.10). 
Successful miRNA-target seed-matched site ranking, although variable, has been averaged as 
8mer (miRNA seed match + A at position 1 (A1) and match at position 8 (m8)) >> 7mer-m8 
(miRNA seed match + m8) > 7mer-A1 (miRNA seed match + A1) >> 6mer > no site; in which 
the last pair barely differs (Bartel, 2009). Thus, target sequence analysis for PDZD2 showed to 
display a miR-31 8mer site (Figure 5.11B’), miR-21 7mer-m8 site (Figure 5.11C’), miR-31 7mer-
8m site (Figure 5.11D’), miR-31 8mer site with a potential 3’ supplementary site which is 
characterized by 1-5 nt loop and supplementary pairing of ≥ 3-4 pairs (Figure 5.11E’)  (Bartel, 
Figure 5.8. Predicted miR-21 target profiling in a model of progressive peritoneal membrane deterioration. 
(A-L) Relative mRNA expression in control omentum-derived mesothelial cells (HPMCs), TGF-β1 treated 
(1ng/ml, 48h) and cultured peritoneal effluent derived (PDE) cells with epithelial (E) and non-epithelial (NE) 
phenotype (n=5 for each group). (A) NPPB. (B) PDZD2. (C) S100A10. (D) SASH1. (E) TIMP3. (F) AIM1L. (G) 
CASKIN1. (H) DUSP8. (I) FGF18. (J) MATN2. (K) NELL2. (L) RHOB. (A’-L’) Scatter plot showing correlation of 
miR-21 and potential mRNA targets in HPMCs – black circle, TGF-β1 treated – light grey, and PDE cells with 
E – dark grey, and NE – pale grey, phenotype. (A’) NPPB. (B’) PDZD2. (C’) S100A10. (D’) SASH1. (E’) TIMP3. 
(F’) AIM1L. (G’) CASKIN1. (H’) DUSP8. (I’) FGF18. (J’) MATN2. (K’) NELL2. (L’) RHOB. Target gene expression 
was analyzed by RT-qPCR and normalized to GAPDH. Data were analyzed by no matched one-way ANOVA 
followed by post-hoc Holm-Sidak’s test. Data represent the mean S.E.M. from five independent donor 
experiments. *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.005 ****p < 0.001.  
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2009), and miR-21 8mer site (Figure 5.11F’) while S100A10 exhibited a 7mer-m8 site (Figure 
5.11G’), and FGF-18 and MATN2 8mer each (Figure 5.11, H’ and I’). Interestingly, multiple 
miRNA-binding sites for miR-21 and miR-31 in PDZD2 3’UTR may be especially effective for 
repression (Bartel, 2009). Nevertheless, PDZD2 miRNA target site conservation was found to 
be considerably poor (0-50%) while S100A10 was 75%, FGF-18 was 100% and MATN2 was 
75% (Figure 5.11, B-I). Overall, all miRNA-target seed-matched sites considered for future 
research belonged to the two site types of miRNA-target with higher relative efficiency 
(Bartel, 2009) and with FGF-18, S100A10 and MATN2 target sites being ≥ 75% conserved.  
Figure 5.9. miR-21 target mRNA expression after miRNA mimic delivery in HPMCs (A-I) Target mRNA 
expression after 48h of miRNA mimic delivery (5pM, 10pM and 20pM) in HPMCs. miR-control – white bars, 
miR-21 – black bars and three independent donor experiments. (A) PDZD2. (B) S100A10. (C) SASH1. (D) 
AIM1L. (E) CASKIN1. (F) DUSP8. (G) FGF18. (H) MATN2. (I) NELL2. Target gene expression was analyzed by 
RT-qPCR and normalized to GAPDH expression respectively. Data were analyzed by matched factor two-way 
ANOVA followed by post-hoc Holm-Sidak’s test. Data represent the mean S.E.M. from three independent 
donor experiments. *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.005.   
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Figure 5.10. miR-21 target mRNA expression after miRNA inhibitor delivery in HPMCs (A-I) Target mRNA 
expression after 48h of miRNA inhibitor delivery (5pM, 10pM and 20pM) in HPMCs. miR-control – white bars, 
miR-21 inhibitor – grey bars and six independent donor experiments. (A) PDZD2. (B) S100A10. (C) SASH1. (D) 
AIM1L. (E) CASKIN1. (F) DUSP8. (G) FGF18. (H) MATN2. (I) NELL2. Target gene expression was analyzed by 
RT-qPCR and normalized to GAPDH expression respectively. Data were analyzed by matched factor two-way 
ANOVA followed by post-hoc Holm-Sidak’s test. Data represent the mean S.E.M. from six independent donor 
experiments. *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.005 and ****p>0.001.   
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Figure 5.11. miR-21 and miR-31 3’UTR target site conservation for PDZD2, S100A10, FGF10 and MATN2 
across different animals. (A-J) Target sequences were acquired using TargetScan and alignment was 
performed with mega 6. Human complementary nucleotide sequences and 10 nucleotides up- and down-
stream are presented. Conserved human complementary nucleotides at the seed binding area are displayed 
in red and whole nucleotide conservation is indicated with stars. (A’-J’) mRNA-miRNA hybrid was predicted 
using Diana v5.0. Seed binding area is displayed in red while remaining nearby nucleotides are shown in 
black (mRNA) and blue (miR-21) and green (miR-31). (A) Esquematic PDZD2 3’UTR displaying miR-21 and 
miR-31 target sequences (B-G, B’-G’) PDZD2. (H, H’) S100A10. (I, I’) FGF18. (J, J’) MATN2.  
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5.2.5.  Luciferase 3’UTR analysis indicates that miR-21 may directly regulate 
S100A10 and FGF-18 
Specific luciferase reporter plasmids were designed and cloned using pMIR-REPORT 
plasmid for each one of the four targets of interest as detailed in Chapter 2. To avoid non-
desired effects on reporter plasmid performance due to PDZD2 3’UTR sequence length (2875 
pb) four different plasmids were generated including PDZD2 3’UTR initial sequence (818 pb), 
middle sequence (863 pb), terminal sequence (864 pb) and full sequence (2545 pb) (Figure 
2.2A) while whole 3’UTR sequences were used for FGF-18 (814 pb), S100A10 (245 pb) and 
MATN2 (1004 pb). The generated plasmids were co-transfected into HeLa cell line and 
primary HPMCs with renilla luciferase reporter plasmids together with miRNA mimic or 
inhibitor molecules (Figure 5.12). Relative luciferase expression was significantly reduced 
when S100A10 3’UTR plasmid was co-transfected with miR-21 mimic while showed a trend in 
increase when co-transfected with miR-21 inhibitor in HeLa cells (Figure 5.12B). Similar trends 
in S100A10 3’UTR driven luciferase expression were observed in two different HPMC donor 
samples (Figure 5.12B’). Although not significant, a trend in relative luciferase expression 
consistent with a direct miR-21 regulation of FGF-18 3’UTR was observed in both, HeLa and 
HPMCs (Figure 5.12, A-A’). No trend in luciferase expression was observed when MATN2 and 
PDZD2 reporters were analyzed in HeLa cells (Figure 5.12, C-H). Thus, although more research 
is needed to confirm these data (see Chapter 5.3), miR-21 may be a real direct regulator of 
S100A10 and FGF-18 in both, HeLa and HPMCs.    
 
 
 
 
 
 
Figure 5.12. FGF-18, S100A10, MATN2 and PDZD2 3’UTR luciferase reporter assay indicates that miR-21 
may directly regulate S100A10 and FGF-18 sequence. Relative luciferase activity of target 3’UTR reporter 
plasmids generated and co-transfected with miR-21/miR-31 mimic or inhibitor molecules were compared 
with co-transfections using specific controls after 48 h. (A, A’) FGF18. (B, B’) S100A10. (C) MATN2. (D) PDZD2 
first 3’UTR sequence. (E) PDZD2 central 3’UTR sequence. (F) PDZD2 terminal 3’UTR sequence. (G) Full PDZD2 
sequence. (A-G) experiments were performed in HeLa cells while (A’-B’) were performed in HPMCs. Firefly 
reporter was co-transfected with 5 pM of miRNA mimic or inhibitor and normalized to Renilla luciferase. 
Data represent the mean S.E.M. from four independent experiments done by duplicate for HeLa and two 
independent donor experiments done by duplicate for HPMCs. **p ˂ 0.01.  
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5.2.6.  Target specific down-regulation and downstream contribution in 
HPMCs 
Specific siRNA molecules were purchased for each one of the four targets of interest 
and were transfected for 48 h into HPMCs to study their broad contribution to the MMT 
process. No differences in mesothelial cell phenotype were observed under light microscopy 
after 48 h of specific siRNA delivery into primary HPMCs compared with controls. Additionally, 
all mesothelial and mesenchymal markers previously associated with TGF-β1 induced MMT 
process (Figure 3.1 and 3.3), were studied in this context. Target specific siRNA molecules 
were, in all cases, able to reduce mRNA expression of the particular target of study (Figure 
5.13). No significant changes in the transcription of mesothelial nor mesenchymal markers 
were identified after FGF-18 down-regulation (Figure 5.13, A-A’’). Unexpectedly, S100A10 
down-regulation showed to increase Claudin mRNA expression in a significant fashion (Figure 
5.13B’). Interestingly, MATN2 up-regulated Snail transcription (Figure 5.13C’’) and PDZD2 
showed to induce Snail mRNA expression in a non-significant manner while down-regulated 
E-cadherin, ZO-1 and Occludin transcriptional levels (Figure 5.13C’ and C’’). There have been 
no previous identification and/or characterization of either of these targets during the MMT 
process associated to peritoneal dialysis and therefore, little is known about their possible 
contribution in this context. Nevertheless, a detailed analysis of each target feasible 
contribution to the MMT process described in literature is discussed during the next section 
(see 5.3). 
 
 
 
 
Figure 5.13. PDZD2 may contribute to MMT process via mesothelial cell adhesion regulation in HPMCs. 
mRNA expression after 48h of siControl, siFGF-18, siS100A10 and siMATN2 (40 nM) and siPDZD2 (30 nM) 
delivery in HPMCs. siControl – white bars, siTarget – black bars and six independent donor experiments. 
Mesothelial mRNA markers studied include E-cadherin, ZO-1, Occludin and Claudin while Mesenchymal 
mRNA markers determined covered Fibronectin, Collagen I, Snail and α-SMA. (A) siFGF-18. (B) siS100A10. 
(C) siMATN2. (D) siPDZD2. Data were analyzed by paired t test or paired multiple t test corrected for multiple 
comparisons by Holm-Sidak. Data represent the mean S.E.M. from six independent donor experiments. *p ˂ 
0.05; **p ˂ 0.01; ***p ˂ 0.005.   
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5.3. Discussion 
miRNA function is ultimately defined by the pool of mRNA that a specific miRNA 
may target and its regulatory effect on their expression in a defined context. 
Undoubtedly, the recognition and study of specific direct miRNA targets is one of the 
most difficult fields in miRNA research. It is important to acknowledge here that a lack 
of change in mRNA levels during a specific context and/or after miRNA mimic/inhibitor 
transfection does not exclude the possibility of studying a real target (Figure 5.3 and 5.4, 
B and C) (Pasquinelli, 2012). Indeed, metazoan miRNAs mediate translational repression, 
mRNA degradation, or a combination of both. The levels of mRNA destabilization by 
miRNAs has been a classic polemic topic in the field of miRNA research. Nevertheless, 
experimental re-evaluation of miRNAs described to down-regulate protein production 
in the absence of mRNA destabilization demonstrated broad transcriptomic imprint on 
seed-matched mRNAs (Guo et al, 2010).  
Of note, miRNA mimic/inhibition transfection into cells may show and/or create 
interactions that do not happen at animal level. Additionally, luciferase 3’UTR reporters 
are an artificial tool to identify direct miRNA regulation in vitro. It is important to 
consider that different cell types will also express a different panel and levels of RNA-
binding proteins, shaping intracellular 3’UTRs tertiary structures which may thus vary 
considerably from algorithm predictions. Additionally, gain and loss of function as well 
as reporter assays are performed here with miRNAs that are already expressed in large 
levels, which may also mask real target modulation due to the lack of profound, easily 
recognizable effects. These considerations may explain the fact that some miR-21 direct 
targets described in the literature were not found to be regulated in HPMCs when 
miRNA levels of expression were manipulated in vitro, including SPRY1, PTEN and TIMP3 
(Figure 5.3 and 5.4, B and C; Figure 5.8 E and E’). This may also be relevant to the lack of 
a trend in MATN2 and PDZD2 3’UTR luciferase reporter expression when co-
administrated with miRNA mimic/inhibitor molecules (Figure 5.12, C-H). Nevertheless, 
experiments based on gain and loss of miRNA function together with the study of the 
3’UTR reporters of possible mRNA targets are broadly accepted and considered to be 
161 
 
the major bench techniques to demonstrate direct and/or indirect mRNA regulation by 
a specific miRNA.  
To understand how miR-21 up-regulation may lead to MMT and fibrosis in the 
peritoneal membrane, the expression of already described miR-21 target genes was 
studied. Here, miR-21 mediated repression of PDCD4 in mesothelial cells, at both mRNA 
and protein levels (Figure 5.3A, 5.4A and 5.5, A-C). PDCD4 down-regulation has been 
shown to trigger an increase in Snail protein and a consequent decrease in E-cadherin 
expression, which in turn stimulates β-catenin/TCF dependent transcription (Asangani 
et al, 2008; Brønnum et al, 2013; Yao et al, 2011) (Figure 5.5D). Thus, miR-21 down-
regulation of PDCD4 in HPMCs may not only contribute to the detachment of inter-
mesothelial adhesions but also to the acquisition of a new molecular program, dictating 
a distinct expression regulation characteristic of an MMT process (Figure 5.5D). 
Additionally, further research to modulate PDCD4 protein levels using miR-21 inhibitor 
molecules would have been interesting, but this was finally not possible due to the 
limited time of this project.  
Target-prediction tools have improved during recent years (Table 2.7). 
Nevertheless, there is still a substantial divergence in their predictions, as shown in 
Figure 5.6. Due to the experimental approach selected to conduct this research there 
was a large number of miRNA-target interactions initially selected for direct miRNA 
regulation inquiry (Figure 5.6), and analysing protein changes at the model of study as 
well as gain and loss of function assays would have been an arduous starting point. 
Therefore, mRNA expression changes were used to screen likely direct and indirect 
changes induced by miRNA in this context. It is possible that some direct miRNA-target 
interactions may have been masked by the selected approach of study due to non-
destabilized mRNA expression and/or mediating translational repression (Figure 5.8 and 
5.9). Nevertheless, this was a necessary choice due to the limited time of the project. 
Although the relative importance of target site conservation is a matter of 
argument in the miRNA field, conserved sites exhibit greater real miRNA recognition 
than non-conserved sites with similar sequence context scores (Bartel, 2009). Doubtless, 
due to large specific favourable context selection of conserved sites while researchers 
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and currently available target prediction algorithms are still unaware of all features 
characterizing these contexts. For this reason, to further study target site conservation 
of the four targets selected for research including FGF-18, S100A10, MATN2 and PDZD2 
(Figure 5.11) was decided.   
Deep genome studies of miRNA target site conservation and efficacy showed 
that 7-8 nt target sites are more effective when located in non-middle regions of long 
3’UTRs (Grimson et al, 2007). This may explain the apparent non-direct regulation of 
PDZD2 by miR-21 and miR-31 even when several target sites were identified (Figure 
5.11A). PDZD2 3’UTR total length was 2875 pb, which is much longer than human 3’UTR 
average ~ 800 pb (Mignone et al, 2002), and miRNA sites contained at the 3’UTR region 
may be blocked by side segment interactions. Nevertheless, the three fractions of 
PDZD2 3’UTR reporters analyzed contained ~ 800 pb in all cases and did not show 
luciferase regulatory trend in expression when co-transfected with miR-21 and miR-31 
miRNA mimic/inhibitory molecules (Figure 5.12, D-H). Additionally, the lack of a trend in 
MATN2 3’UTR luciferase expression when administrated with miR-21 mimic/inhibitory 
molecules indicated that MATN2 is unlikely to be a direct miR-21 target (Figure 5.12C).  
FGF-18 3’UTR reporter was found to have a non-significant trend in luciferase 
expression regulation when co-transfected with miR-21 mimic/inhibitory molecules, in 
both HeLa and primary HPMCs (Figure 5.12 A and A’). S100A10 3’UTR reporter displayed 
a significant luciferase expression down-regulation when co-administrated with miR-21 
in HeLa cells, while a trend in increase if delivered with miR-21 inhibitory molecules 
(Figure 5.12B). Additionally, S100A10 3’UTR showed similar luciferase expression trends 
when co-administrated with miR-21 mimic/inhibitory molecules in primary HPMCs 
(Figure 5.12B’). Although not definitive, these results indicate that miR-21 may regulate 
both targets in a direct manner. In order to definitively prove this possibility, 4 nt seed 
region site mutagenesis has been used to generate mutant versions of FGF-18 and 
S100A10 3’UTR luciferase reporters (see Chapter 2). Due to the limited time of this 
project, to show the significance of wild-type FGF-18 and S100A10 3’UTR luciferase 
reporter expression when co-administrated with miR-21 mimic/inhibitory molecules as 
well as its abrogation by the use of 3’UTR luciferase reporters containing miR-21 seed 
region site mutations was not possible. Thus, future research approaching the above 
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mentioned experimental conditions would be necessary to conclusively identify FGF-18 
and S100A10 as miR-21 direct targets.   
The research developed during this chapter identified two new indirect miR-21 
targets, MATN2 and PDZD2, as well as two direct and/or indirect miR-21 target genes 
comprising FGF-18 and S100A10 (Figure 5.12) all of which were down-regulated in a 
MMT model mRNA array and may be important during the MMT process associated to 
PD therapy. During this process, miR-21 may regulate the above mentioned targets to 
control cellular decisions pivotal in MMT progression and/or finely tune specific protein 
networks. Of note, no previous description of MATN2 and PDZD2 expression in 
mesothelial cells have been reported before this research was performed. Additionally, 
none of these genes have been characterized as downstream miR-21 targets, neither 
have they been linked to the process of mesothelial to mesenchymal transition during 
PD therapy. A summary of the possible implications of work in other fields for these 
newly identified miR-21 targets is presented below.  
FGF-18 
FGF-18 belongs to the FGF family of polypeptides, involved in cell growth, 
differentiation, morphogenesis, tissue remodelling, inflammation, angiogenesis, tumour 
growth and developmental processes (Haque et al, 2007). The FGF family includes 22 
members in humans which signal via tyrosine phosphorylation mediated by FGF 
receptors (FGFR1-4 and FGFRL1) and auxiliary intermediate molecules (Haque et al, 
2007). Although structurally related, FGFs display distinct functions, secretory and 
receptor-mediated machinery and, therefore, trigger different ultimate biological 
functions.  
FGF-18 is expressed during embryonic development and throughout lifespan. 
Transgenic FGF-18-/- mice are viable during embryonic development but die soon after 
birth due to cyanosis (Liu et al, 2002). FGF-18-/- mice expressed a distinct phenotype 
characterized by skeletal abnormalities, incomplete development and 10-15% size 
reduction (Liu et al, 2002) and mice with conditional deletion of FGF-18 in the lung 
displayed thicker interstitial mesenchymal compartments, embedded capillaries and 
reduced cell proliferation (Usui et al, 2004). On the other hand, overexpression of FGF-
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18 in transgenic mice induced epithelial and mesenchymal proliferation in numerous 
tissues demonstrating FGF-18 pleiotropic growth factor effects (Hu et al, 1998) later 
shown to be highly dependent on context. Indeed, FGF-18 function has been shown to 
be deeply dependent on its spatial and temporal expression as well as on the expression 
of its receptors and the presence of specific growth factors. FGF-18 binds with high 
affinity to FGFR3 and FGFR4 but modestly to FGFR2 (Haque et al, 2007; Zhang et al, 2006) 
acting in a paracrine and/or autocrine fashion. Mesothelial cells express FGFR1-4, 
sustaining higher levels of FGFR4 and FGFR1 (Schelch et al, 2014). Thus, FGF-18 may act 
in mesothelial cells in an autocrine manner via FGFR4 stimulation.   
In control fibroblasts, FGF-18 inhibited cell growth and enhanced migration 
(Joannes et al, 2016). The authors observed a non-significant increase in MMP2 and 
MMP3 expression, two matrix metalloproteinases implicated in extracellular matrix 
degradation and cell migration which are often necessary to acquire a cell migratory 
phenotype (Joannes et al, 2016). FGF-18 induction also enhances the expression of 
Snail1/2 homologs in a lung-targeted FGF-18 mouse model (Franco-Montoya et al, 
2011). Additionally, FGF-18 partially inhibited TGF-β1-induced fibroblast activation 
(Joannes et al, 2016) and down-regulated collagen I expression in chondrocytes 
(Yamaoka et al, 2010). Of note, FGF-18 over-expression in lung decreased extracellular 
matrix and connective tissue components including matrilin-2 (Franco-Montoya et al, 
2011). Interestingly, FGF-18 transcript was increased here, in a model of early 
mesothelial to mesenchymal trans-differentiation while decreased during later stages 
of the process (Figure 5.7I), and may act fine-tuning MMT associated to PD therapy. 
Thus, initial mesothelial FGF-18 up-regulation may be important for mesothelial cell 
acquisition of migratory capabilities to colonize the peritoneal submesothelial compact 
zone while later FGF-18 down-regulation may be necessary in order to develop a 
secretory phenotype contributing to extracellular matrix deposition.  
Of note, FGF-18 was up-regulated in de-differentiated chondrocytes and was 
suggested to be a marker of de-differentiation (Yamaoka et al, 2010). Conversely, TGF-
β1 has also been shown to stimulate the expression of FGF-18 in chondrocytes 
(Mukherjee et al, 2005). Following these and Franco-Montoya et al. 2011 observations 
indicated above it would be especially interesting to study time courses of HPMC 
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incubated with TGF-β1 for FGF-18 and matrilin-2 expression, as well as HPMCs incubated 
with FGF-18 for genes associated with TGF-β1 signalling and MMT. Additionally, it would 
also be interesting to investigate MMP2, MMP3, Snail1 and Snail2 HPMCs time-profiles 
after exogenous FGF-18 stimulation and knockdown via siFGF-18.  
S100A10 
S100A10, also known as p11, belongs to the S100 gene family together with 19 
additional small isoforms in humans which have been involved in transcription, 
secretion, contraction, motility, cell growth, differentiation and cell cycle progression 
(Madureira et al, 2012). S100A10 is ubiquitously expressed and its distinctiveness from 
S100 family members lies in its incapability to bind Ca2+ and its constitutively active 
structure (Réty et al, 1999). Although S100A10 can be found as a homodimer, the 
predominant form of S100A10 is in a heterotetrameric complex with annexin A2 (AIIt), 
consisting of two copies of annexin A2 and S100A10 homodimers (Bharadwaj et al, 2013; 
Madureira et al, 2012). Indeed, annexin A2 is essential for S100A10 extracellular 
transport via the exosomal pathway (Fang et al, 2012), AIIt anchorage to the plasma 
membrane in a Ca2+ dependent fashion (Deora et al, 2004; Filipenko et al, 2000), and 
S100A10 protection from ubiquitin-dependent degradation (Yang et al, 2011).  
Between the multiple functions attributed to S100A10 probably the most 
physiologically remarkable is its extracellular function as a plasminogen receptor. Within 
the cell surface AIIt complex, S100A10 binds plasminogen and mediates its activation by 
plasminogen activators, stimulating plasminogen conversion to wide protease plasmin 
and promoting fibrinolysis (Surette et al, 2011). S100A10 depletion using small 
interfering RNA in a human microvascular endothelial cell line in vitro showed a 
significant impairment in plasminogen binding (50%) and plasmin generation (60%) 
compared with controls (Surette et al, 2011). S100A10-null mice, although viable, 
showed impaired fibrinolysis and increased tissue fibrin deposition including in lungs, 
liver, spleen and kidney compared to wild-type mice litter mates (Surette et al, 2011). 
Thus, reduced S100A10 expression in HPMCs associated to PD therapy may reduce their 
fibrinolytic activity contributing to the accumulation of fibrin in the peritoneal 
membrane. 
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In kidney cells, S100A10 is involved in the formation of E-cadherin-based 
adherens junctions (Yamada et al, 2005) and mediates annexin A2:AHNAK interaction at 
the plasma membrane regulating actin cytoskeleton organization and cell membrane 
cyto-architecture (Benaud et al, 2004). Indeed, actin confocal microscopy analysis 
showed more flattened cell morphology when S100A10 depleted cells were compared 
with controls (Benaud et al, 2004) and sub-membranous complex between AHNAK and 
AIIt physically interacting with the actin cytoskeleton has been proposed (Hohaus et al, 
2002). In this regard, it would have been also especially interesting to further study the 
downstream effects of miR-21 driven S100A10 down-regulation in HPMCs cell-cell 
adhesions as well as actin cytoskeleton.   
In PD therapy, peritoneal dialysis fluids may impair the function of macrophages 
affecting pathogen clearance. This hypothesis was suggested by Ogata et al. 2011 who 
raised the possibility that potential of mesothelial cells to recruit 
monocyte/macrophages would be affected in PD patients (Ogata et al, 2011). Indeed, 
intraperitoneal administration of PDF suppressed infiltration of mononuclear cells in the 
peritoneum of mice following lipopolysaccharide injection (Ogata et al, 2011). Cell 
surface plasmin production is required for leukocyte recruitment to areas of 
inflammation (Gong et al, 2008) and macrophage recruitment may be partially impaired 
during PD therapy due to lower S100A10 expression levels and therefore, lower plasmin 
production.  
In cancer, S100A10 levels have been described to be generally up-regulated. 
Nevertheless, mass spectrometry used to identify S100 isoform expression in thyroid 
samples found a significant decrease in S100A10 and annexin A2 in follicular adenoma 
and carcinoma and lower expression in papillary carcinoma when compared with normal 
thyroid samples (Martínez-Aguilar et al, 2015). Serial analysis of gene expression also 
identified S100A10 down-regulation in breast cancer irrespective of pathological state 
(Carlsson et al, 2005). Immunohistochemistry of prostate cancer patients also indicated 
S100A10 reduction of expression in all patients and 65% of prostate intraepithelial 
neoplasia (prostate cancer precursor) (Yee et al, 2007). The mechanism by which 
S100A10 is expressed and post-transcriptionally regulated is largely known and appears 
to be cell-type-specific. The research developed during this thesis showed a possible 
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direct regulation of S100A10 by miR-21 in peritoneal membrane fibrosis associated to 
PD treatment but may also establish the basis to understand S100A10 post-
transcriptional regulation in further contexts.  
MATN2 
Matrilin-2 is a protein encoded by MATN2 gene that belongs to a four-member 
family of multi-subunit extracellular matrix proteins which are intimately structurally 
related and have been involved in the development of fibrillary structures and to act as 
adaptors between matrix components (Klatt et al, 2011). Matrilin-2 is widely expressed 
in connective tissue cells, smooth muscle and epithelia in which is pericellularly 
deposited (Klatt et al, 2011). Matrilin-2 has been shown to directly bind collagen I and 
non-collagenous proteins such as fibrillin-2, fibronectin and laminin-1-nidogen-1 
complexes (Piecha et al, 2002), as well as weakly binding to α1β1 integrin (Mann et al, 
2007), contributing to extracellular matrix supra-molecular organization and 
homeostasis. Transgenic matrilin-2-/- mice is viable, fertile and histologically normal 
during different embryonic and postnatal stages (Mátés et al, 2004). The lack of a 
distinct matrilin-2-/- mice phenotype may be due to redundant matrilin functions, but 
still affect animal survival under natural conditions. Indeed, matrilin-2-/- mice developed 
inferior axonal growth recovery after injury (Jonas et al, 2014), was a key molecule 
during myogenic differentiation (Deák et al, 2014), grew sporadic microscopic tumour 
in the liver at 10 months age (Fullár et al, 2014) and cellular matrilin-2 knock-down 
induced serious defects in skin wound healing (Ichikawa et al, 2008).  
Interestingly, matrilin-2 has been involved in the control of the early stages of 
myogenic differentiation (Deák et al, 2014). In vitro and in vivo models of muscle 
differentiation exhibited a transient but crucial increase in matrilin-2 mRNA and protein 
level during myoblast differentiation followed by a decline in its expression during 
myofiber maturation (Deák et al, 2014). Indeed, matrilin-2 showed to induced a switch 
of the core transcription machinery associated to myofibroblast differentiation (Deák et 
al, 2014). Additionally, Ichikawa et al. 2008 studies showed that matrilin-2 regulated 
wound healing in an in vitro model using human keratinocyte cells (Ichikawa et al, 2008). 
In this model, matrilin-2 reduction induced cell migration into wound without cell 
proliferation and in a temporal regulated fashion (Ichikawa et al, 2008). Throughout 
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wound healing, extracellular matrix surrounding the wound area is degraded to facilitate 
subsequent wound cell migration and cellular repopulation together with new 
extracellular matrix deposition into the area. Taking together, these research indicate 
that proper temporal regulation of matrilin-2 expression may be especially important in 
mesothelial cell acquisition of a mesenchymal phenotype and mediating inflammatory 
responses as well as a possible migration into the submesothelial compact zone. 
Similarly, matrilin-2 transcript was shown here to be increased in a model of early 
mesothelial to mesenchymal trans-differentiation while decreased during later stages 
of the process and after TGF-β1 stimulation (Figure 5.7J), and may act fine-tuning MMT 
associated to PD therapy. 
Of note, TGF-β1 showed to decrease matrilin-2 expression in myoblasts (Deák et 
al, 2014) and keratinocytes (Ichikawa et al, 2008), and may mediate the adequate 
matrilin-2 expression timing during myoblast differentiation and keratinocyte migration. 
Matrilin-2 promoter contains seven putative Smad sites that may mediate TGF-β1 
inhibitory effect (Deák et al, 2014; Ichikawa et al, 2008). Additionally, this study 
proposed that TGF-β1 mediated miR-21 up-regulation may indirectly contribute to 
regulate differentiation programs and cell migration via matrilin-2 mRNA regulation 
(Figure 5.7J, 5.8H, 5.9H and 5.11C).  
Matrilins have been shown to weakly interact with integrins promoting mild cell 
attachment which downstream capability to activate signal transduction and induce 
gene expression is unknown (Mann et al, 2007). Here, transient matrilin-2 mRNA know-
down in primary HPMCs greatly induced Snail transcription in a significant fashion 
(Figure 5.12D). Nevertheless, future research should be conducted to establish the 
possible significance of these results at both, mRNA and protein levels, as well as their 
contribution during the MMT process associated to PD therapy and fibrosis.   
PDZD2 
PDZD2 (also known as PAPIN, AIPC, PIN1 and PDZK3) is a 301 kDa protein 
encoded by PDZD2 gene. PDZD2 is a ubiquitously expressed six-PDZ (PSD95, Discs-large 
and ZO-1) domain protein which domains are conserved protein-protein interaction 
modules that recognize specific carboxy-terminal sequences acting as molecular 
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scaffolds to enable macromolecular complexes assembly (Yeung et al, 2003). PDZD2 
shows homology with pro-interleukin-16, an atypical cytokine that has been shown to 
function as a growth and differentiation factor in various cell types (Richmond et al, 
2014; Yeung et al, 2003). C-terminal PDZD2 has been shown to be cleaved in a caspase-
3-dependent mechanism to generate secreted PDZD2 (sPDZD2, of 37 kDa) containing 
two PDZ domains which may also interact with extracellular proteins facilitating the 
formation of extracellular complexes (Yeung et al, 2003).   
In rats, PDZD2 was shown to interact with the basic helix-loop-helix transcription 
factor E12. Rat tagged PDZD2 over-expression experiments showed endoplasmic 
reticulum and nuclear localization in COS-7 cells (kidney from African monkey) (Yeung 
et al, 2003). Nevertheless, previous reports have detected PDZD2 at cell-cell contacts in 
lung sections and rat kidney cells (Deguchi et al, 2000) and at cytoplasm in prostate 
section (Chaib et al, 2001). PDZD2 has also been shown to interact with p0071, a 
ubiquitous member of the p120 catenin family of proteins, and to co-localize with 
classical cadherins at cell-cell junctions in lung sections and rat kidney cells (Deguchi et 
al, 2000; Keil et al, 2013). Thus, reduced PDZD2 expression in HPMCs associated to PD 
therapy may lessen cellular scaffolding function contributing to the loss of epithelial 
junctions in the peritoneal membrane. 
In vitro treatment with recombinant sPDZD2 has been shown to induce p53 
mRNA and protein up-regulation in human prostate cancer (DU-145), breast 
adenocarcinoma (MCF-7) and liver cancer (Hep-G2) cell lines (Tam et al, 2008). Of note, 
p53 protein is a transcriptional trigger of cell cycle arrest, senescence, and apoptosis 
which gene (TP53) is frequently mutated in human cancer (Vousden & Lane, 2007). 
Termen et al. 2013 showed that a unique allele p53 mutated is enough to speed 
mammary cell response to TGF-β1 driven EMT compared with wild type p53 which 
inhibits EMT and mammosphere growth (Termén et al, 2013). Interestingly, the authors 
also indicated that TGF-β1 stimulation led to a significant down-regulation of total p53 
protein levels (Termén et al, 2013) which was explained via Mdm2 as indicated by Araki 
et al. 2010 (Araki et al, 2010). Indeed, co-treatment with p53 siRNA and TGF-β1 showed 
quicker E-cadherin and ZO-1 down-regulation as well as actin cytoskeleton 
reorganization into stress fibers with N-cadherin and fibronectin induction in mammary 
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cells (Termén et al, 2013). Taken together, in HPMCs, TGF-β1 induced PDZD2 down-
regulation may also decrease sPDZD2 driven autocrine stimulation reducing p53 cellular 
levels and leading a more robust MMT response. Of note, PDZD2 has also been found to 
be expressed at the nucleus (Yeung et al, 2003) and may, therefore, have a direct nuclear 
function during the MMT process. Here, PDZD2 down-regulation was able to induce 
Snail mRNA expression in a non-significant fashion while significantly down-regulated E-
cadherin and Occludin transcriptional levels (Figure 5.11D).   
FGF-18, S100A10, MATN2 and PDZD2: four miR-21 targets in context 
miR-21 was one of the first members of the small non-coding miRNA family to be 
characterized (Cai et al, 2004). Human miR-21 is located on chromosome 17q23.3 (mice, 
chr.11), in an intronic region of transmembrane protein 49 (TMEM49) gene, a homolog 
of rat vacuole membrane protein (VMP1) involved in cell-to-cell adhesion. Different 
promoters and primary transcripts have been characterized within the terminal intronic 
regions of TMEM49 resulting in a complex, and not fully understood, regulation network 
of miR-21 encoding transcripts (Cai et al, 2004; Fujita et al, 2008; Ribas et al, 2012). 
Primary miR-21 (pri-miR-21) originates within the last TMEM49 introns and bypass 
TMEM49 polyadenylation signals to include miR-21 hairpin (Cai et al, 2004). Conversely, 
TMEM49 transcripts initiate ~ 130 kb upstream miR-21 and can splice and polyadenylate 
upstream miR-21 hairpin but also bypass these polyadenylation signals to include miR-
21 transcript, TMEM49-miR-21-regulation(Ribas et al, 2012). Mature miR-21 and 
consensus promoter regions are highly conserved sequences among vertebrates which 
may indicate a highly conserved transcriptional regulatory mechanism. miR-21 
promoter holds conserved conserved enhancer elements including binding sites for 
activation protein 1 (AP-1; Fos and Jun family nuclear oncogenes), Ets/PU.1,C/EBP-α 
(factors governing haematopoietic lineage differentiation), nuclear factor I (NFI), serum 
response factor (SRF), p53 and signal transducer and activator of transcription 3 (STAT3) 
(Krichevsky & Gabriely, 2009).  
miR-21 is one of the most highly expressed miRNAs in mammalian cells and its 
expression is further enhanced in many disease states including solid tumors and 
inflamed tissue. In this context, miR-21 has been highly associated with glioma, breast, 
ovarian, colorectal, stomach, HCC, prostate, pancreas, lung, head, thyroid, cervical, 
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leukemia and B-cell cancers in which has been mainly involved in proliferation, invasion 
and metastasis. Nevertheless, for the majority of cancers pri-miR-21 does not change 
while there is an increase in mature miR-21. Indeed, it has been shown that different 
molecules including SMAD2/3 recruit pri-miR-21 in a complex with the RNA helicase p68, 
a component of the Drosha microprocessor complex leading to a quick (< 30 min). pri-
miR-21 processing to pre-miR-21 and following miRNA maturation. 
Phenotypic repercussions of transiently disturbing unique miRNA and/or miRNA-
target interplay are predicted to be subtle. Transient specific miRNA modulation as well 
as independent target down-regulation using specific siRNA molecules in HPMCs did not 
display evident phenotypic differences compared with controls. Additionally, 
mesothelial and mesenchymal markers studied after specific target down-regulation 
were not affected in a drastic manner (Figure 5.13). Nevertheless, target siRNA 
downregulation was probably suboptimal and greater target downregulation may show 
more obvious phenotypic as well as mesothelial and mesenchymal markers effects. 
Single miRNA-target site interaction is expected to trigger an mRNA down-regulation of 
less than 50% (Bartel, 2009). Additionally, the majority of mRNAs that contain conserved 
target sites for a specific miRNA also own further conserved regions for independent 
miRNAs (Lewis et al, 2005) and, therefore, multiple miRNA may have to be modulated 
before dramatic effects are seen on some targets. Similarly, target genes may be able to 
exhibit a certain degree of mRNA and protein changes in the absence of measurable 
repercussions. Thus, cellular regulatory networks may be able to absorb here a defect 
and/or excess of a specific target and/or miRNA. In this context, several particular 
perturbations more likely mimicking context real situations may be needed in order to 
achieve detectable phenotypic effects. Finally, the level of miRNA and/or target gain 
and/or loss of function triggered by the experimental conditions may be only able to 
produce a relatively mild phenotype that may be accurately measured by comparative 
sequencing analysis. Due to study time limitations to perform further research on 
simultaneous multiple target perturbations in order to characterize a possible 
characteristic phenotype was not possible, but future research addressing this potential 
may be especially interesting.   
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In conclusion, this research demonstrated that miR-21 and miR-31 up-regulation 
may lead to MMT and fibrosis in the peritoneal membrane via previously described 
targets including, respectively, PDCD4 and LATS2/STK40 (Figure 5.1, 5.3 and 5.4). In 
particular, miR-21 PDCD4 regulation may trigger an increase in Snail contributing not 
only to inter-mesothelial adhesions loss but also to the acquisition of a new 
transcriptional program characteristic of an MMT process (Figure 5.5). Additionally, miR-
21 expression was shown in Chapter 3 to better correlate with peritoneal membrane 
deterioration and may be an especially important molecule driving MMT. miR-21 in silico 
target determination and mRNA array scrutiny of candidates identified thirteen novel 
putative targets for miR-21 that may be important for the MMT associated with PD 
therapy (Figure 5.6 and 5.7). From these, PDZD2 was also predicted to be a common 
miR-21/miR-31 target (Figure 5.6 and 5.7). The mRNA expression of gene candidates was 
evaluated in a combined in vitro and ex vivo model of progressive MMT associated to 
PD treatment. Interestingly, only three predicted targets did not follow an inverse 
pattern of expression with miR-21, while three candidates had already been described 
as miR-21 targets in previous studies (Figure 5.8). miR-21 mimic and inhibitor molecules 
showed to modulate the expression of four remaining candidates FGF-18, S100A10, 
MATN2 and PDZD2 (Figure 5.9 and 5.10). From these, the research developed here 
identified two indirect miR-21 targets, MATN2 and PDZD2, as well as two direct and/or 
indirect miR-21 target genes comprising FGF-18 and S100A10 (Figure 5.11 and 5.12). 
Interestingly, MATN2 and PDZD2 expression have not been reported before in 
mesothelial cells and none of these targets has been previously linked to the MMT 
process associated to PD therapy. Finally, this project showed for first time that MATN2 
and PDZD2 down-regulation was able to induce an increase in Snail transcription in 
HPMCs, which was significant for MATN2 down-regulation (Figure 5.13C’’ and D’’). 
Interestingly, FGF-18 expression has been previously associated with Snail1/2 regulation 
(Franco-Montoya et al, 2011) and S100A10 has been involved in the formation of E-
cadherin-based adherent junctions (Yamada et al, 2005). Thus, the four miR-21 targets 
identified here may contribute to the acquisition of a transcriptional cell machinery able 
to induce MMT in mesothelial cells. Indeed, PDZD2 down-regulation was shown to 
trigger a significant decrease in E-cadherin, ZO-1 and Occludin levels in HPMCs 
decreasing primary mesothelial cell characteristics in vitro (Figure 5.13D’). Thus, the 
173 
 
research developed in this chapter stablished the bases of novel pathways by which miR-
21 may drive peritoneal mesothelial MMT via FGF-18, S100A10, MATN2 and PDZD2 
down-regulation which may, in turn, increase Snail1 transcription triggering a new 
cellular transcription program.   
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Chapter 6 – General Discussion  
175 
 
Long-term PD therapy is characterized by the loss of the structural and functional 
integrity of the peritoneal membrane which leads to a progressive fibrosis, angiogenesis 
and ultrafiltration failure resulting in a discontinuation of the therapy and, ultimately, 
transition to hemodialysis (Aroeira et al, 2007; Davies et al, 1998; Williams et al, 2002). 
PET can provide therapy functional information, but continuous morphological biopsy 
analysis is impractical. In PD patients, continuous dialysis fluid exchanges allows easy 
access to monitor potential peritoneal biomarkers for structural and functional 
peritoneal membrane changes. PDE contains several intra-peritoneal and leukocyte-
derived macromolecules, proteins and RNA species, which may serve as potential 
biomarkers. 
The development of biomarkers in complex multifactorial disease, such as PD 
therapy, is especially challenging. Thus, peritoneal therapy may require multiple 
biomarkers to achieve the degree of accuracy needed and different biomarkers may be 
required to address distinct specific questions. My research conducted during this 
project has allowed to measure miRNAs in PDE-supernatant samples for first time in the 
field stabilising the methodology necessary for future investigation. Eventually, PDE-
miRNAs used as biomarkers may contribute individualizing PD therapy by indicating the 
adequacy of switching therapy, interrogating and discriminating clinical trials 
competence and to guiding the development of therapy innovations.  
There is an obvious growing interest on miRNA research in the PD field. A clear 
indication is that while only two studies had been published before my PhD research 
started, during the course of my experiments a considerable amount of investigations 
were published (Table 6.1). Up-to-date literature on miRNA regulation of peritoneal 
cavity homeostasis during PD therapy is summarized in Table 6.1 and has been mainly 
focused on reported miRNAs associated with EMT in other contexts (Lopez-Anton et al, 
2015). Additionally, a compendium of literature on miRNA regulation during PD therapy 
showing particular evidences in HPMCs are displayed in Figure 6.1.  
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miRNA 
Study 
Selection 
Model (s) Target(s) 
Downstream 
Signaling 
Ref. 
Down-regulation: 
miR-31*, miR-93, 
miR-100, miR-
152, miR-497*, 
miR-192, miR-198 
and miR-200b* 
Up-regulation: 
miR-122 
Microarray 
analysis 
(Rat PD model, 
4 weeks, 
total peritoneal 
tissue) 
 
Rat PD model 
(4 weeks, total 
peritoneal tissue) 
No No 
(Morishita 
et al, 
2016) 
Down-regulation: 
miR-30a 
Microarray 
analysis 
(Rat PD model, 
4 weeks, 
total peritoneal 
tissue) 
Rat PD model 
(4 weeks, total 
peritoneal tissue) 
HMrSV5 and 
primary rat PMCs 
TGF-β1 stimulated 
Total peritoneal 
tissue from PD 
patients 
miR-30a stable 
overexpression in 
HMrSV5 
 
Snail1& 
miR-30a acts as a 
negative regulator of 
TGF-β1 and induces 
Snail1-dependent EMT 
during peritoneal 
fibrosis 
(Lin et al, 
2015) 
Down-regulation: 
miR-653*, miR-
598* 
Up-regulation: 
miR-136, miR-
703#, miR-30b, 
miR-107 
Microarray 
analysis 
(Rat PD model, 
MGO-induced 
MMT, 
1-2 weeks, 
total peritoneal 
tissue) 
Rat MGO-induced 
MMT PD model 
(1-2 weeks, total 
peritoneal tissue) 
Rat MGO-induced 
MMT PD model. 
with miR-30b-ASO 
Ex vivo rat PMCs 
cultured in vitro 
 
BMP7 
(miR-30b) 
 
BMP-7 is down-
regulated in rat MGO-
induced EMT PD model, 
reverted by miR-30b-
ASO and directly 
targeted by miR-30b, 
which could antagonize 
TGF-β1 effects. 
(Zhou et 
al, 2013) 
Down-regulation: 
miR-200a-3p 
Up-regulated: 
miR-182-5p*, 
miR-488-5p, miR-
296-3p, miR-292-
5p* 
 
Microarray 
analysis 
(mouse PD 
model, 4 weeks, 
total peritoneal 
tissue) 
 
Mouse PD model 
(4 weeks, total 
peritoneal tissue) 
No No 
(Liu et al, 
2014) 
Down-regulation: 
miR-129-5p 
Microarray 
analysis (PDE-
derived HPMCs 
from PD 
patients) 
PDE-derived 
HPMCs from PD 
patients HMrSV5 
TGF-β1 stimulated 
miR-129-5p 
overexpression and 
SIP1/SOX4 
knockdown in 
HMrSV5 TGF-β1 
stimulated 
 
SIP1 
SOX4 
miR-129-5p modulates 
E-cadherin and vimentin 
expression by targeting 
SIP1 and SOX4 genes or 
by modulating the 
promoter activity of E-
cadherin and vimentin 
by the TGF-β1/SIP1 
pathway. 
miR-125-5p protects 
MCs undergoing MMT 
TGF-β1-induced during 
PD and may exert 
protective effect 
targeting SIP1 and 
SOX4. 
(Liu et al, 
2015) 
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miRNA 
Study 
Selection 
Model (s) Target(s) 
Downstream 
Signaling 
Ref. 
Up-regulation: 
miR-142-3p, miR-
21-5p, miR-221-
3p, miR-223-3p, 
miR-34a-5p, miR-
327# 
 
Microarray 
analysis (Rat PD 
model, MGO-
induced MMT,  
5 days/week 
treatment 
during 3 weeks, 
total peritoneal 
tissue) 
Rat MGO-induced MMT 
PD model 
(2 weeks, total 
peritoneal tissue) 
Mice MGO-induced 
MMT PD model 
with anti-miR-21-5p-
LNA 
Total PDE from PD 
patients 
 
PPAR-α& No 
(Xiao et al, 
2015) 
Up-regulation: 
miR-21-5p, miR-
31-5p 
Microarray 
analysis 
(omentum-
derived HPMCs 
TGF-β1 induced 
MMT) 
Omentum-derived 
HPMCs 
(TGF-β1 and PD solution 
stimulated, miRNA 
mimic/inhibitor) 
PDE-derived HPMCs 
from PD patients 
(E and NE phenotype) 
PD patients and uremic 
PD mouse model 
(mesothelial and sub-
mesothelial, FFPE) 
PDE-supernatant from 
PD patients 
PDCD4& 
 
 
PDCD4 down-
regulates SNAIL. E-
cadherin  
down-regulation 
and 
β-catenin/TCF 
dependent 
transcription 
activation may be a 
mechanism by 
which miR-21 
contributes to 
peritoneal fibrosis 
Lopez-
Anton et 
al.) 
Omentum-derived 
HPMCs 
(TGF-β1 stimulated, 
miRNA mimic/inhibitor) 
PDE-derived HPMCs 
from PD patients 
(E and NE phenotype) 
FGF-18$ 
S100A10$ 
No 
(Lopez-
Anton et 
al.) 
Down-regulation: 
miR-589 
Un-published 
(pre-experiment 
CAPD profile 
miRNAs) 
PDE-derived HPMCs 
from PD patients 
PDE-derived HPMCs and 
HMrSV5 
TGF-β1 stimulated 
miR-589 overexpression 
in HMrSV5 
 
No No 
(Lopez-
Anton et 
al) 
Down-regulation: 
miR-29b 
Literature 
based: studies 
on TGF-β1-
mediated 
fibrosis 
Mouse PD model with 
miR-29b overexpression 
(total omentum and 
peritoneal tissue) 
SP1& 
 
Blockade of the  
Sp1/ TGF-
β1/Smad3 pathway 
may be a 
mechanism by 
which  
miR-29b inhibited 
peritoneal fibrosis. 
 
(Yu et al, 
2014) 
Down-regulation: 
miRNA-200c 
Literature based 
PDE-derived HPMCs 
from PD patients 
 
 
No No 
(Lopez-
Anton et 
al) 
 
178 
 
miRNA Study Selection Model (s) 
Target
(s) 
Downstream 
Signaling 
Ref. 
Up-regulation: miR-
15, miR-21, miR-192 
No-changes:  
miR-377, miR-30, 
miR-17 
No-detection: miR-
216a, miR-217 
 
Literature-based: studies 
on potential EMT 
miRNAs 
PDE-derived cells 
from PD patients 
 
No No 
(Chen 
et al, 
2012a) 
Down-regulation:  
miR-15a, let-7e 
Up-regulation:  
miR-193a 
No-changes:  
miR-16, miR-21 
Literature-based: studies 
related to kidney 
development and 
diseases 
 
Cultured HPMCs 
stimulated by D-
glucose (Time course, 
48 h) as a EMT model 
No No 
(Bao et 
al. 
2015) 
 
Table 6.1. miRNAs implicated in the regulation of Peritoneal Cavity Homeostasis during Peritoneal 
Dialysis Therapy. (Table modified from Lopez-Anton et al. 2015) 
*miRNA sequence is not conserved between the model of study and human. 
#miRNA sequence is not present in miRBase (v21, June 2014) for rat or human. 
&Putative targets already described (Bao et al, 2015). 
$Future research is needed for direct target confirmation.  
 
 
 
 
 
 
 
 
 
 
My thesis addressed the role of miRNAs in peritoneal fibrosis associated to PD 
therapy. Differently from the above mentioned research (Table 6.1 and Figure 6.1), I 
based my thesis on miRNA profiles of mesothelial cell expression in an in vitro model of 
TGF-β1 induced MMT. I found TGF-β1-driven MMT process in mesothelial cells 
comprised several research advantages including simplicity, unique stimulus, and cell 
specificity. These same characteristics can be also considered study limitations as a 
result of a lack of context. Therefore, I further confirmed the biological relevance of the 
Figure 6.1: miRNA dysregulation in 
Peritoneal Dialysis. Up-to-date miRNAs for 
which specific evidence in HPMCs exists are 
shown. miRNAs and downstream targets 
studied during this thesis are shown in bold. 
(Figure modified from Lopez-Anton et al. 
2015) 
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miRNAs identified by the validation of miRNA changes in different, well characterized ex 
vivo and in vivo models of peritoneal MMT associated to PD therapy. The described in 
vitro model allowed me the identification of miR-21 and miR-31 up-regulation during 
the MMT process. Consequently, I validated this increase in miRNA expression in 
different set of MMT models associated to PD therapy including (i) in vitro HPMCs 
treated with diverse PD solutions (cellular and supernatant study), (ii) ex vivo PD effluent 
derived HPMCs with epithelial and non-epithelial phenotype, (iii) peritoneal membrane 
from an in vivo uremic PD mouse model (mesothelial and sub-mesothelial compact 
zone), (iv) ex vivo PDE-supernatant from PD patients, and (v) peritoneal membrane from 
PD patients (mesothelial and sub-mesothelial compact zone) (see Chapter 3 and 4).  
During this project I developed a solid methodology to use small PD effluent 
samples to quantify supernatant miRNA expression. This protocol optimization allowed 
me the association of miR-21 and miR-31 transcript levels with peritoneal membrane 
fibrosis and TGF-β1 pathway activation driving peritoneal MMT. Furthermore, miR-21 
showed to specially correlate with different important parameters associated with poor 
membrane conditions and fibrosis and may contribute to peritoneal MMT in several 
manners (see Chapter 4). A significant strength of my research was the use of Global 
Fluid Study registry which is the largest cohort of stable PD patients available worldwide 
(Lambie et al, 2013). Assessing the comparability of my results with the outcomes 
obtained by different groups on the matter would be a future milestone. Nevertheless, 
the goal above mentioned will be especially challenging due to the limited studies 
published on the field and no-biobank availability.  
An especially interesting future application of the technique that I developed 
here would be the detection of pathogen-specific miRNA signatures during acute 
peritoneal infection to discriminate individual micro-organisms and impact on 
treatment outcomes. Indeed, point-of-care tests are urgently sought to diagnose and 
specifically treat microbial infections to avoid multidrug resistance as recognized by the 
World Health Organization (WHO). Previous work developed at the Institute of Infection 
and Immunity in Cardiff University indicated that the host response evoked by distinct 
organisms is characteristic enough to identify pathogen-specific differences or ‘immune 
fingerprints’ before traditional culture results become available. These results combined 
180 
 
with my research developed here rises the idea of using miRNAs to allow the 
development of a pathogen-specific point-of-care diagnosis for patients with acute 
infections. MSc Amy Brook, who has just started her PhD in the laboratory, aims to use 
the technique that I have developed to study PD effluent miRNA content from bacterial 
infected patients to predict clinical outcome and/or the nature of infection.  
Although miRNA point-of-care techniques are still in its infancy several analytical 
approaches have been developed for diagnostic purposes during the last twenty years 
including RT-qPCR, northern blot and luminescence tagging (Labib & Berezovski, 2015; 
Wang et al, 2013). Nevertheless, these techniques are not ideal and hold important 
disadvantages including high cost and long analysis course. Electrochemical biosensors 
are particular new promising tools for miRNA point-of care diagnostics due to their 
simplicity, speed, sensitivity and reasonable multiplexing feasibility. MSc Daniel Smith, 
who is based within the department in collaboration with the Chemistry department of 
Cardiff University and the industry, is interested in this line of investigation. Cardiff 
Institute of Nephrology has been traditionally interested in urine miRNA detection as 
biomarkers while my PhD was the first research developed at the center that addressed 
PD miRNAs. Thus, MSc Daniel Smith research is focussed on the development of an 
electrochemically active disposable ‘dip-stick’ to quantify urine miRNA concentration in 
a quick, non-specialist, non-invasive diagnostic test that will not require expensive 
equipment or highly specialised technicians to operate. Indeed, this biosensor has been 
tested and gave 6 fM sensitivity limit with synthetic urine while remaining specific within 
1 mismatch. Although further research will be needed during the following years, these 
results indicate that future electrochemical ‘dip-stick’ technique adaptation to PD 
effluent miRNA detection may be doable within a reasonable time-scale.  
My research identified PDCD4, an already described miR-21 target that down-
regulates Snail while downstream controlling E-cadherin and β-catenin/TCF dependent 
transcription activation (see Chapter 5). Additionally, I performed In silico analysis 
combining 4 target prediction algorithms (Targetscan, miRanda, miRDB and Diana-
microT) for miR-21 alone and in combination with miR-31. I integrated the resulting 
outcome with mRNA arrays comparing omentum vs PD effluent-derived HPMCs with 
epithealial (E) and non-epithelial (NE) phenotype. I identified 13 possible direct targets 
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for miR-21 and one for miR-31 during the MMT process associated to PD therapy and I 
model scrutinized them. I confirmed four of these miR-21 targets. Specifically, I 
identified two indirect miR-21 targets, PDZD2 and MATN2, as well as two possible direct 
miR-21 targets FGF-18 and S100A10 (see Chapter 5). As detailed in Chapter 5 (see 5.3.), 
there are specific experimental approaches that I would be especially interested to 
perform in order to understand the particular pathways and contribution of each one of 
these targets to the peritoneal MMT process. Overall functional gene analysis indicated 
that selected targets may be modulators of Snail and cooperate driving MMT during 
peritoneal fibrosis (see 5.3.).  
Additionally, the application of CRISPR/Cas9 technology for miR-21 gene 
manipulation combined with relevant in vivo mice PD therapy models would be 
especially interesting to consider for future research. Indeed, Dr Robert Jenkins, who is 
based in the department, is interested in exploring this option in a mice model of 
Staphylococcus epidermidis cell-free supernatant (SES)-induced peritoneal 
inflammation. In particular, his research aims to define in vivo miRNA regulation of tissue 
resident and inflammatory macrophage phenotype in the above mentioned murine 
model of peritoneal fibrosis. Thus, macrophage specific CRISPR/Cas9 driven miRNA gene 
manipulation will allow him to study macrophage population differences and associate 
those with tissue-specific functions during PD associated fibrosis. Similarly, the 
establishment of this methodology at the department will allow future technique 
adaptation for miR-21 manipulation in HPMCs to study changes in MMT associated to 
PD therapy within a reasonable time-scale.  
Of note, miR-21 up-regulation has been synchronously identified in the field by 
Morishita et al. 2016, who studied total PDE samples from 33 patients and found no 
correlations with PD duration and PET results (D/P-Cr and D/D0 glucose) (Morishita et 
al, 2016). Nevertheless, the lack of association between miR-21 and PD duration as well 
as PET results in Morishita et al. 2016 studies may be merely due to limitations in the 
numbers of patients for study. Indeed, anti-miR-21-LNA intraperitoneally injected with 
MGO showed to significantly decrease peritoneal membrane thickening and MMT 
(Morishita et al, 2016) undoubtedly demonstrating miR-21 importance during the 
fibrosis process associated to PD therapy in vivo . 
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miR-21 therapeutic potential has built high interest between the pharmaceutical 
industries. Regulus therapeutics, Inc is a biopharmaceutical company leading miRNA 
therapies towards clinical development in fibrosis, hepatitis C, immune-inflammatory 
diseases, metabolic diseases and oncology. The above company owns miR-21 patient 
rights including miR-21 sequence and complement, chemically modified anti-miR-21 
oligonucleotides and methods of anti-miR-21 use for the treatment of fibrosis. Similar 
patents owned by different research centers and universities can be found for promoter 
driven targeted therapy as well as for broad diagnostic, prognostic and treatment 
applications (For additional information of these patents see: Bhat; Balkrishen, 
Marcusson; Eric, microRNA compounds and methods for modulating miR-21 activity, 
citing patient US9267137, filing date January 15, 2015, and publication date February 
23, 2016, Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2= 
HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND 
&d=PTXT&s1=miR-21.TI.&OS=TTL/miR-21&RS=TTL/miR-21). 
Taken together, my data provide a detailed characterisation of mesothelial 
miRNA expression and responses to TGF-β1, and identified miR-21 and miR-31 as 
promising biomarkers for peritoneal fibrosis associated to PD therapy. Additionally, my 
research identified new miR-21 targets that may be interesting downstream 
contributors for the MMT process. These targets possess unknown therapeutic potential 
not only in the MMT process associated to PD therapy but also in other contexts in which 
miR-21 up-regulation has been characterized. My work presented in this thesis, together 
with parallel reports constitutes a solid research indicating the importance of miR-21 
during PD fibrogenesis.  
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Appendix: Buffers and Reagents 
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Reduccing Gel Loading Buffer 3x TBS (10x) 
0.5 M Tris-HCl, pH 6.8 ................... 1 ml Tris ..................... 24.2 g/l 
Glycerol ........................................ 2.4 ml NaCl ................... 80 g/l 
10% (w/v) SDS ............................... 4.8 ml pH 7.4 
0.05% (w/v) Bromophenol Blue .... 2 drops  
Beta-mercaptoethanol .................. 1.2 ml 
Running Buffer (10x) YTx2 
Tris-HCl ......................................... 30 g/l Tryptone ............ 16 g/l 
Glycine .......................................... 144 g/l Yeast extract ...... 10 g/l 
SDS ............................................... 10 g/l NaCl ................... 5 g/l 
pH 8.3 
Transfer Buffer (10x) YTx2 agar plates 
Tris-HCl ......................................... 30 g/l Tryptone ............ 16 g/l 
Glycine .......................................... 144 g/l Yeast extract ...... 10 g/l 
pH 8.3 (no adjustment necessary)   NaCl ................... 5 g/l 
  Agar ................... 20 g/l 
Transfer Buffer (1x) 
Transfer Buffer 10x  ...................... 100 ml/l 
Methanol ...................................... 200 ml/l 
